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Abstract 
Asthma and chronic obstructive pulmonary disease (COPD) are characterized by airflow 
limitations resulting from airway obstruction and/or tissue destruction.  The diagnosis and 
monitoring of these pulmonary diseases is primarily performed using spirometry, specifically 
the forced expiratory volume in one second (FEV1), which measures global airflow obstruction 
and provides no regional information of the different underlying disease pathologies.  The 
limitations of spirometry and current therapies for lung disease patients have motivated the 
development of pulmonary imaging approaches, such as computed tomography (CT) and 
magnetic resonance imaging (MRI).  Inhaled hyperpolarized noble gas MRI, specifically using 
helium-3 (3He) and xenon-129 (129Xe) gases, provides a way to quantify pulmonary ventilation 
by visualizing lung regions accessed by gas during a breath-hold, and alternatively, regions 
that are not accessed - coined “ventilation defects.”  Despite the strong foundation and many 
advantages hyperpolarized 3He MRI has to offer research and patient care, clinical translation 
has been inhibited in part due to the cost and need for specialized equipment, including 
multinuclear-MR hardware and polarizers, and personnel.  Accordingly, our objective was to 
develop and evaluate imaging biomarkers of pulmonary structure and function using MRI and 
CT without the use of exogenous contrast agents or specialized equipment.  First, we developed 
and compared CT parametric response maps (PRM) with 3He MR ventilation images in 
measuring gas-trapping and emphysema in ex-smokers with and without COPD.  We observed 
that in mild-moderate COPD, 3He MR ventilation abnormalities were related to PRM gas-
trapping whereas in severe COPD, ventilation abnormalities correlated with both PRM gas-
trapping and PRM emphysema.  We then developed and compared pulmonary ventilation 
abnormalities derived from Fourier decomposition of free-breathing proton (1H) MRI 
(FDMRI) with 3He MRI in subjects with COPD and bronchiectasis.  This work demonstrated 
that FDMRI and 3He MRI ventilation defects were strongly related in COPD, but not in 
bronchiectasis subjects.  In COPD only, FDMRI ventilation defects were spatially related with 
3He MRI ventilation defects and emphysema.  Based on the FDMRI biomarkers developed in 
patients with COPD and bronchiectasis, we then evaluated ventilation heterogeneity in patients 
with severe asthma, both pre- and post-salbutamol as well as post-methacholine challenge, 
using FDMRI and 3He MRI.  FDMRI free-breathing ventilation abnormalities were correlated 
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with but under-estimated 3He MRI static ventilation defects.  Finally, based on the previously 
developed free-breathing MRI approach, we developed a whole-lung free-breathing 
pulmonary 1H MRI technique to measure regional specific-ventilation and evaluated both 
asthmatics and healthy volunteers.  These measurements not only provided similar information 
as specific-ventilation measured using plethysmography, but also information about regional 
ventilation defects that were correlated with 3He MRI ventilation abnormalities.  These results 
demonstrated that whole-lung free-breathing 1H MRI biomarker of specific-ventilation may 
reflect ventilation heterogeneity and/or gas-trapping in asthma.  These important findings 
indicate that imaging biomarkers of pulmonary structure and function using MRI and CT have 
the potential to regionally reveal the different pathologies in COPD and asthma without the 
use of exogenous contrast agents.  The development and validation of these clinically 
meaningful imaging biomarkers are critically required to accelerate pulmonary imaging 
translation from the research workbench to being a part of the clinical workflow, with the 
overall goal to improve patient outcomes. 
Keywords 
X-ray Computed Tomography, Magnetic Resonance Imaging, Hyperpolarized Noble Gas 
MRI, Fourier Decomposition MRI, CT Parametric Response Mapping, Four-dimensional 
MRI, Specific Ventilation, Pulmonary Imaging, Imaging Biomarkers, Asthma, Bronchiectasis, 
Chronic Obstructive Pulmonary Disease 
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CHAPTER 1 
1 INTRODUCTION 
Lung diseases, including but not exclusive to asthma and chronic obstructive pulmonary 
disease (COPD), are characterized by airflow limitation resulting from airway obstruction 
and/or tissue destruction.  In this thesis, the nature of airflow limitation is studied using 
non-contrast enhanced imaging biomarkers of pulmonary structure and function and 
compared with inhaled contrast magnetic resonance imaging (MRI) to develop a better 
understanding of the role of ventilation heterogeneity in the etiology and progression of 
lung disease. 
1.1 Motivation and Overview 
Pulmonary diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, 
affect hundreds of millions of people throughout the world and account for millions of 
deaths each year.  According to the World Health Organization (WHO), respiratory disease 
is the 4th leading cause of death worldwide,1 as shown in Figure 1-1.  Globally, COPD 
and asthma affect over 500 million people2 and were, in 2015, the leading causes of death 
among all other chronic respiratory diseases (Figure 1-1).2 
In Canada, asthma and COPD were reported to affect over 3 million people in 2014,3 where 
COPD accounted for the highest rate of hospitalization, followed by angina and asthma,4 
as shown in Figure 1-2.  These hospitalizations contribute significantly to the economic 
burden, where on average the cost for a COPD patient’s hospital stay is approximately 
$10,000 per patient and the total cost was approximately $1.5 billion per year in 2008.5  In 
Ontario, the total economic burden (including both direct and indirect costs) of asthma and 
COPD in 2011 were $1.8 billion and $3.9 billion, respectively.6 
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Figure 1-1 Global Deaths Worldwide and Due To Chronic Respiratory Diseases 
Above: Top five leading causes of death.  Below: Deaths globally from chronic lung 
disease in 2015 using a logarithmic scale. 
These alarming statistics, as well as the overwhelming health care and economic burden of 
lung disease patients, provides evidence of the gap that still remains in the management 
and treatment of these patients.  Currently, volumes derived from pulmonary function tests 
are used as objective measures for diagnosis, management, and treatment effectiveness.  
Although pulmonary function tests are easy to obtain and the generated measurements are 
reproducible,7 they do not provide any regional information about the different underlying 
pathophysiology in lung disease patients and only provide a global measurement of lung 
function.  This major limitation of pulmonary function tests has motivated the development 
of pulmonary imaging approaches, such as computed tomography (CT) and magnetic 
resonance imaging (MRI), to identify and provide regional measurements of lung structure 
and function for longitudinal monitoring and image-guided treatments. 
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Figure 1-2 Repeated Hospitalizations by Condition at First Admission 
Number of patients (in Canada excluding Quebec) with a single, one repeat, and two or 
more repeat hospitalizations at first admission. This was adapted from the Canadian 
Institute for Health Information (2008).4 
Emerging methods based on pulmonary MRI are being developed to quantify lung 
structure and function regionally with the use of inhaled contrast agents.  However, despite 
the numerous studies demonstrating the undeniable opportunities for clinically relevant 
pulmonary biomarkers, translation of these imaging approaches has been hampered due to 
a number of key limitations including the relatively high cost associated with inhaled gas 
contrast and requirement of multinuclear MR hardware and analysis software, restricting 
these techniques to a few specialized research centres.  This thesis focuses on the 
development and application of imaging biomarkers of pulmonary structure and function 
using MRI and CT without the use of exogenous contrast agents or specialized equipment.  
These methods were used to evaluate pulmonary structure-function regionally in subjects 
with COPD and asthma and validated using hyperpolarized noble gas MRI.  The 
development and validation of these clinically meaningful non-contrast enhanced imaging 
biomarkers are critically required to accelerate translation of pulmonary imaging from the 
research workbench to the clinical workflow with the overall goal to improved patient 
outcomes. 
In this Chapter, the background knowledge relevant to this thesis is provided in order to 
motivate the original research presented in Chapters 2 to 5.  A general overview of 
 4 
 
structure and function in the respiratory system will be presented (1.2), followed by the 
underlying disease mechanisms of asthma and COPD (1.3).  The current clinical standard 
to measure and evaluate lung function will be presented next (1.4) followed by a discussion 
on current and developing pulmonary imaging techniques used both in clinic and in the 
research setting (1.5).  Lastly, the hypotheses and objectives of this thesis will be 
introduced (1.6). 
1.2 The Respiratory System: Structure and Function 
The chief responsibility of the respiratory system is to deliver air from the external 
environment to the blood for gas exchange between oxygen and carbon dioxide.  To 
perform this task, the respiratory system is composed of nasal and oral cavities, the lungs, 
the chest wall, and the diaphragm.  Specifically, the lungs are composed of bronchi, 
bronchioles, alveolar ducts, and alveolar sacs.  All of these components function together 
to deliver air from outside of the body to the alveoli in order to perform gas exchange.  In 
this section, the processes involved with the movement of air from the external 
environment through the body to the alveoli are discussed. 
1.2.1 The Airways: Respiratory and Conducting Zones 
The airways can be separated into the respiratory and conducting zones within the lungs.  
As shown in Figure 1-3, the conducting zone consist of the first 17 airway generations (0-
16), while the remaining seven generations in the airway tree make up the respiratory 
zone.8  The conducting airways are responsible for guiding air from outside the body to the 
locations in the lungs where gas exchange occurs.  Following inspiration, air enters the 
nasal and oral cavities where it travels through the pharynx, larynx, and then into the 
trachea, where it enters the conducting zone.  The trachea, generation 0 in the branching 
structure illustration in Figure 1-3, is a hollow pipe ribbed with cartilage rings that 
branches into the primary bronchi, where each bronchus feeds air into the left and right 
lung.  Asymmetrical branching of the airway tree continues while the bronchi decrease in 
diameter, but growing geometrically in number.  The branching bronchi, similar to the 
trachea, are also supported by cartilage to hold open the airway tree.  This bronchi 
branching then leads into bronchioles that are no longer supported by cartilage and are 
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collapsible.  It should be noted that the conducting zone does not participate in gas 
exchange directly and that this region of the airway tree is considered the “dead-space” 
(approximately 150mL).   
 
Figure 1-3 A Schematic of the Human Airway Tree 
The conducting airways consist of generations 0-16, and the last 7 generations make up the 
respiratory zone.  The conducting zone is responsible for guiding air to the alveoli, while 
the respiratory zone is lined with alveoli and is where gas exchange occurs. This was 
adapted from West, JB, Respiratory Physiology: The Essentials, Ninth Edition.8 
Following the airway tree to the respiratory zone, starting at generation 17 shown in Figure 
1-3, this is the region of the lung where gas exchange occurs.  The airways at this point in 
the airway tree start to be lined with alveoli in the respiratory bronchioles.  As the airways 
further divide, they start to form alveolar ducts where the number of alveoli dramatically 
increase in number.  The alveolar ducts are then followed by the alveolar sacs of the 
terminal airways, which are completely surrounded by alveoli to provide the maximum 
amount of surface area for gas exchange to occur.  As a result of the dramatic number of 
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airways in the respiratory zone, the overall cross sectional area is very large, where these 
airways account for most of the volume in the lung (approximately 2.5-3L).8,9 
1.2.2 The Alveoli: Site of Gas Exchange 
The alveoli, as mentioned above, are the functional units of the lungs where gas exchange 
occurs -specifically diffusion of oxygen and carbon dioxide.  Approximately 480 million 
alveoli line the respiratory zone10 each with an approximate diameter of 300μm.8  The 
extremely thin walls of the alveoli (approximately 0.2μm thick) are composed of two types 
of cells (Type I and Type II) to maximize diffusion.  The thinner Type I cells allow for gas 
exchange while the thicker Type II cells secrete surfactant. 
1.2.3 Ventilation 
Ventilation can be expressed as the volume of air that is exchanged between the body and 
the external environment as a function of time.  Accordingly, the average adult inhales 
approximately 500mL of air with every breath.  Of this 500mL, only 350mL reaches the 
alveoli because of the dead-space in the conducting zone.  The generation of negative 
pressure within the lungs via diaphragmatic and intercostal muscle contractions results in 
air being drawn into the lungs.9  The compliance of the lungs, which is a description of 
volume change related to pressure change, dictates the rate and force of inspiration and 
expiration.  Assuming a rate of 15 breaths per minute, the total ventilation8 and alveolar 
ventilation8 would be 7500mL and 5250mL of air exchange per minute, respectively. 
1.3 Pathophysiology of Lung Disease: Asthma and COPD 
Lung diseases, specifically asthma and COPD, are characterized by airflow limitation, 
measured at the mouth using pulmonary function tests, which is persistent and caused by 
changes in the airway lumen, airway wall or peribronchial region.  Airflow obstructions 
are not uniform in nature, but rather heterogeneously distributed throughout the lungs.  
Accordingly, ventilation abnormalities that result in ventilation heterogeneity are a 
hallmark finding in many respiratory disorders that involve the airways, such as asthma, or 
both the airways and pulmonary parenchyma, such as COPD.  This section of the thesis 
will focus on the pathophysiology of lung disease, specifically in asthma and COPD. 
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1.3.1 Asthma 
Asthma is a chronic and often debilitating airways disease, characterized by intermittent 
worsening of breathlessness, cough, chest-tightness and wheeze, which are typically 
reversible with the use of a bronchodilator.11  Airflow limitations in asthma derive from 
the narrowing of the airway lumen, as illustrated in Figure 1-4, caused by increased hyper-
responsiveness of the smooth muscle lining the airways, inflammation, and the presence of 
mucus due to hypersecretion.12  These affects are observed throughout both the central and 
peripheral airways in an asthmatic13 and involve both cellular (i.e. infiltration of 
eosinophils) and structural (i.e. airway remodeling) changes.  Eosinophils in the walls of 
the airways promote constriction and bronchial smooth muscle shortening.  The structural 
changes include increases in smooth muscle mass, bronchial wall edema, and mucous 
gland hypertrophy.  These all lead to remodeling of the airways towards thickened walls 
that contribute to the overall airflow limitation and increased airways resistance.  
Furthermore, this airways resistance contributes to difficulty in emptying the lungs, 
resulting in hyperinflation (i.e. gas-trapping).  The hyper-responsive nature of the airways 
in an asthmatic result in sudden and rapid airway narrowing in response to an 
environmental stimuli (i.e. allergens),14 which is referred to as an “asthma attack.” 
1.3.2 Chronic Obstructive Pulmonary Disease 
COPD is diagnosed and disease severity stratified based on not fully reversible airflow 
obstruction.  Irreversible airflow obstruction develops over a COPD patient’s lifetime as a 
result of primarily exposure to cigarette smoke,15,16 but also can advance due to genetic 
conditions, such as alpha-1 antitrypsin deficiency (AATD), as well as via exposure to 
occupational chemicals and dust, air pollution.  Airflow obstruction, symptoms, and 
exercise capacity measurements in COPD are related to both parenchyma destruction and 
airway remodeling, as shown in Figure 1-4.7,17  Specifically, obstruction in COPD occurs 
in both the large (chronic bronchitis) and small airways (small airway disease), as well as 
the parenchyma (emphysema).  Chronic bronchitis is characterized by excessive mucus 
production and airway inflammation of the large airways (greater than 4mm in diameter), 
specifically the epithelium of the central airways and extending to the mucous gland 
ducts.18-20  The small airways, which are the bronchioles (less than 2mm in diameter) in 
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the airway tree illustrated in Figure 1-3, are the major site of airflow obstruction in 
COPD.21  As mentioned in Section 1.2.1, although each airway has a small diameter, the 
number of airways increases rapidly, increasing the overall cross sectional area.  
Consequently, the small airways attribute very little to the overall measured airway 
resistance, where airway resistance is mainly dominated by the large airways.  As a result, 
small airways disease may silently accumulate over many years without being detected.22 
 
Figure 1-4 Parenchyma and Small Airways Pathologies in Asthma and COPD 
Above: Healthy - normal small airways, asthmatic - muscle constriction/thickening of 
airway wall/increased smooth muscle mass resulting in luminal occlusion, and COPD - 
lumen partly filled with inflammatory exudate with airways inflamed and walls thickened.  
This was adapted from Hogg JC, Lancet (2004)19 and Saetta M et al. Eur Respir J (2001).12  
Below: Healthy - normal lung parenchyma, and COPD - parenchymal destruction.  This 
was adapted from Woods et al. Magnetic Resonance in Medicine (2006).23 
Emphysema is the destruction of parenchymal tissue, where airspaces in the lung are 
permanently enlarged, as illustrated in Figure 1-4.24,25  This permanent enlargement results 
in the loss of alveolar walls and the number of small airways, as compared to a healthy 
subject, and consequently reduces the overall surface area.  Emphysema can be divided 
into three major types: centrilobular, paraseptal, and panlobular emphysema.26  
Centrilobular emphysema, mostly associated with cigarette smoking, mainly affects the 
respiratory bronchioles while preserving the distal alveolar ducts and sacs.  In contrast, 
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paraseptal emphysema affects the peripheral airspaces near the lung pleura and septa.  
Panlobular emphysema, more common in non-smoking patients with COPD (i.e. AATD), 
uniformly affects the entire distal bronchiole starting from respiratory bronchioles to the 
alveoli.  
1.4 Established Clinical Measurements of Lung Function 
Currently, the clinical standard for evaluating lung function is through the use of 
pulmonary function tests, which involve patients performing a variety of breathing 
maneuvers that provide global lung function and lung volume measurements.  The 
measurements that are generated from pulmonary function testing are used to diagnose, 
monitor, and evaluate treatment effective and efficacy in patients with lung disease at in 
the clinic.  These tests can be divided into spirometry, plethysmography, diffusing capacity 
of the lung for carbon monoxide, and multiple breath nitrogen washout.  Furthermore, these 
measurements are often expressed as a percent predicted value (%pred) based on the 
patient’s age, height, sex, and ethnicity.27 
1.4.1 Spirometry 
Measurements made using spirometry can be derived from breathing maneuvers made 
using a handheld device, such as the one shown in Figure 1-5.  While sitting in the upright 
position, patients are instructed to make a tight seal with their lips around the mouthpiece 
while wearing nose plugs.  As shown in the volume-time curve in Figure 1-5, patients are 
instructed to start with normal tidal breathing, for approximately 3-4 breaths, and then 
instructed to inhale using maximum effort, until they reach total lung capacity, followed 
by a maximally forced exhalation, until they cannot expel any more air.28  The important 
measurements that are acquired through spirometry are the forced vital capacity (FVC), 
which is the amount of air that the patient can exhale after a full inspiration, and the forced 
expiratory volume in one second (FEV1), which, as the name suggests, is the amount of air 
that the patient can exhale in one second.  
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Figure 1-5 Pulmonary Function Test - Spirometry 
Left: Handheld spirometer.  Right: Volume-time curve that is measured by the spirometer 
to determine the forced expiratory volume in one second (FEV1) and the forced vital 
capacity (FVC). 
1.4.2 Plethysmography  
A plethysmograph, shown in Figure 1-6, is an air-sealed chamber (or “body-box”) where 
patients sit upright to perform breathing maneuvers to generate volume-time traces, as 
shown in Figure 1-6.  The primary volume that is measured in plethysmography is 
functional residual capacity (FRC), from which residual volume (RV) and total lung 
capacity (TLC) can be quantified.29  FRC is the volume of air that is within the lung after 
passive expiration, RV is the volume of air after forceful expiration, and TLC is the total 
volume of air within the lung after full inspiration.  Other volumes that are obtained using 
plethysmography are the following: inspiratory capacity (IC), vital capacity (VC), and tidal 
volume (TV).  IC is the volume of air that can be inhaled from the end of a normal 
exhalation during a tidal breathing maneuver, VC is the volume of air expelled from total 
lung capacity down to residual volume, and TV is the volume of air that is inhaled/exhaled 
during the respiratory cycle.29  Furthermore, specific-ventilation (SV),30 which is the 
movement of air into and out of the lungs during normal tidal breathing, is a dimensionless 
quantity that measures how efficiently the lungs are being ventilated, as shown below in 
Equation 1-1: 
 𝑆𝑆𝑆𝑆 = 𝑇𝑇𝑆𝑆
𝐹𝐹𝐹𝐹𝐹𝐹
 (1-1) 
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Figure 1-6 Pulmonary Function Test - Plethysmography 
Left: Whole body plethysmograph.  Right: Volume-time curve used to determine lung 
volumes measured by the plethysmograph. 
1.4.3 Diffusion Capacity of the Lung 
The diffusing capacity of the lung for carbon monoxide (DLCO) can be measured through 
pulmonary function testing to evaluate patients with emphysema since this metric provides 
an indirect measure of gas diffusion across the alveolar membrane.  When performing this 
test, patients are instructed to completely empty their lungs (to RV), and to forcefully inhale 
a gas mixture until they are completely filled (to TLC), where they are instructed to hold 
their breath for 10s before exhalation.  The gas mixture that the patients inhale contains a 
very low concentration of carbon monoxide (0.3%).  The breath-hold with the gas mixture 
allows the carbon monoxide to diffuse through the alveolar membrane into the blood, 
where the exhaled gas after the breath-hold is analyzed.  It should be noted that the first 
approximately 150mL of exhaled gas is discarded because of the dead-space in the lungs.  
The analysis of the exhaled gas is performed by comparing the concentration of carbon 
monoxide exhaled versus the concentration that was inhaled to determine the amount of 
carbon monoxide diffusion.31 
1.4.4 Multiple Breath Nitrogen Washout 
Multiple breath nitrogen washout (MBNW) is a technique to measure lung volumes and 
ventilation heterogeneity.32  This test is generally performed with participants sitting in the 
upright position and breathing 100% oxygen through a mouthpiece while wearing nose 
clips.  While breathing in pure oxygen during normal tidal breathing, and knowing that air 
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contains mostly nitrogen gas, after each tidal breath, there is a decrease in the concentration 
of exhaled nitrogen.  When the nitrogen gas concentration has decreased to 1/40th of the 
starting concentration by washing-out the lungs using pure oxygen, the test is complete.  
One measurement that is most commonly derived from MBNW tests is the lung clearance 
index (LCI).33  LCI is calculated as the cumulative expired gas volume, based on the 
number of lung turnovers needed to clear the lungs of nitrogen gas, normalized to FRC, 
which is thought to be representative of whole lung ventilation heterogeneity.34 
1.5 Pulmonary Imaging 
Although pulmonary function tests are inexpensive and easily implemented, they only 
provide a global measurement of airflow obstruction with no regional information.35,36  In 
COPD, they are weakly predictive of disease progression, as well as insensitive to early 
disease stages37-39 where in asthma, they are relatively insensitive to changes in the small-
airways,40,41 which are thought to be the main sight of inflammation.42  These limitations 
have motivated the development of pulmonary imaging approaches to provide direct and 
regional measurements of the underlying pathological features in both asthma and COPD 
patients.  Pulmonary imaging provides regional structural (anatomical) and functional 
(physiological) information with high spatial and temporal resolution, and has been used 
for longitudinal monitoring and image-guided treatments with the overall goal of 
improving patient outcomes.  The functional and structural imaging techniques discussed 
in this thesis include planar chest x-ray, x-ray computed tomography (CT), positron 
emission tomography (PET), single photon emission computed tomography (SPECT), and 
magnetic resonance imaging (MRI). 
1.5.1 Structural Imaging 
The anatomy of the lung can be identified and monitored non-invasively using high 
resolution structural imaging.  Planar chest x-ray, x-ray CT, and MRI have previously been 
investigated to image the anatomy of the lung, including the airways and parenchyma. 
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1.5.1.1 Planar Chest X-ray 
Since the advent of planar x-ray imaging, in 1895 by Wilhelm Rӧntgen where he notably 
captured an image of his wife’s hand, it has now become the most common imaging method 
in lung disease.  The broad dissemination of x-ray imaging was due in part to the low cost, 
low radiation dose, and short acquisition window, making it a commanding diagnostic tool.  
A typical dose associated with a chest x-ray is approximately 0.01mSv,43 where in 
comparison, the average annual background radiation dose is 2-3mSv.43  Chest x-ray 
images (or radiographs) are generated by having an x-ray source directed towards a 
patient’s chest.  The x-ray beam then travels from the source to the patient, where some of 
the x-rays are absorbed by the body.  The absorption (or attenuation) of x-rays by the body 
depends on the path that the x-ray travels through.  The x-rays that are not absorbed pass 
through the body to the detector, which is located on the other side of the patient.  These 
x-rays are then measured by the detector to generate an x-ray image.  The resulting image 
is thus a superposition of all anatomy in the path of the x-ray.  The contrast of the image is 
related to the number of absorbed (or attenuated) x-rays along each path and is dependent 
on the mass attenuation coefficient of the tissue.  The mass attenuation coefficient is 
dependent on the photon (x-ray) energy, atomic number, and mass density of the absorbing 
material.  Highly attenuating (absorbs many x-rays) material, such as bone, appears white 
on an x-ray image, while low attenuating (absorbs fewer x-rays) structures, such as lung 
tissue, appears black, as shown in Figure 1-7.   
Lung abnormalities can be visibly identified using chest radiographs in patients with 
asthma and COPD (Figure 1-7).  In asthma, the most common abnormalities are associated 
with increased lung volumes (hyperinflation) and bronchial wall thickening.44,45  In COPD, 
radiographs are used to detect hyperinflation in moderate-to-severe emphysema46 and 
appear as elongated lung volumes, change in the cardiac silhouette, and flattened 
diaphragm.47  The limiting factors of planar chest radiographs, including the poor contrast 
and loss of depth information, have motivated the development of three-dimensional 
imaging approaches, specifically x-ray CT imaging. 
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Figure 1-7 Chest Radiographs (Posterior-Anterior) of a Healthy, Asthmatic, and COPD 
Patient 
Asthmatic: Lung appears hyperlucent and the diaphragm is flattened indicative of 
hyperinflation.  COPD: Lung is hyperinflated, which is consistent with a flat diaphragm 
and secondary to emphysema.  Healthy volunteer case courtesy of Dr Bruno Di Muzio, 
Radiopaedia.org, rID: 37906. Asthmatic case courtesy of Dr. Ian Bickle, Radiopaedia.org, 
rID: 33470. COPD patient case courtesy of A.Prof Frank Gaillard, Radiopaedia.org, rID: 
8512. 
1.5.1.2 X-ray Computed Tomography 
Similar to planar x-ray imaging, x-ray CT leverages the attenuating properties of x-rays in 
material, but alternatively acquires many different x-ray projections at different angles 
around the patient to generate a three-dimensional volume of the anatomy.  CT was first 
pioneered in the 1970s, and over the past few decades, has become the modality of choice 
for evaluating lung disease patients because it allows for the assessment of the airways and 
parenchymal density changes, while eliminating the structural superposition inherent to 
chest radiographs.48-50   
X-ray CT images are acquired by having a patient lay supine on the scanner bed, where the 
bed is passed through the imaging components of the scanner.  The x-ray source and an 
array of detector elements are positioned opposite to one another, where the source and 
detector rotate around the patient to acquire multiple x-ray projections. The projections can 
be reconstructed into a three-dimensional volumetric image using computational 
reconstruction techniques, such as filtered back projection and iterative reconstruction.51  
In the generated CT volumetric image, each voxel is represented as a relative measurement 
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of the tissue density to that of water using the Hounsfield Unit (HU),52 as shown below in 
Equation 1-2: 
 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑈𝑈𝐻𝐻𝐻𝐻𝑈𝑈 = �𝜇𝜇𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 − 𝜇𝜇𝑤𝑤𝑤𝑤𝑡𝑡𝑡𝑡𝑤𝑤
𝜇𝜇𝑤𝑤𝑤𝑤𝑡𝑡𝑡𝑡𝑤𝑤
� × 1000 [𝐻𝐻𝑈𝑈] (1-2) 
where 𝜇𝜇𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 and 𝜇𝜇𝑤𝑤𝑤𝑤𝑡𝑡𝑡𝑡𝑤𝑤 are the linear attenuation coefficients of tissue and water, 
respectively.  A typical dose associated with a chest CT is approximately 7-8mSv,53 which 
is approximately 3-4 times the dose received annually from natural background radiation.  
More recent advancements in image reconstruction have resulted in the reduction of the 
typical CT dose to approximately 0.1mSv (ultra-low-dose CT),54 although these techniques 
have not yet been implemented in the clinic.55 
CT imaging of the chest has been used to evaluate both airways disease and parenchymal 
destruction in lung disease, such as asthma and COPD.  In asthma, expiratory CT provides 
regional visualization of air-trapped regions,56 while inspiratory CT has been used to 
evaluate airway remodelling.57  Air-trapping can be quantified automatically based on 
thresholds of the expiratory CT density histogram.  CT estimates of airways disease can be 
generated using measurements of airway wall area percent (WA%) and lumen area (LA) 
and quantified using software, such as Pulmonary Workstation V.2.0 (VIDA Diagnostics, 
Coralville, Iowa, USA), for the reconstruction of the large airways (to the fifth-sixth airway 
generation) from volumetric datasets.  Relative to healthy subjects, CT bronchial wall 
thickness measurement in asthma are greater58 and have been shown to be associated with 
airflow obstruction.59,60  In regard to the small airways, the spatial resolution limitation of 
CT restricts the direct evaluation of these airways (diameter <2mm).  As a result, an indirect 
measurement of small airways disease can be evaluated using a densitometry threshold on 
expiratory CT to measure air-trapping (relative area under <-856HU [RA856]).61  Similarly 
in COPD patients, inspiratory CT can be used to visualize and quantify airways disease62,63 
and emphysema.64-66  Emphysema can be automatically quantified based on thresholds in 
inspiratory CT (relative area under <-950HU [RA950]),64,66,67 as shown in yellow in Figure 
1-8. 
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Figure 1-8 Coronal X-ray CT Images and Corresponding Lung Density Threshold Maps 
for a Healthy, Asthmatic, and COPD Subject 
Shown in yellow are lung regions below -950HU. 
Thoracic x-ray CT has been shown to provide a wealth of information about the anatomical 
structures within the lung, but it should be noted that the use of such x-ray based methods 
is limited, especially in serial studies of treatment response and longitudinal studies, 
particularly in children and younger adults with chronic lung disease.  This is a result of 
the potential risks related to radiation doses stemming from ionizing x-ray radiation.68 
1.5.1.3 Magnetic Resonance Imaging 
Unlike x-ray imaging methods, magnetic resonance imaging (MRI) uses non-ionizing 
radiation radiofrequency (RF) waves to manipulate nuclear spins (mainly proton [1H] 
atoms) to generate images that provide excellent soft tissue contrast of the anatomy with 
high spatial resolution.  Conventional 1H MRI of the lung, despite all the advantages, has 
been challenging to develop due to a number of limitations. 
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First, MRI signal is dependent on the number of 1H, specifically in water molecules.  
Unfortunately in the lung, it is mostly air-filled and consists of only 800g of tissue across 
4-6L,69 and as a result, the signal-intensity of the lung is low.  Furthermore, the countless 
air-tissue interfaces, as a result of the millions of alveoli within the lung, leads to local 
magnetic field inhomogeneities,70,71 which are problematic for high spatial resolution MRI.  
The protons at these air-tissue interfaces spin at different rates since proton spin precession 
frequency is determined by the local magnetic field, which causes the transverse signal to 
decay very quickly (0.4-0.9ms).72,73  As a result, this leads to increased dephasing of the 
magnetization and signal loss.  Additionally, cardiac and respiratory motion during tidal 
breathing causes blurring artefacts in the image.  The accumulative result of all these 
limitations result in the lungs appearing as black holes with no information that can be 
obtained about lung anatomy, as shown in Figure 1-9, making images acquired in a healthy 
volunteer indistinguishable from those of a lung disease subject. 
 
Figure 1-9 Representative Conventional 1H MR Coronal Images for a Healthy, Asthmatic, 
and COPD Subject 
Structural information with the lung is difficult to visually distinguish due to the inherent 
low tissue and 1H density. 
In order to overcome the increased dephasing of the transverse signal, ultra-short echo time 
(UTE) MRI acquisition protocols have been developed to reduce the time between the RF 
excitation pulse and data acquisition to acquire signal from the parenchymal tissue before 
it decays.70  The enhancement in signal due to the reduced echo time (TE) has resulted in 
recent studies showing that UTE MRI provides comparable visualization of pulmonary 
anatomy as compared with CT.74  As compared to Figure 1-9, there is an enhancement in 
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signal in the UTE MRI for a healthy, asthmatic, and COPD subject (Figure 1-10).  In 
asthmatics, UTE MRI lung signal intensities were lower as compared with healthy 
volunteers, and correlated with lung function and CT radiodensity measurements.75  
Similarly in COPD, previous studies have shown correlations between CT emphysema 
measurements and lung function tests with UTE MRI lung signal-intensity 
measurements.76 
 
Figure 1-10 Representative UTE 1H MR Coronal Images for a Healthy, Asthmatic, and 
COPD Subject 
In contrast to the conventional 1H MR images in Figure 1-9, regions of low signal-intensity 
are visually obvious in the UTE MR images for the obstructive lung disease subjects 
compared to the healthy volunteer. 
1.5.2 Functional Imaging 
The chief function of the lung is ventilation where oxygenated air is delivered to the alveoli 
within the lung and carbon dioxide is removed.  With regard to medical imaging, there are 
several methods to generate functional maps to identify regions of the lung that are 
ventilating versus regions that are not.  Ventilation imaging can be performed either with 
(contrast enhanced) or without (non-contrast enhanced) inhaled gases. 
1.5.2.1 Contrast Enhanced Functional Imaging 
Inhaled contrast agents can be used to directly image the distribution of the contrast within 
the lung to measure ventilation.  Nuclear medicine, CT, and MRI all provide measurements 
of ventilation with the use of inhaled gases. 
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Nuclear Medicine 
Nuclear medicine methods use radioactive tracers that emit radiation.  These methods 
involve inhalation of the radioisotopes to the peripheral airspaces to generate functional 
images of ventilation.  The two nuclear medicine imaging techniques that have been 
developed to generate ventilation images are single photon emission computed tomography 
(SPECT) and positron emission tomography (PET). 
SPECT imaging involves patients inhaling radioisotopes that emit a single gamma-ray as 
they decay.  Patients lay on a bed where three-dimensional tomographic images are 
generated by using a ring of gamma cameras or by rotating a single or multiple gamma 
cameras around the patient to acquire multiple projections at different angles.  These 
projections can be reassembled to provide volumetric information about the radioisotope 
distribution within the lungs.  Ventilation scans require gaseous radioisotopes, such as 
81mKr, 133Xe, aerosolized 99mTc-diethylenetriaminepentaacetate (DTPA) or an ultrafine 
dispersion of 99mTc-labeled carbon (“Technegas”), to generate regional ventilation images 
by measuring the distribution of the gas within the lungs as the radionuclide decays. 
In a similar manner, PET imaging involves patients inhaling a radioisotope, but in this case, 
the radioisotope emits positrons as it decays through the process of beta decay.  As the 
radioisotope decays, a positron is ejected from the nucleus of the unstable atom.  Once 
ejected, the positron travels a short distance where it will encounter an electron and undergo 
a process known as annihilation.  The annihilation of both of these particles will result in 
the generation of two photons, each with equal energy of 0.511MeV, that are emitted 
approximately 180° from one another.  The simultaneous creation of these gamma-rays 
travelling antiparallel to each other can be detected at or very close to the same time, and 
are considered to be coincident.  The spatial location of the source particle can therefore 
be determined from detection of the coincident gamma-rays detected by two detector 
elements geometrically.  The location of the radioactive decay of the radioisotope is 
therefore restricted to that line, which can then be sorted out and reconstructed into a 
volumetric image of the distribution of the inhaled radionuclide in the lungs.  Ventilation 
imaging using PET can be performed using inhaled 68Ga-carbon nanoparticles (“Galligas”) 
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or 13N isotope (either by bolus injection or inhalation).  For 13N, it is not soluble in 
blood/tissue,77 so following bolus injection of this radioisotope, it will travel to the lungs 
via the bloodstream and cross the alveolar membrane.  Accordingly, gas-trapped regions 
of the lung retain the tracer while well ventilated regions of the lung quickly wash away 
the tracer.  Alternatively, using the inhaled methods, the tracers do not reach the poorly 
ventilated regions of the lung. 
SPECT imaging has been used to evaluate airway closure,78 and changes following 
bronchoconstriction79,80 and bronchodilation in asthma.81  Similarly, poorly ventilated 
regions post bronchoconstriction have been identified using PET imaging.82  In COPD 
subjects, the evaluation of airflow limitation severity83,84 and intrabullous ventilation in 
emphysema patients85 have been performed using SPECT imaging.  The 
ventilation/perfusion ratio that can be generated using PET imaging has been identified as 
a measurement to separate the different phenotypes of COPD (i.e. emphysema “pink 
puffer” versus airways disease “blue bloater”).86  Although promising, limitations of 
SPECT and PET include the risk of cumulative radiation exposure for longitudinal 
monitoring, low spatial resolution, and specifically for PET, the need for a cyclotron for 
the production of isotopes. 
X-ray Computed Tomography 
CT imaging, specifically imaging at two energies (dual-energy CT), provides a way to 
regionally measure ventilation using inhaled xenon.87  This method leverages the differing 
x-ray attenuation properties of xenon at two separate energies.  Recent developments in 
CT technology, specifically dual-source CT scanners, has allowed the simultaneous 
acquisition of data at different tube voltages for material differentiation.  This method 
involves the patient fitted with a positive pressure ventilation mask laying supine on the 
CT bed, where they are instructed to breathe in a mixture of xenon and oxygen for 
approximately 2-3 minutes.  The images that are acquired at both the high and low energies 
are then used to perform three-material decomposition, by which xenon can be 
differentiated from other materials in the lung (air and soft tissue), to generate a xenon 
distribution map. 
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Dual-energy CT using inhaled xenon has been used to evaluate patients with asthma where 
ventilation defects that appeared in the xenon-enhanced images were related to airflow 
limitation and airway wall thickening,88 and are sensitive to both bronchodilation89 and 
bronchoconstriction.90  Xenon-enhanced dual-energy CT has also been used to evaluate the 
regional distribution of structural and ventilation abnormalities simultaneously in patients 
with COPD.91  Although this technique is promising, there are several limitations including 
radiation exposure, side effects of xenon (specifically respiratory depression), and cost. 
Magnetic Resonance Imaging 
There are several different inhaled contrast agents that have been developed for MRI.  MR 
ventilation images can be generated with the use of O2, 19F, 3He, and 129Xe. 
O2-enhanced MRI was first developed in the 1990s to non-invasively assess regional 
ventilation in the human lung.92  This method involves measuring the change that occurs 
in the longitudinal relaxation time (T1) of protons in lung tissue with differing 
concentration of O2.  Molecular O2 is weakly parametric magnetic and the presence of O2 
accelerates the longitudinal relaxation of protons.  Ventilation images using O2 are 
generated by comparing T1-weighted 1H images acquired whilst breathing room air (~21% 
[O2]) and pure oxygen (100% [O2]).  Previous studies that have evaluated asthma patients 
using O2-enhanced MRI showed that the measured O2-enhancement ratio related with 
pulmonary function tests and disease severity.93,94  In COPD patients, O2-enhanced MRI 
was shown to be correlated with lung diffusion capacity,95 pulmonary function tests,96 and 
the presence of emphysema evaluated using CT.96 
Inert 19F gas MRI involves patients inhaling fluorinated gases, such as tetrafluoromethane 
(CF4), sulfur hexafluoride (SF6), hexafluoroethane (C2F6) and perfluoropropane (C3F8 or 
PFP) which are nontoxic and contain multiple 19F nuclei.  Despite the weak signal from 
thermal equilibrium polarization, the rapid longitudinal relaxation time of 19F allows for 
extensive signal averaging.97  Additionally, the presence of O2 does not have a dramatic 
effect on the T1 of fluorinated gases, thus fluorinated gases can be mixed with O2 to 
improve patient safety.  Current imaging protocols in vivo involve patients breathing 5-7 
breaths of a fluorinated gas mixture (C3F8/O2) to reach an approximate steady state gas 
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concentration in the lung and then performing a breath hold maneuver with inhalation of 
1L of the same fluorinated gas mixture.98,99  Recent studies have shown the application of 
19F MRI in both asthma and COPD patients where there was a visual increase in 
heterogeneity of the distribution of gas within the lung as compared to a never-smoker with 
normal lungs.98 
Noble gas MRI, using either hyperpolarized 3He or 129Xe gases which are stable isotopes, 
since its first description100,101 has provided non-invasive measurements of lung 
ventilation.  3He and 129Xe nuclei, although MR visible, have a low spin density compared 
with solid tissue which prohibits its detectability using MRI under thermal equilibrium 
polarization, thus the process of hyperpolarization is performed.   Hyperpolarization is a 
process by which angular momentum is added to a system.  Specifically for noble gases, 
optical pumping and spin exchange is used to achieve hyperpolarization.  Optical pumping 
involves a circularly polarized laser, with a wavelength corresponding to the electronic 
orbital transition energy of an alkali metal (i.e. Rb), which serves as the carrier of the 
angular momentum.  The laser is used to excite the electrons of vaporized alkali metal 
where the excited vapor is within an optical cell also filled with either 3He or 129Xe.  The 
angular momentum of the electrons of the excited alkali metal vapour is transferred to the 
noble gas nuclei through collisions; this process is known as spin-spin interaction.  This 
method increases the nuclear polarization of the unpaired nuclear proton of the noble gases 
up to five orders of magnitude compared to thermal equilibrium polarization.102  It should 
be noted that the optical cell is maintained in a constant magnetic field; this is performed 
to reduce the decay rate of the polarized atoms to their ground state.  Initially, lung imaging 
was developed using hyperpolarized 129Xe,100 but quickly converted to 3He due to the high 
signal-to-noise ratio that could be achieved because of the inherent properties of the two 
noble gases.  The gyromagnetic ratio of 3He is approximately three times greater than 129Xe 
(gyromagnetic ratio of -32.3MHz/T for 3He versus -11.8MHz/T for 129Xe) and the 
achievable polarization of 129Xe is lower than 3He (129Xe: 8-25%; 3He: 30-40%).103  
However, due to the limited supply and increasing price of 3He104 and recent advances in 
technology, there has been renewed interest in 129Xe where similar signal-to-noise ratios 
are becoming more attainable.105 
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Ventilation imaging using noble gas MRI provides a visualization of the spin density of 
noble gas nuclei within the lung after inhalation, which reflect regions of the lung that are 
ventilated and those that are not.  Figure 1-11 shows hyperpolarized 3He MR ventilation 
images (cyan) co-registered to conventional 1H MR images (gray) for a healthy volunteer, 
an asthmatic, and a subject with COPD.  As compared to the healthy volunteer, where there 
is a homogenous distribution of 3He gas within the lung, the asthmatic and COPD subjects 
both have visibly obvious regions within the lung that are not gas filled (signal voids); these 
regions are known as “ventilation defects.”  These ventilation defects can be quantitatively 
evaluated using the imaging biomarker known as the ventilation defect percent (VDP), 
where 𝑆𝑆𝑉𝑉𝑉𝑉 is the normalized region of the lung that is not participating in ventilation 
(ventilation defect volume [𝑆𝑆𝑉𝑉𝑆𝑆]) to the whole lung volume (thoracic cavity volume 
[𝑇𝑇𝐹𝐹𝑆𝑆]),106 shown below in Equation 1-3: 
 𝑆𝑆𝑉𝑉𝑉𝑉 = �𝑆𝑆𝑉𝑉𝑆𝑆
𝑇𝑇𝐹𝐹𝑆𝑆
� × 100% (1-3) 
 
Figure 1-11 Representative Hyperpolarized 3He (cyan) MR Coronal Images Co-registered 
to Conventional 1H (gray) MR Coronal Images for a Healthy, Asthmatic, and COPD 
Subject 
Homogeneous distribution of 3He MR signal intensities within the lung are observed in the 
healthy volunteer, while heterogeneous signal intensities (regions or signal void) are seen 
in both the asthmatic and COPD subject. 
This imaging biomarker of ventilation heterogeneity has been shown to be a robust measure 
that is reproducible107,108 and related to relevant clinical measurements.109-111  In asthmatic 
patients, ventilation defects that appeared in hyperpolarized noble gas MR images have 
 24 
 
been shown to be significantly correlate with spirometry,110-112 disease severity110 and CT 
measurements of gas trapping,111 and are spatially and temporally persistent.107,113,114  
Importantly in asthmatics, ventilation is characteristically heterogeneous as compared with 
healthy volunteers.110,115-117  Ventilation defects are larger and more numerous in older 
asthmatic patients, with greater inflammation and worse airway remodeling118 and are also 
related to quality of life and asthma control.119  In COPD patients, VDP is related to 
spirometry,109 symptoms and exercise capacity,120 CT-derived emphysema 
measurements,121 and exacerbations122 using hyperpolarized 3He and 129Xe gases.  
Furthermore, for both asthma and COPD patients, ventilation defects are sensitive to 
bronchodilation,123,124 while in asthmatics, ventilation defects are also sensitive to 
bronchoconstriction.125 
Another application of hyperpolarized noble gas MRI is to probe the microstructure within 
the lung using diffusion imaging.126  Diffusion-weighted noble gas MRI, which is sensitive 
to the self-diffusion of the gases based on the random Brownian motion of the atoms, can 
be used to measure the apparent diffusion coefficients (ADC) of both hyperpolarized 3He 
and 129Xe.  ADC reflects the restricted diffusion of the gases within the airways and 
airspaces.  As a result, the diffusion time interval can be used as a surrogate measurement 
of airspace dimension.127  Accordingly, an increase in ADC value reflects a greater mean 
square displacement of the gas molecule or an enlarged airspace as a result of, for example, 
emphysema-related airspace enlargements.  ADC measured using hyperpolarized 3He MRI 
have been validated using histology23 and shown to be highly reproducible.128-130  
Furthermore, hyperpolarized 3He MRI ADC have been used to validate hyperpolarized 
129Xe MRI ADC measurements.131  In asthma, ADC was significantly elevated in 
asthmatics as compared to healthy volunteers, potentially suggesting gas-trapping,132 
although other studies have reported otherwise showing no difference.133,134  3He MRI 
ADC has also been used to evaluate the response to methacholine in asthmatics, where 
ADC values were elevated after bronchoconstriction and decreased following 
bronchodilation.135  In patients with COPD, ADC values measured using 3He and 129Xe 
were elevated compared to age matched healthy volunteers,109 and correlated with age,136 
lung function tests,137 smoking history,136 and CT measurements of emphysema.109  
 25 
 
Furthermore, ADC measurements were also sensitive to administration of a bronchodilator, 
suggesting reduction in gas-trapping in patients with COPD.138 
A number of key limitations have hampered the use of hyperpolarized noble gas MRI in 
the clinic, which has restricted this technique to a few specialized research centres.  These 
approaches incur relatively high costs due to the need for inhale contrast agents and require 
access to multinuclear MR hardware and analysis software.  Furthermore, except for in the 
United Kingdom, hyperpolarized noble gas MRI is not yet approved for clinical use in 
Asia, North America or the rest of the European Union despite numerous demonstrations 
of safety and efficacy in chronic lung disease patients.139,140  With this in mind, there has 
been growing interest for the development and implementation of non-contrast enhanced 
pulmonary MRI approaches to overcome these challenges specifically with resource 
accessibility. 
1.5.2.2 Non-contrast Enhanced Functional Imaging 
As mentioned above, non-contrast enhanced methods to indirectly evaluate lung function 
can be performed by measuring tissue density or deformation changes as the lungs expand 
and contract using structural imaging.  Ventilation-weighted lung images can be extracted 
via structural CT or MR images while patients free-breathe or at multiple lung volumes, 
including full inspiration and full expiration.  Ventilation information from structural 
images is performed by exploiting the aggregate signal changes caused by density 
variations in the lung during breathing. 
Computed Tomography 
Thoracic CT images acquired at different phases in the breathing cycle (i.e. full expiration 
and full inspiration), can be used to generate and quantify the expansion of lung tissue 
regionally using non-rigid or deformable image registration methods.141-144  Imaging 
biomarkers of ventilation using lung deformation information include measures of local 
volume change, estimates of tissue compliance and deformation biomarkers during 
breathing.  Local volume changes, such as during normal tidal breathing (specific-
ventilation),30 can be measured and generated using a density-based method,142 which 
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quantifies the difference in lung tissue density at different lung volumes as air enters and 
leaves voxels.145  This measurement reflects the quantity of inhaled gas moving into the 
lung during normal breathing.  Alternatively, local lung tissue expansion can be described 
using the deformation field maps that are generated from the co-registration of images.  
More specifically, the determinant of the Jacobian matrix that is generated from the 
deformation field vector map can be used to quantify specific volume,146 which has 
previously been shown to reflect regional ventilation.147  This imaging biomarker has been 
evaluated in patients with asthma148,149 and COPD,150-152 where abnormal lung 
biomechanical properties were observed in severe asthmatics, which may be due to gas-
trapping.149  In COPD patients, imaging biomarkers of lung biomechanical properties were 
related to clinical outcomes,151 disease severity150 and progression.152  The techniques can 
also be applied to four-dimensional CT (4DCT),153-155 where images are reconstructed at 
many different points during the respiratory phase, and changes in volume can be measured 
throughout the entire process.  This technique was used to show that deformation 
throughout the respiratory cycle is nonlinear156 and that this deformation is greater in 
asthmatics than in healthy subjects.148  In COPD patients, 4DCT ventilation measured 
using the density and Jacobian based methods were shown to be related to emphysema.157 
An alternative approach using parametric response maps (PRM) of co-registered 
inspiratory-expiratory CT, which was first developed as a voxel-based method for 
improving the sensitivity of diffusion-MRI data for identifying early therapeutic response 
in glioma patients,158 has recently been used to evaluate COPD patients.159  In COPD, co-
registered inspiratory-expiratory CT in addition to well-established density 
thresholds,61,160,161 can be used to classify lung tissue into normal, emphysematous and gas-
trapping regions.159  In other words, PRM provides a way to classify lung tissue based on 
the presence of pulmonary air.  To generate PRM, voxel-wise comparisons are performed, 
where co-registered inspiration and expiration images are used to classify lung tissue into 
four categories based on expiration and inspiration thresholds as previously described:159 
1) inspiration >-950HU and expiration >-856HU (normal tissue [green]), 2) inspiration >-
950HU and expiration <-856HU (gas-trapping [yellow]), 3) inspiration <-950HU and 
expiration <-856HU (emphysema [red]), and, 4) inspiration <-950HU and expiration >-
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856HU, as shown in Figure 1-12.  The fourth category of voxels was hypothesized to 
reflect noise in the data due to image registration error.159  As shown in Figure 1-12, with 
increasing severity of airflow limitation, regions of PRM-normal tissue are reduced while 
both lung regions of PRM-gas-trapping and PRM-emphysema increase. 
 
Figure 1-12 Parametric Response Mapping of Co-registered Inspiratory-Expiratory CT 
Images 
Above: A schematic of the generation of PRM.  Below: PRM co-registered to CT images 
of a representative ex-smoker without COPD, mild COPD, and severe COPD subjects. 
Although PRM measurements of gas trapping, suggested to be related to “functional” small 
airway disease, have been shown to be reproducible over short periods of time,162 
differentiated current and former smokers with and without COPD,163 correlated with 
pulmonary function,159 and were associated with longitudinal changes in FEV1,164 the 
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clinical relevance and etiology of this measurement is uncertain and has not yet been 
pathologically validated. 
Magnetic Resonance Imaging 
Similar to non-contrast enhanced CT, aggregate signals are extracted from multiple lung 
volumes of free-breathing 1H MR images to detect changes in air volume regionally within 
the lung, without the use of ionizing radiation.  The first approach, pioneered in 2006, 
involved a series of coronal images acquired over a time period of one minute during slow, 
maximum amplitude respiration, where fractional ventilation weighted images of the lung 
(𝐹𝐹𝑆𝑆) were generated from signal intensity differences between full inspiration (𝑆𝑆𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖) and 
full expiration (𝑆𝑆𝑆𝑆𝑡𝑡𝑒𝑒𝑖𝑖), as shown below in Equation 1-4:165 
 𝐹𝐹𝑆𝑆 = 𝑆𝑆𝑆𝑆𝑡𝑡𝑒𝑒𝑖𝑖 − 𝑆𝑆𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖
𝑆𝑆𝑆𝑆𝑡𝑡𝑒𝑒𝑖𝑖
 (1-4) 
This method was originally developed and used to evaluate healthy volunteers, asthmatics, 
and cystic fibrosis patients, along with other lung disease patients.  Visually obvious 
ventilation defects appeared in the lung disease patients as compared to the healthy subjects 
and these ventilation defects were correlated with pulmonary function tests.165 
Since the original development using 1H MRI to derive surrogate measurements of 
ventilation, a variety of approaches have been investigated.  Multiple lung volumes breath-
hold approaches where whole lung MR images are acquired and co-registered to measure 
signal intensity differences have been developed,75,166,167 using conventional 1H MRI167 or 
UTE MRI.75,166  Conventional 1H MR signal intensity differences were related to 
pulmonary function tests in asthma and COPD patients with emphysema, and that these 
differences were related to 3He MR signal intensities.167  Furthermore, measurements of 
1H MR signal differences generated from dynamic proton maps (DPM) using multi-volume 
UTE MRI were greater in healthy volunteers as compared to asthma subjects, and 
correlated with lung function and CT radiodensity measurements.75 
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Figure 1-13 Fourier Decomposition of Free-breathing Pulmonary 1H MR Images 
Above: A schematic of generating FDMR ventilation-weighted images. Below: FDMR 
ventilation-weighted images (magenta) co-registered to conventional 1H MR coronal 
images (gray) for a healthy, asthmatic, and COPD subject. 
Fourier-decomposition of free-breathing 1H MRI (FDMRI) is another alternative approach 
that exploits non-rigid registration and fast pulmonary MR image acquisitions protocols to 
generate ventilation-weighted images of a single slice coronal image.168,169  As shown in 
Figure 1-13, this technique involves acquiring a time series of free-breathing 1H MR 
images and after performing deformable image registration, fast Fourier transforms (FFT) 
are performed on the signal intensity oscillation pattern (caused by the compression and 
expansion of the lung parenchyma) generated from the pulmonary voxel intensities in the 
co-registered free breathing 1H MR images.  The magnitude of the first ventilation 
harmonic (which corresponds to the respiratory rate) is determined for each and every 
voxel and this is used to generate the ventilation-weighted image.  As can be seen when 
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comparing Figure 1-11 and Figure 1-13, FDMRI methods can provide similar spatial 
information about ventilation as compared to hyperpolarized noble gas MR methods. 
Reproducibility of FDMRI has previously been investigated in healthy volunteers while 
ventilation abnormalities measured using FDMRI in porcine models have shown to be 
spatially localized with SPECT-CT170 and hyperpolarized 3He MRI171 ventilation defects.  
Thus far, in asthma and COPD, limited work has been done using FDMRI.  Furthermore, 
while the MRI techniques described above acquire images in breath-hold at multiple lung 
volumes166,167 or free-breathing images for a single slice,168,169 development of approaches 
that provide a way to generate whole lung functional maps that probe functional 
abnormalities using conventional equipment and pulse sequences while patients are free-
breathing has been limited.  These methods, although requiring sophisticated post-
processing methods, open the opportunity for functional lung imaging on clinically 
available MR systems for serial lung function measurements without the dependence of 
inhaled gases in lung disease patients. 
1.6 Thesis Hypotheses and Objectives 
The diagnosis and monitoring of pulmonary diseases, such as asthma and COPD, is 
primarily done using pulmonary function tests.  These tests, although inexpensive and 
easily implemented, are limited because they only provide a measure of global airflow 
obstruction and provide no regional information, potentially concealing independent 
underlying pathologies.  The limitations of spirometry and current therapies for lung 
disease patients have motivated the development of pulmonary imaging approaches.  
Pulmonary imaging has the potential to provide regional measurements of lung function 
for image-guided treatments and longitudinal monitoring.  Inhaled hyperpolarized noble 
gas MRI has previously been shown to provide a way to quantify pulmonary ventilation 
by visualizing lung regions accessed by gas during a breath-hold, and alternatively, regions 
that are not accessed coined “ventilation defects.”  Despite the strong foundation and many 
advantages this contrast enhanced technique has to offer research and patient care, clinical 
translation has been limited in part due to the need for specialized equipment, including 
multinuclear-MR hardware and polarizers, and personnel.  Thus, the overarching objective 
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of this thesis was to develop and evaluate imaging biomarkers of pulmonary structure and 
function using MRI and CT without the use of exogenous contrast agents or specialized 
equipment.  The objectives and hypotheses specific to each chapter are described below. 
In Chapter 2, our objective was to develop and directly compare CT parametric response 
maps with 3He MRI ventilation measurements of gas-trapping and emphysema in ex-
smokers with and without COPD.  We wanted to determine the quantitative and spatial 
relationships of PRM gas-trapping and PRM emphysema measurements with MRI 
measurements of parenchymal tissue integrity and ventilation, because these are clinically-
important imaging findings and phenotypes of COPD.  We hypothesized that 3He 
ventilation defects would be spatially related to PRM measurements of both gas-trapping 
and emphysema. 
In Chapter 3, our objective was to develop and compare pulmonary ventilation 
abnormalities derived from Fourier decomposition of free-breathing 1H magnetic 
resonance imaging with 3He MRI in subjects with COPD and bronchiectasis.  Based on 
previous work, we hypothesized that ventilation defects measured using FDMRI and 3He 
MRI would be spatially and quantitatively correlated in subjects with COPD and those with 
bronchiectasis. 
In Chapter 4, based on the FDMR biomarkers developed in patients with COPD and 
bronchiectasis, our objective was to evaluate ventilation heterogeneity in patients with 
severe asthma, both pre- and post-salbutamol as well as post-methacholine challenge using 
FDMRI and 3He MRI.  Based on previous work, we hypothesized that FDMRI VDP would 
be quantitatively related to 3He MRI VDP and show similar responses to both methacholine 
and salbutamol as compared to baseline measurements in patients with severe asthma. 
In Chapter 5, based on the free-breathing MR approaches previously developed, our 
objective was to develop a whole-lung free breathing pulmonary 1H MRI technique to 
measure regional specific-ventilation and evaluate asthmatics and healthy volunteers.  We 
then wanted to compare 1H MRI specific-ventilation with 3He MRI ventilation in healthy 
and asthmatic participants, and, determine the relationships between 1H MRI specific-
ventilation with both 3He MRI and pulmonary function measurements.  We hypothesized 
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that dynamic whole-lung MR specific-ventilation would be related to static ventilation 
measurements derived from 3He MRI as well as pulmonary function tests.  
In Chapter 6, an overview and summary of the important findings and conclusions of 
Chapters 2-5 is provided.  The study specific and general limitations of these studies will 
be discussed and some potential solutions are suggested.  The thesis concludes with an 
outline of future studies that can build on the work presented in this thesis. 
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CHAPTER 2 
2 PULMONARY IMAGING BIOMARKERS OF GAS 
TRAPPING AND EMPHYSEMA IN COPD: 3HE MR 
IMAGING AND CT PARAMETRIC RESPONSE MAPS 
To better understand the potential of CT parametric response maps (PRM), we directly 
compared the imaging biomarkers derived from CT PRM with well-established 
measurements of airways disease and emphysema, including MRI and pulmonary function 
tests, to provide for the first time a deeper understanding of the relationship between 
ventilation abnormalities and gas-trapping in COPD. 
The contents of this chapter were previously published in the journal Radiology: DPI 
Capaldi, N Zha, F Guo, D Pike, DG McCormack, M Kirby, and G Parraga. Radiology 
2016; 279(2):597-608.  Permission to reproduce this article was granted by the 
Radiological Society of North America (RSNA) and is provided in Appendix A.  
2.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow 
limitation related to airway remodeling, inflammation and emphysematous destruction1.  
These pathophysiological features can be quantified regionally using high resolution x-ray 
computed tomography (CT) measurements of the airways2,3 and parenchyma.4,5  For 
example, airways disease can be estimated using CT measurements of airway wall area 
percent (WA%) and lumen area (LA) while emphysema may be estimated using CT density 
thresholds such as -950 Hounsfield units (HU)4 or the 15th percentile value6 from 
inspiratory CT.  The expiratory CT density-histogram threshold of -856HU also provides 
a way to estimate gas trapping7 reflecting the longer time constants for emptying the 
parenchyma via obstructed airways. 
Parametric response mapping (PRM)8 was recently used to evaluate COPD,9 breast cancer 
treatment response10 and osteoporosis.11  In COPD patients, co-registered inspiratory and 
expiratory thoracic CT can be evaluated using well-established density thresholds,12 
resulting in the classification9 of normal, emphysematous and gas-trapping lung regions.  
However, the relationship of PRM classified tissue with other established measurements 
of airways disease and emphysema is not well-understood.  Very recently PRM 
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phenotyping was used to differentiate current and former smokers with and without 
COPD,13 but the clinical relevance and etiology of PRM measurements of airways disease 
is yet uncertain.  
Single photon emission computed tomography (SPECT)14 and positron emission 
tomography (PET),15 have also been used to identify pulmonary function abnormalities in 
COPD patients.  In addition, hyperpolarized inhaled noble gas MRI using 3He and 129Xe 
gases,16,17 as well as oxygen-enhanced18 and 19F MRI19 provide other ways to quantify both 
functional and structural pulmonary biomarkers of COPD.  Hyperpolarized 3He MRI 
apparent diffusion coefficients (ADC) reflect the size of the lung acinar units.  Such values 
are abnormally elevated in smokers with and without COPD.20,21  3He MRI ventilation 
defects may reflect both airways disease and emphysema in advanced COPD,22 but in mild 
COPD and in asthma,23 ventilation defects reflect airways disease.  Despite the potential 
of 3He MRI, limited and unpredictable global quantities and high cost have hampered 
clinical translation.  
We wanted to determine the quantitative and spatial relationships of PRM-gas-trapping 
and PRM-emphysema measurements with MRI measurements of parenchymal tissue 
integrity (i.e. ADC) and ventilation, because these are clinically-important imaging 
findings and phenotypes of COPD.  Thus, our objective was to directly compare magnetic-
resonance-imaging and computed-tomography parametric-response-map measurements of 
gas-trapping and emphysema in ex-smokers with and without chronic obstructive 
pulmonary disease. 
2.2 Materials and Methods 
2.2.1 Study Volunteers 
Participants provided written-informed-consent to a protocol approved by a local research 
ethics board and Health Canada and compliant with the Health-Insurance-Portability-
Accountability-Act (HIPAA, USA) (IRB-Reg. #00000940), in a prospectively planned 
study performed from March-December 2014. 
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2.2.2 MR Imaging 
MRI acquisition of conventional proton (1H), 3He static ventilation, and 3He diffusion-
weighted images was performed using a whole-body 3T Discovery MR750 system 
(General Electric Health Care [GEHC], Milwaukee, Wisconsin, USA), as previously 
described.24  Polarization was achieved (HeliSpin; Polarean, Durham, North Carolina, 
USA) to 40%, and the magnetized gas was diluted with medical-grade N2 gas to 5mL/kg 
of body weight.  Coronal MRI was acquired (multi-slice acquisition with no gaps) in 
breath-hold from FRC after subjects inhaled a 1L gas mixture (4He/N2 mixture for 1H MRI 
and 3He/N2 mixture for 3He MRI).   
1H MRI was acquired using the whole-body radiofrequency coil and fast spoiled gradient-
recalled echo (FGRE) sequence with a partial echo (total-data-acquisition-time=12s; 
repetition-time [TR]/echo-time [TE]/flip-angle=4.3ms/1.0ms/30°; field-of-view 
[FOV]=40×40cm2; matrix=128×80 [zero-padded to 128×128]; partial-echo-
percent=62.5%; bandwidth [BW]=62.50kHz; number-of-excitations [NEX]=1; number-
of-slices=14; slice-thickness=15mm, gap=0). 
3He MR static ventilation images were acquired using a fast gradient-recalled echo method 
with a partial echo (total-data-acquisition-time=10s; TR/TE/flip-angle=3.8ms/1.0ms/7°; 
FOV=40×40cm2; matrix=128×80 [zero-padded to 128×128]; partial-echo-percent=62.5%; 
BW=62.50kHz; NEX=1; number-of-slices=14; slice-thickness=15mm, gap=0).  3He MR 
diffusion-weighted images were also acquired using an FGRE sequence with centric k-
space sampling (total-data-acquisition-time=14s; TR/TE/flip-angle=6.8ms/4.5ms/8°; 
FOV=40×40cm2; matrix=128×128; BW=62.50kHz; NEX=1; number-of-slices=7; slice-
thickness=30mm, gap=0) with two interleaved images (with and without additional 
diffusion sensitization) (G=1.94G/cm; b=1.6s/cm2; rise-and-fall time=0.5ms; gradient 
duration=0.46ms; diffusion time=1.46ms). 
2.2.3 CT Imaging 
CT images were acquired with subjects in the supine position, approximately 10 minutes 
prior to MRI and one hour post-salbutamol administration.  A 64 slice Lightspeed VCT 
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scanner (GEHC) was used to acquire breath-hold images at full-inspiration and at full-
expiration using a spiral acquisition approach (detector configuration=64×0.625mm; peak 
x-ray tube voltage=120kVp; effective x-ray tube current=100mA; x-ray tube rotation 
time=500ms; pitch=1.0, slice thickness=1.25mm; number of slices=200-250 [patient size 
dependent]; matrix=512×512), as previously described.25  CT data were reconstructed 
using a standard convolution kernel to 1.25mm.  The ImPACT CT patient dosimetry 
calculator (based on the Health Protection Agency [UK] NRPB-SR250) and our 
manufacturer settings were used to calculate total effective dose (1.8mSv for inspiration 
and 1.4mSv for expiration CT).  The approach of Christener and colleagues26 was used to 
calculate the size-specific dose estimate (SSDE)27 for inspiration CT using volumetric CT 
dose index (CTDIvol) (4.4mGy), total effective dose of 1.8mSv, and size-dependent 
conversion factor (fsize) of 1.00-2.00 and this ranged from 5-9mGy.  For expiration CT, the 
SSDE was 3-7mGy (CTDIvol =3.3mGy, total effective dose =1.4mSv, and fsize=1.00-2.00). 
2.2.4 MR Image Analysis 
3He MRI semi-automated segmentation was performed by a single observer (DP, 3 years 
experience), as previously described,28 to generate ventilation defect percent (VDP) – the 
ventilation defect volume (VDV) normalized to 1H MRI thoracic cavity volume (TCV).  A 
detailed description is provided in the Supplement. 
2.2.5 CT Image Analysis 
CT images were analyzed using Pulmonary Workstation 2.0 (VIDA Diagnostics Inc, 
Coralville, Iowa, USA) by a single observer (DPIC, 2 years experience) for the 
measurement of wall area percent and to segment the lung regions; these analyses are fully-
automated, as previously described and validated.29,30  The relative area of the CT density-
histogram <−950HU (RA950) and −856HU (RA856) were determined using MATLAB for 
inspiratory and expiratory CT, respectively.   
Briefly, pulmonary PRM results can be generated by co-registering inspiratory and 
expiratory CT scans and then classifying voxels based on their specific thresholds into 
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normal, gas-trapping or emphysema tissue components.  The specific details are provided 
in the Supplement. 
2.2.6 Statistics 
Analysis of variance (ANOVA) with post-hoc analysis using the Tukey correction was 
performed to determine differences in participant characteristics and imaging 
measurements using SPSS Statistics V22.0 (SPSS Inc., Chicago, Illinois, USA).  Pearson 
correlation coefficients (r) were determined for MRI and PRM measurements and adjusted 
using the Holm-Bonferroni correction. The agreement between CT-PRM and 3He MRI 
measurements were evaluated using the Bland-Altman method using GraphPad Prism V6.0 
(GraphPad Software Inc., La Jolla, California, USA).  Multivariate regression models for 
both PRM-gas-trapping and PRM-emphysema were determined using the step-wise 
method; variables were added to the model when p<0.15, and removed when p≥0.15, using 
SPSS. 
2.3 Results 
2.3.1 Participant Characteristics 
Table 2-1 shows demographic and pulmonary function measurements for 58 participants 
(73±9yrs) including 26 ex-smokers with normal spirometry (70±11yrs) and 32 ex-smokers 
(74±7yrs) with COPD.  The patient subgroups were significantly different with respect to 
body mass index (p<.001), smoking history (pack-years, p=.01), FEV1 (p<.001), 
FEV1/FVC (p<.001), and DLCO (p<.001) but not age (p=.1). 
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Table 2-1 Subject Demographics 
Parameter 
Mean (±SD) 
Normal   
Ex-smokers 
(n=26) 
COPD Ex-smokers (n=32) Sig 
Dif 
p 
All 
(n=32) 
GOLD I 
(n=12) 
GOLD II 
(n=13) 
GOLD III/IV 
(n=7) 
Age yrs  70 (11) 74 (7) 75 (8) 74 (8) 73 (6) .104 
Male n 15 25 11 9 5 -- 
BMI kg/m2 30 (4) 26 (3) 26 (3) 27 (3) 26 (4) <.001 
Pack years 28 (16) 43 (26) 31 (17) 50 (28) 51 (30) .012 
FEV1 %pred  103 (19) 73 (27) 101 (14) 64 (10) 39 (7) <.001 
FEV1/FVC % 80 (7) 55 (11) 63 (4) 55 (8) 40 (5) <.001 
TLC %pred 96 (13) 110 (16)** 103 (34)* 106 (17) 115 (20) <.001 
IC %pred 103 (23) 91 (27) 100 (23) 94 (32) 70 (10) .078 
RV %pred 100 (21) 140 (39) 123 (16) 134 (33) 180 (53) <.001 
DLCO %pred 89 (18)# 68 (23)** 73 (29)* 66 (24) 51 (15) <.001 
Sig Dif: Significant difference between subgroups (p<.05) determined by ANOVA with 
Tukey correction; SD: standard deviation; GOLD: The Global Initiative for Chronic 
Obstructive Lung Disease; %pred: percent of predicted value; BMI: body mass index; FEV1: 
forced expiratory volume in one second; FVC: forced vital capacity; TLC: total lung 
capacity; IC: inspiratory capacity; RV: residual volume; DLCO: diffusing capacity for 
carbon monoxide; #n=25; *n=11; **n=31. 
2.3.2 Qualitative Ventilation and PRM Results 
Figure 2-1 shows MRI and CT for a representative ex-smoker without airflow limitation 
and three COPD ex-smokers.  For the two ex-smokers with more advanced COPD (GOLD 
II: 84yrs-male, FEV1=52%pred, FEV1/FVC=44%; GOLD III: 67yrs-female, FEV1=33%pred, 
FEV1/FVC=39%) there was more pronounced 3He ventilation defects, a greater number of 
PRM voxels reflective of emphysema, and elevated ADC.  Alternatively, for ex-smokers 
with mild or no disease (ex-smoker: 55yrs-male, FEV1=83%pred, FEV1/FVC=77%; GOLD 
I: 69yrs-male, FEV1=89%pred, FEV1/FVC=69%) there was more homogeneous ventilation 
and greater number of PRM voxels reflective of normal or healthy tissue. 
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Figure 2-1 Ventilation and Parametric Response Maps for a representative ex-smoker and 
COPD subjects 
Ex-smoker: 55 yrs-male, FEV1=83%pred, FEV1/FVC=77%, RV/TLC=45%, DLCO not 
available; GOLD I: 69 yrs-male, FEV1=89%pred, FEV1/FVC=69%, RV/TLC=39%, 
DLCO=67%pred; GOLD II: 84 yrs-male, FEV1=52%pred, FEV1/FVC=44%, RV/TLC=62%, 
DLCO=47%pred; GOLD III: 67 yrs-female, FEV1=33%pred, FEV1/FVC=39%, 
RV/TLC=72%, DLCO=28%pred.  Top row: 3He MRI static ventilation in blue co-registered 
with 1H MRI in grey-scale.  Second row: 3He MRI ADC maps (0.0 cm2/s - 0.8 cm2/s).  
Third row: CT density masks where yellow = attenuation < -950 Hounsfield units. Last 
row: PRM where green=normal tissue, yellow=gas-trapping, and red=emphysema. 
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2.3.3 Ventilation and PRM Measurements by GOLD Severity 
Table 2-2 summarizes MRI ventilation and emphysema measurements as well as CT-
derived gas-trapping/emphysema and PRM measurements.  COPD ex-smokers reported 
significantly greater VDP (p<.001), ADC (p<.001), and RA950 (p<.001) as well as PRM 
gas-trapping (p<.001) and emphysema (p<.001) than ex-smokers without airflow 
limitation.  There were no significant differences for CT airway measurement of WA% 
(p=.9).  
Table 2-2 Imaging Measurements 
Parameter 
Mean (±SD) 
Normal   
Ex-smokers 
(n=26) 
COPD Ex-smokers (n=32) Sig 
Dif 
p 
All 
(n=32) 
GOLD I 
(n=12) 
GOLD II 
(n=13) 
GOLD III/IV 
(n=7) 
CT RA950 % 2 (1) 10 (9) 6 (4) 10 (10) 15 (12) <.001 
CT RA856 % 14 (10) 37 (18) 34 (13) 35 (20) 53 (16) <.001 
CT 6th gen. WA % 65 (2) 65 (2) 65 (2) 66 (2) 66 (2) .882 
3He MRI Ventilation % 92 (4) 20 (13) 88 (6) 80 (11) 63 (9) <.001 
3He MRI VDP % 8 (4)# 12 (4) 12 (6) 20 (11) 37 (9) <.001 
3He MRI ADC cm2/s .29 (.08)# .36 (.06)* .34 (.03)** .36 (.06)## .41 (.05) <.001 
PRM Normal % 85 (11) 60 (18) 64 (13) 63 (20) 46 (17) <.001 
PRM Gas-Trapping % 13 (10) 31 (12) 31 (11) 27 (14) 41 (9) <.001 
PRM-Emphysema % .5 (.5) 7 (10) 3 (3) 8 (11) 13 (12) .001 
Sig Dif: Significant difference between subgroups (p<.05) determined by ANOVA with 
Tukey correction; SD: standard deviation; GOLD: The Global Initiative for Chronic 
Obstructive Lung Disease; RA950: relative area of the lung with attenuation values <-
950HU that is in an inspiration CT; RA856: relative area of the lung with attenuation values 
<-856HU that is in an expiration CT; 6th gen.: sixth generation airway; WA: wall area; 
VDP: ventilation defect percent; ADC: apparent diffusion coefficient; PRM: parametric 
response map; #n=24; ##n=12; *n=30; **n=11. 
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Figure 2-2 shows that VDP was significantly different between normal ex-smokers 
(8±4%) and moderate-severe COPD subjects (GOLD II: 20±11%, p<.001; GOLD III/IV: 
37±9%, p<.001), but not mild COPD (GOLD I: 11±6%, p=.5).  VDP was also significantly 
different between GOLD I and GOLD II (p=.04), GOLD II and GOLD II/IV (p<.001), and 
GOLD I and GOLD III/IV (p<.001) ex-smokers.  PRM measurements were significantly 
different for normal ex-smokers (gas-trapping: 13±10%, emphysema: 0.5±0.5%) and 
moderate-severe COPD subjects (gas-trapping: GOLD II: 27±14%, p=.003; GOLD III/IV: 
41±8%, p<.001; emphysema: GOLD II: 8±11%, p=.003; GOLD III/IV: 13±12%, p<.001).  
PRM gas-trapping was significantly different between ex-smokers and mild COPD (GOLD 
I: 31±11%, p<.001).  PRM emphysema was significantly different between GOLD I and 
GOLD III/IV (p=.03).  ADC was significantly different between normal ex-smokers 
(.29±.08cm2/s) and GOLD II (.36±.06cm2/s, p=.02) GOLD III/IV (.41±.05cm2/s, p<.001), 
but not GOLD I (.34±.03cm2/s, p=.2) COPD. 
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Figure 2-2 3He MRI ventilation and PRM measurements by COPD grade 
A) 3He MRI VDP for ex-smokers=8±4%, GOLD I=11±6%, GOLD II=20±11%, and 
GOLD III/IV=37±9%.  Significant difference for VDP between ex-smokers and GOLD II 
(p<.001), ex-smokers and GOLD III/IV (p<.001), GOLD I and GOLD II (p=.04), GOLD 
II and GOLD III/IV (p<.001), and GOLD I and GOLD III/IV (p<.001). 
B) PRM-derived gas-trapping voxels for ex-smokers=13±10%, GOLD I=31±11%, GOLD 
II=27±14%, and GOLD III/IV=41±8%.  Significant difference for PRM gas-trapping 
between ex-smokers and GOLD I (p<.001), ex-smokers and GOLD II (p=.003), and ex-
smokers and GOLD III/IV (p<.001). 
C) 3He MRI ADC for ex-smokers=.29±.08cm2/s, GOLD I=.34±.03cm2/s, GOLD 
II=.36±.06cm2/s, and GOLD III/IV=.41±.05cm2/s.  Significant difference for ADC 
between ex-smokers and GOLD II (p=.02), ex-smokers and GOLD III/IV (p<.001), and 
GOLD I and GOLD III/IV (p=.04). 
D) PRM-derived emphysema voxels for ex-smokers= 0.5±0.5%, GOLD I=3±3%, GOLD 
II=8±11%, and GOLD III/IV=13±12%.  Significant difference for PRM emphysema 
between ex-smokers and GOLD II (p=.009), ex-smokers and GOLD III/IV (p=.001), and 
GOLD I and GOLD III/IV (p=.03). 
Significant difference between subgroups (p<.05) were determined by ANOVA with a 
Post-hoc Tukey analysis. 
Error bars represent the standard deviation of the data. 
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2.3.4 Relationships for MR Imaging and PRM Measurements 
Table 2-3 shows the Holm-Bonferroni-corrected Pearson correlations as well as 
multivariate regression model results for CT-derived PRM gas-trapping and emphysema 
measurements.  In ex-smokers with COPD only, PRM gas-trapping was significantly 
related to FEV1/FVC (r=-.58, p=.003), ADC (r=.53, p=.01), and VDP (r=.47, p=.03).  PRM 
emphysema was significantly correlated with FEV1 (r=-.43, p=.03), FEV1/FVC (r=-.52, 
p=.008), DLCO (r=-.69, p<.001), ADC (r=.69, p<.001), and VDP (r=.62, p<.001) in COPD 
ex-smokers.  Figure 2-3 provides linear regressions for PRM-gas-trapping and emphysema 
and shows that VDP was significantly correlated with PRM-gas-trapping (r=.58, p<.001) 
and PRM-emphysema (r=.68, p<.001) in all subjects and in the COPD ex-smoker subgroup 
(gas-trapping: r=.47, p=.03; emphysema: r=.62, p<.001), but not in normal ex-smokers.  
ADC was also significantly correlated with PRM-gas-trapping (r=.55, p<.001) and PRM- 
emphysema (r=.62, p<.001) in all subjects, and the COPD ex-smoker subgroup (gas-
trapping: r=.53, p=.01; emphysema: r=.69, p<.001), but not in normal ex-smokers.  Figure 
2-3 also shows Bland-Altman plot for PRM-gas-trapping and emphysema; in relation to 
VDP, there was a negative bias for PRM gas-trapping (-9±12% [-32%-15% 95% CI]) and 
a positive bias for PRM emphysema (11±9% [-6%-28% 95% CI]).  Table 2-3 shows that 
in the multivariate regression model that explains PRM-gas-trapping, FEV1/FVC (ßS=-.69, 
p=.001) and WA% (ßS=-.22, p=.02) make significant contributions, whereas for the PRM-
emphysema model, DLCO (ßS=-.29, p=.03) and VDP (ßS=.41, p=.001) were significant. 
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Table 2-3 Pearson Correlations and Multivariate Regressions for PRM Gas-Trapping and 
Emphysema Measurements 
 Pearson Correlations* Multivariate Regressions^ 
 PRM  Gas-Trapping 
PRM 
Emphysema 
PRM 
Gas-Trapping 
PRM  
Emphysema 
 Normal (n=26) 
COPD 
(n=32) 
Normal 
(n=26) 
COPD 
(n=32) 
All 
(n=58) 
All 
(n=58) 
Variables r/p r/p r/p r/p ßU ßS Partial R2 p ßU ßS 
Partial 
R2 p 
FEV1 %pred  -.09/.9 -.29/.1 -.11/.9 -.43/.03 -- -- -- -- -- -- -- -- 
FEV1/FVC % -.33/.6 -.58/.003 -.34/.6 -.52/.008 -.65 -.69 .53 .001 -- -- -- -- 
DLCO %pred -.06/.8 -.36/.09 -.21/.9 -.69/<.001 -- -- -- -- -.10 -.29 .10 .03 
ADC cm2/s .08/.9 .53/.01 .30/.8 .69/<.001 -- -- -- -- -- -- -- -- 
6th  WA % -.16/.9 -.44/.07 -.22/.9 -.14/.4 -1.72 -.22 .08 .02 -- -- -- -- 
VDP % .13/.9 .47/.03 .10/.7 .62/<.001 -- -- -- -- .29 .41 .20 .001 
%pred: percent of predicted value; GOLD: The Global Initiative for Chronic Obstructive 
Lung Disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 
DLCO: diffusing capacity for carbon monoxide; ADC: apparent diffusion coefficient; 6th: 
sixth generation airway; WA: wall area; VDP: ventilation defect percent; PRM: parametric 
response map; r: Pearson correlation coefficient; ßU: unstandardized regression 
coefficients; ßS: standardized regression coefficients; *Holm-Bonferroni corrected p-
value; ^Adjusted for age, sex, height, weight, and smoking history and all variables in the 
model significant at the p=0.15 level. 
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Figure 2-3 Relationships for 3He MRI VDP and ADC with PRM-derived gas-trapping and 
emphysema voxels 
A) Linear regression for 3He MRI VDP with PRM for all subjects (gas-trapping voxels: 
r=.58, r2=.34, p<.001, y=0.73x–12.88; emphysema voxels: r=.68, r2=.47, p<.001, y=0.47x–
2.78), normal ex-smokers (gas-trapping voxels: r=.13, r2=.02, p=.9, y=0.35x+10.92; 
emphysema voxels: r=.10, r2=.009, p=.7, y=0.01x+0.39), and COPD subjects (gas-trapping 
voxels: r=.47, r2=.23, p=.03, y=0.46x+22.12; emphysema voxels: r=.62, r2=.38, p<.001, 
y=0.46x–2.22). 
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B) Linear regression for 3He MRI ADC with PRM for all subjects (gas-trapping voxels: 
r=.55, r2=.30, p<.001, y=122x-17; emphysema voxels: r=.62, r2=.39, p<.001, y=77x–22), 
normal ex-smokers (gas-trapping voxels: r=.08, r2=.006, p=.9, y=14x+10; emphysema 
voxels: r=.30, r2=.09, p=.8, y=2.5x–0.3), and COPD subjects (gas-trapping voxels: r=.53, 
r2=.28, p=.01, y=119x-12; emphysema voxels: r=.69, r2=.48, p<.001, y=121x–37). 
C) Bland-Altman analysis of agreement for 3He MRI VDP and PRM for all subjects (gas-
trapping voxels: bias=-9±12%, lower limit=-32%, upper limit=15%; emphysema voxels: 
bias=11±9%, lower limit=-6%, upper limit=28%), normal ex-smokers (gas-trapping 
voxels: bias=-6±10%, lower limit=-26%, upper limit=15%; emphysema voxels: 
bias=8±4%, lower limit=1%, upper limit=15%), and COPD subjects (gas-trapping voxels: 
bias=-11±13%, lower limit=-36%, upper limit=14%; emphysema voxels: bias=13±10%, 
lower limit=-7%, upper limit=33%). 
Dotted lines = 95% confidence intervals. 
2.3.5 Spatial and Regional Relationships 
Given the significant quantitative relationships for MRI and PRM COPD measurements, 
we evaluated the spatial correlations of ventilation defects with PRM measurements.  
Qualitative examples are shown in Figure 2-4 for an ex-smoker with mild COPD and 
another with GOLD grade III COPD.  The spatial relationship for ventilation defects with 
PRM gas-trapping is more obvious in the ex-smoker with mild disease whereas there is co-
localization of PRM emphysema and ventilation defects in the ex-smoker with severe 
airflow limitation.  
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Figure 2-4 Spatial relationship of 3He MRI ventilation defects with PRM gas-trapping and 
emphysema for a representative (A) mild and (B) severe COPD subject 
A) GOLD I: age=69, sex=male, FEV1=89%pred, FEV1/FVC=69%, RV/TLC=39%, 
DLCO=67%pred;  
B) GOLD III: age=78, sex=male, FEV1=47%pred, FEV1/FVC=37%, RV/TLC=50%, 
DLCO=57%pred.  3He MRI ventilation (blue) co-registered with 1H MRI and PRM normal 
(green), gas-trapping (yellow) and emphysema (red) tissue co-registered with CT.  Arrows 
show spatial relationship between ventilation defects with PRM gas-trapping and 
emphysema regions. 
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To explore these relationships in more detail, we quantitatively evaluated the spatial 
overlap of PRM gas-trapping and emphysema voxels with ADC (Figure 2-5) and 
ventilation defects (Table 2-4).  As shown in Figure 2-5, 3He ADC was significantly 
elevated in PRM gas-trapping as compared to normal tissue (normal ex-smoker: p=.004, 
GOLD I: p=.01, GOLD II: p=.01, GOLD III/IV: p=.03).  3He ADC was also significantly 
greater in the regions of PRM-emphysema as compared to regions of PRM-gas-trapping 
for GOLD I (p=.03), but not for normal, GOLD II, or GOLD III/IV ex-smokers.  Table 
2-4 shows that in mild and moderate COPD, the spatial overlap coefficient (SOCMRI) for 
3He ventilation defects with PRM-gas-trapping tissue (mild: SOCMRI=36±28%; moderate: 
SOCMRI=34±28%) was significantly greater than for PRM-emphysema voxels (mild: 
SOCMRI=1±2%, p=.001; moderate: SOCMRI=7±15%, p=.006).  Thus for mild and moderate 
COPD subjects, 3He ventilation defects showed a greater spatial relationship with PRM- 
gas-trapping versus emphysema voxels.  For severe COPD, SOCCT for 3He ventilation 
defects with PRM-emphysema (SOCCT=64±30%) was significantly greater than for PRM- 
gas-trapping voxels (SOCCT=36±18; p=.01).  Therefore for severe COPD subjects, PRM-
emphysema was mainly localized within 3He ventilation defect regions.  In addition, in 
severe COPD, SOCMRI for 3He ventilation defects with PRM-gas-trapping voxels 
(SOCMRI=62±25%) was significantly greater than with PRM-emphysema 
(SOCMRI=11±20%, p=.009).  Hence, in severe COPD, 3He ventilation defect regions 
mostly consisted of PRM-gas-trapping voxels, although there was a mixture of PRM-gas-
trapping and emphysema. 
Table 2-4 Quantitative Spatial Relationships for 3He MRI ventilation defects with CT-
PRM Voxels 
Mean (±SD) 
Normal 
Ex-smokers 
(n=26) 
COPD Ex-smokers (n=32) Sig 
Dif 
p 
All 
(n=32) 
GOLD I 
(n=12) 
GOLD II 
(n=13) 
GOLD III/IV 
(n=7) 
Spatial Overlap Coefficient Normalized using CT voxels 
   Gas-Trapping-to-VDP (%) 3 (12) 15 (16) 4 (4) 13 (13) 36 (18) <.001 
   Emphysema-to-VDP (%) 0 (0) 22 (32) 3 (9) 16 (27) 64 (30) <.001 
Sig Dif* .2 .06 .5 .5 .01  
Spatial Overlap Coefficient Normalized using MRI voxels 
   VDP-to-Gas-Trapping (%) 3 (8) 41 (29) 36 (28) 34 (28) 62 (25) <.001 
   VDP-to-Emphysema (%) 0 (0) 6 (14) 1 (2) 7 (15) 11 (20) .04 
Sig Dif* .09 <.001 .001 .006 .009  
Sig Dif: Significant difference between groups (p<.05) using ANOVA and corrected using 
Tukey’s method; SD: standard deviation; GOLD: The Global Initiative for Chronic 
Obstructive Lung Disease; VDP: ventilation defect percent; PRM: parametric response 
map; *Significant difference measured using paired t-test for spatial overlap coefficients 
of MRI ventilation defects with PRM gas-trapping and emphysema 
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Figure 2-5 3He MRI apparent diffusion coefficient measurements spatially within PRM 
regions of normal, gas-trapped, and emphysematous tissue 
3He ADC measurements for PRM normal tissue (ex-smokers=.27±.05cm2/s, GOLD 
I=.34±.03cm2/s, GOLD II=.36±.09cm2/s, GOLD III/IV=.41±.07cm2/s), gas-trapped (ex-
smoker=.28±.05cm2/s, GOLD II=.35±.04cm2/s, GOLD II=.38±.11cm2/s, GOLD 
III/IV=.44±.08cm2/s), and emphysema tissue (ex-smoker=.29±.06cm2/s, GOLD 
I=.36±.05cm2/s, GOLD II=.39±.12cm2/s, GOLD III/IV=.46±.10cm2/s). 
Error bars represent the standard deviation of the data. 
2.4 Discussion 
We evaluated 58 ex-smokers in the first direct comparison of PRM and MRI measurements 
of COPD.  We acquired inspiration/expiration CT and noble gas MRI within an hour and 
observed: 1) with increasing severity of airflow limitation, PRM-gas-trapping, PRM-
emphysema, ADC and VDP measurements were significantly greater, 2) 3He ventilation 
and PRM measurements were correlated in COPD, but not in normal ex-smokers, 3) in a 
multivariate model that predicted PRM-gas-trapping, WA% and FEV1/FVC were 
significant, while for PRM-emphysema, VDP and DLCO were significant, and, 4) 3He ADC 
was significantly elevated in regions of PRM- gas-trapping and there were quantitative and 
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spatial correlations for both PRM-gas-trapping and emphysema with 3He ventilation 
defects that differed according to COPD severity. 
Parametric-response-mapping9 classifies lung tissue based on the presence of pulmonary 
air – either as a consequence of emphysema and gas-trapping due to airways disease and/or 
emphysema.9  We were curious about the potential relationships between PRM and MRI 
phenotypes of COPD, especially because both ventilation defects and PRM-gas trapping 
have been suggested as biomarkers of small-airways disease.  First, we observed that with 
increasing severity of airflow limitation, PRM-gas-trapping, PRM-emphysema, ADC and 
VDP measurements were significantly greater.  We also noted that 3He VDP and PRM 
measurements were correlated in COPD ex-smokers but not in ex-smokers with normal 
pulmonary function.  This might be expected because correlations in ex-smokers with 
mainly normal pulmonary function are statistically difficult to ascertain in small sample 
sizes since the range of values for normal lung function is small.31  It is also worth noting 
that in this study, CT emphysema measurements for normal ex-smokers were in agreement 
with previously reported values for healthy subjects.7,32  Importantly, CT may not be 
adequately sensitive to very mild or subclinical parenchymal33 and obstructive disease and 
this may also partially explain the negligible VDP and PRM correlations in normal ex-
smokers.   
In addition to these bilateral relationships, multivariate modelling identified the parameters 
that significantly added to the model for PRM-gas-trapping (WA% and FEV1/FVC) and 
PRM-emphysema (VDP and DLCO).  The PRM-gas-trapping model is intuitive, based on 
our prior knowledge of the role of airway wall morphology in functional small airways 
disease.34  This finding is also consistent with the major pulmonary imaging and clinical 
phenotypes recently summarized by the Fleischner Society.35  We note, however, that while 
the significant contribution of DLCO to PRM-emphysema is also consistent with a large 
body of previous work,36 the contribution of PRM-emphysema to ventilation defects is a 
novel and somewhat surprising result.  Strong hints that ventilation defects may stem from 
emphysematous bullae were previously reported in patients with advanced/severe COPD 
and numerous exacerbations requiring hospitalization.22 Together, this information 
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suggests a role for pulmonary imaging to phenotype COPD patients beyond FEV1 to help 
guide therapy to change exacerbations and other outcomes.     
These quantitative associations and some obvious qualitative regional relationships led to 
our exploration of potential spatial correlations.  Notably, and unexpectedly, we observed 
that 3He ADC was significantly elevated in regions of PRM-gas-trapping.  This surprising 
result suggested that PRM ‘functional small-airway disease’ that leads to gas-trapping may 
be detected as enlarged airspaces reflected by elevated ADC.  This is one of the first studies 
to spatially compare 3He ADC to gas-trapping measurements.  This novel finding is in 
agreement with other studies that demonstrated gravitational37,38 and lung volume effects39 
on pulmonary ADC values.  This also suggests that abnormally elevated ADC may not 
always reflect emphysematous abnormalities in COPD patients.  There were also spatial 
correlations in mild and moderate COPD patients in whom 3He MRI ventilation defects 
were spatially related to PRM-gas-trapping.  In contrast, in the small group of seven severe 
COPD patients, MRI ventilation defects were spatially related to both PRM-gas-trapping 
and emphysema identified using SOCCT and SOCMRI.   The rationale for performing the 
SOC analysis in both directions was the need to evaluate the overlap of 3He defects within 
PRM regions (SOCCT) and the overlap of PRM voxels within 3He defects (SOCMRI).  While 
the quantitative results showed differences between the two methods, this was not due to 
non-symmetry between registering from the fixed to moving image because we performed 
registration in a symmetric manner to mitigate this potential bias.40,41  It was important to 
perform the spatial overlap analysis in both directions because the results showed that in 
severe COPD, PRM emphysema voxels were mainly occupied by ventilation defect voxels 
and in contrast, ventilation defect voxels were mainly occupied by PRM gas-trapping 
voxels.   This means that both PRM emphysema and gas-trapping voxels are spatially 
coincident with ventilation defects.  This exciting result provides, for the first time, a deeper 
understanding of the source of ventilation defects and gas-trapping in COPD.  We think 
these findings underscore the importance of phenotyping COPD patients with quantitative 
imaging.  Future work should aim to determine the spatial relationships between 
continuous pixel wise data and PRM, as this may provide a better understanding of these 
relationships.  
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Numerous studies have used paired inspiratory/expiratory lung CT-images42-44 to provide 
COPD phenotypes.  In COPD subjects, gas-trapping is influenced by both emphysema and 
small-airways disease43,45 for which PRM attempts to differentiate.  In addition, severe 
small-airways disease sometimes appears on CT as emphysema, making it challenging to 
delineate between the two phenotypes.  Regardless, here we determined the different 
relationships between MRI and CT phenotypes of COPD across GOLD grades of severity.  
We think these results underscore the need to adopt multimodality approaches to deeply 
phenotype COPD patients so that the independent contributions of emphysema and airways 
disease may be ascertained, which may help to optimize COPD therapy and improve 
outcomes. 
In summary, in all ex-smokers, ventilation defects and ADC were correlated with PRM-
gas-trapping and emphysema measurements. In a subset of ex-smokers with mild-moderate 
COPD, ventilation defects were quantitatively and spatially related to PRM-gas-trapping 
whereas in severe COPD, there were spatial and quantitative relationships for ventilation 
defects with both PRM-gas-trapping and emphysema. 
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2.6 Supplement  
2.6.1 Materials and Methods 
2.6.1.1 Study Subjects 
We recruited participants from a local tertiary care centre and by advertisement.  Briefly, 
inclusion criteria comprised ambulatory males and females with a previous clinical 
diagnosis of COPD, aged 50-90 with a smoking history >10 pack-years.  Exclusion criteria 
included claustrophobia, current smoker, body mass index >40 and any MRI 
contraindications (i.e. metal/electronic/magnetic implants).  All participants were 53-88 
years (mean age=73±9yrs) of age (male: mean age=73±9yrs, age range=55-88yrs; female: 
mean age=71±7yrs, age range=53-84yrs; p=.4).  In a single two hour visit, participants 
underwent the following evaluations in the same order: 1) salbutamol administration, 2) 
spirometry, 3) plethysmography and DLCO, 4) inspiration and expiration CT, and, 5) MRI.  
COPD subjects were classified according to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) grades.1 
2.6.1.2 Pulmonary Function 
Post-bronchodilator plethysmography and spirometry were performed using a body 
plethysmograph (MedGraphics Corporation, St. Paul, Minnesota, USA) to measure the 
forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and static lung 
volumes including total lung capacity (TLC), inspiratory capacity (IC), residual volume 
(RV), and functional residual capacity (FRC).  The diffusing capacity of lung for carbon 
monoxide (DLCO) was also determined using the attached gas analyzer.  Measurements 
were performed according to the American Thoracic Society (ATS) guidelines.2 
2.6.1.3 MR Image Analysis 
3He static ventilation images were segmented using a k-means approach that classifies 
voxel intensity values into five clusters ranging from signal void (cluster 1[C1] or VDV) 
and hypo-intense (cluster 2 [C2]) to hyper-intense signal (cluster 5 [C5]), therefore 
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generating a gas distribution cluster-map.  The delineation of the ventilation defect 
boundaries was performed using a seeded region-growing algorithm that segmented the 1H 
MRI thoracic cavity, as previously described.3 
3He MRI ADC values were determined using a custom-built algorithm using MATLAB 
R2014b (MathWorks, Natick, Massachusetts, USA). To ensure that ADC were generated 
for voxels corresponding to ventilated lung regions, a k-means clustering algorithm,3 was 
applied to the non-diffusion weighted images to obtain a binary mask for each slice. The 
resulting binary masks were applied to the corresponding non-diffusion weighted images, 
and the ADC maps were generated on a voxel-by-voxel basis according to Equation 2-1: 
 𝐴𝐴𝑉𝑉𝐹𝐹 = 1
𝑏𝑏
ln �𝑆𝑆0
𝑆𝑆
� (2-1) 
where S0 is the segmented non-diffusion weighted image, S is the diffusion-weighted 
image, and b=1.6s/cm2. 
2.6.1.4 CT Image Analysis 
PRM measures were generated by co-registering inspiratory and expiratory images using 
an affine method followed by a deformable step provided in the NiftyReg package4 which 
is ranked among the top registration algorithms for thoracic CT.5  The affine registration 
step was performed on a coarse-to-fine scheme to achieve both accuracy and computational 
efficiency.  Voxel-wise comparisons were performed, where co-registered inspiration and 
expiration images were imported into MATLAB and voxels classified into four categories 
based on expiration and inspiration thresholds as previously described:6 1) inspiration >-
950HU and expiration >-856HU (normal-tissue), 2) inspiration >-950HU and expiration 
<-856HU (gas-trapping), 3) inspiration <-950HU and expiration <-856HU (emphysema), 
and, 4) inspiration <-950HU and expiration >-856HU.  As previously described,6 the fourth 
category of voxels were hypothesized to reflect noise in the data due to registration error 
because previously, these did not correlate with FEV1, FEV1/FVC, or RA950. 
 72 
 
2.6.1.5 MRI-to-CT Spatial Overlap 
3He MRI was registered to 1H MRI using a landmark-based approach3 and 1H MRI was 
registered to expiratory CT using deformable registration via the modality-independent-
neighbourhood-descriptor (MIND) method, previously shown suitable for cross-modality 
image registration.7  The deformation field was applied to the 3He MRI slices for MRI-to-
CT co-registration.  The deformable registration consisted of voxel-wise similarity 
measurements of MIND of the two images, rather than the image themselves, as well as 
diffusion regularization of the deformation field and optimization using the Gauss-Newton 
framework.  The registration was performed with three-levels (down-sampling factor of 4, 
2, and 1) in a symmetric manner so that the algorithm was not dependent on the choice of 
moving or fixed image.   
Spatial overlap for 3He ventilation defects and PRM voxels was evaluated using the spatial 
overlap coefficient (SOC), which is the intersection of 3He ventilation defect and PRM 
voxels expressed as a fraction of the total number of CT PRM voxels (SOCCT) or 3He MRI 
ventilation defect voxels (SOCMRI).  The rationale for performing spatial overlap 
measurements in this manner was to determine the contribution of 3He defect voxels within 
PRM gas-trapped or emphysema regions.  The spatial overlap of PRM voxels within 3He 
defect regions (SOCMRI) was also evaluated to determine the contribution of PRM (gas-
trapping and/or emphysema) to 3He ventilation defects.  CT and 3He images were evaluated 
once because the CT analysis was fully-automated and MRI semi-automated segmentation 
method was previously reported3 to provide high inter- and intra-observer reproducibility.  
In total, CT and MR image analysis per subject was completed in approximately one hour. 
2.6.1.6 Statistics 
The variables considered were based on univariate relationships.  The unstandardized ß 
coefficients were reported and show how a single-unit change in the independent variable 
influenced a change in the dependent variable.  We also reported the standardized ß 
coefficients, expressed in units of standard deviation (SD) and these showed the 
independent variable with the greatest ß coefficient reflecting the greatest relative effect on 
the dependent variable.  Multi-co-linearity was evaluated using the variance inflation factor 
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(VIF) and deemed acceptable when <10.8  For spatial overlap coefficients, significant 
differences were measured using paired t-tests.  Results were considered significant when 
the probability of two-tailed type I error (α) was less than 5% (p<.05). 
2.6.2 Discussion 
2.6.2.1 Limitations 
The limitations of spirometry have motivated us and others to continue developing thoracic 
imaging methods including ventilation MRI and CT-PRM measurements to better 
phenotype patients using direct and regional measurements of the underlying disease.9  
Spirometry measurements of FEV1 and FEV1/FVC are reproducible and inexpensive, but 
these provide only a global measure of lung function that is dominated by larger airway 
function.  For this reason, pulmonary function tests are relatively insensitive to early 
disease stages.10  In addition, FEV1 and FEV1/FVC are relatively poor surrogates of COPD 
symptoms11 and other outcomes perhaps because disease heterogeneity derives from the 
pathological features of COPD, including parenchyma destruction (emphysema) and 
airway remodeling (airways disease), which also differ in individual patients with the same 
FEV1.1,12      
We recognize that this study has a number of limitations.  First, this work was limited by 
the relatively small study group and the fact that we mainly evaluated ex-smokers with 
mildly abnormal and normal spirometry.  This was prospectively planned and driven by 
our interest to investigate very early or mild disease, but given our understanding of the 
heterogeneity of COPD patients, we must be cautious about extrapolating our results.  We 
must also acknowledge that the results generated here were not compared with results 
stemming from commercially available software such as Apollo Workstation 2.0 (VIDA 
Diagnostics Inc., Coralville, Iowa, USA) or Lung Density Analysis software (IMBIO, 
Minneapolis, Minnesota, USA). It should be noted that any potential differences would 
likely stem from the different image registration/warping algorithms used because the 
density thresholds used are generally the same.  Registration errors pose a challenge that 
has been previously reported for PRM in the liver13 and we caution that registration errors 
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would result in tissue misclassification because PRM analysis relies heavily on voxel-by-
voxel comparisons.  Notably, in the parametric-response-maps generated here, there was 
consistent scattering of misclassified voxels and this underscores the need for optimized 
thoracic CT registration techniques to minimize these effects.  We recognize that MRI-CT 
registration error will certainly affect the analysis of spatial agreement.  For this reason, we 
used a pulmonary MRI-CT deformable registration method7 previously described as highly 
suitable for cross-modality image registration and which achieved significantly better 
results than other methods, such as normalized mutual information.7  Differences between 
PRM and 3He may be related to the fact that PRM measurements are inherently more 
indirect as these are based on the abnormal presence of air due to both emphysema and 
airways disease.  In contrast, inhaled gas methods provide static snapshots of regional 
ventilation.  In advanced COPD, ventilation defects have been previously shown to reflect 
both emphysema and airways disease,9 whereas in mild asthma, ventilation defects were 
shown to be directly related to abnormal airway wall thickening or airways disease.14  
Similar to four-dimensional CT,15 Fourier decomposition MRI16 and paired 
inspiratory/expiratory CT,17-19 PRM exploits the image signal differences from inspiration 
and expiration as air moves in and out and tissue contracts and expands.  All these 
approaches rely on either computational or intuitive co-registration of inspiratory and 
expiratory CT and assume that the abnormal presence of air can be regionally related to 
emphysema and/or functional small airways disease.  Finally, hyperpolarized 3He MRI is 
still limited to a few research facilities worldwide and is unlikely to be translated clinically 
due to the depleted global supply of 3He.  However, with recent improvements in 129Xe 
polarization20 and the development of 19F MRI,21 inhaled gas MRI may yet be considered 
for regulatory approval and future clinical workflows. 
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CHAPTER 3 
3 FREE-BREATHING PULMONARY 1H AND 
HYPERPOLARIZED 3HE MRI: COMPARISON IN 
COPD AND BRONCHIECTASIS 
To better understand the potential for Fourier-decomposition MRI (FDMRI) to provide 
quantitative endpoints for COPD and bronchiectasis subjects, we developed and evaluated 
pulmonary ventilation abnormalities derived from free-breathing 1H MRI.  We 
quantitatively and qualitatively compared these measurements to those derived from 3He 
MRI and pulmonary function tests. 
The contents of this chapter were previously published in the journal Academic Radiology: 
DPI Capaldi, K Sheikh, F Guo, S Svenningsen, R Etemad-Rezai, HO Coxson, JA Leipsic, 
DG McCormack, and G Parraga. Acad Radiol 2015; 22(3):320-329.  Permission to 
reproduce this article was granted by Elsevier Publishing and is provided in Appendix A.  
3.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is diagnosed and disease severity stratified 
based on not fully reversible airflow obstruction measured using spirometry.  Airflow 
obstruction, symptoms, and exercise capacity measurements in COPD are related to both 
parenchyma destruction (emphysema) and airway remodeling (airways disease and 
bronchiectasis).1,2  While spirometry is relatively easy to implement, reproducible, and 
inexpensive, it can only provide a global measure of lung function and is weakly predictive 
of COPD progression, as well as insensitive to early disease stages.3-5  The limitations of 
spirometry measurements of COPD have motivated the development of thoracic imaging 
approaches to provide direct and regional measurements of the underlying pathological 
features of COPD - airways disease and emphysema.  
High resolution computed tomography (HRCT) is the clinical imaging tool of choice for 
visualizing and quantifying airways disease6,7 and emphysema8-10 in COPD patients.  
Emphysema can be quantified automatically based on thresholds of the CT density 
histogram (<-950 Hounsfield units [HU]).8,10,11  Thoracic CT estimates of airways disease 
can also be generated using measurements of airway wall area percent (WA%) and lumen 
area (LA).  Indirect measurements of airways disease include CT measurements of gas 
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trapping using densitometry thresholds (-856HU) on expiratory CT images12 or parametric 
response maps (PRM) using co-registered inspiratory and expiratory CT.13  Finally, 
bronchiectasis can be readily observed in thoracic CT in up to 50% of patients with severe 
COPD,14,15 and this is typically identified by enlarged bronchial diameters and evidence of 
significant mucous plugging.   
Pulmonary magnetic resonance imaging (MRI) using inhaled hyperpolarized 3He or 129Xe 
gas also provides a way to visualize regional ventilation abnormalities and lung 
microstructure in subjects with COPD.16-25  Ventilation abnormalities may be quantified 
using the ventilation defect percent (VDP), that represents the volume of ventilation defects 
normalized to the thoracic cavity.24,26  While rapid (8-15s acquisition time) and well-
tolerated, inhaled noble gas MRI is dependent on polarized gas and multinuclear MR 
hardware.  An alternative approach that exploits Fourier decomposition of free-breathing 
pulmonary MRI (FDMRI) was first developed by Bauman and colleagues at 1.5T.27  This 
method provides a way to generate quantitative pulmonary maps of ventilation and 
perfusion using fast pulmonary MRI acquisitions of free-breathing 1H MRI and non-rigid 
registration.27-33  FDMRI was recently compared and validated with SPECT-CT28 and 3He 
MRI30 in a porcine model.   
Until now, FDMRI has not been evaluated in COPD or bronchiectasis subjects, nor at 3T 
where there is diminished signal intensity at higher field strengths due to T2* effects.34  
Hence, our objective was to generate FDMRI (first developed at 1.5T) and 3He MRI 
ventilation measurements acquired at 3T in subjects with COPD or bronchiectasis.  We 
hypothesized that ventilation defects measured using FDMRI and 3He MRI would be 
spatially and quantitatively correlated in subjects with COPD and those with 
bronchiectasis. 
3.2 Materials and Methods 
3.2.1 Study Subjects 
All subjects were previously diagnosed with COPD or bronchiectasis by a pulmonologist 
and provided written informed consent to the study protocol approved by a local research 
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ethics board and Health Canada.  COPD subjects were classified according to the Global 
initiative for chronic Obstructive Lung Disease (GOLD) grades.1  COPD subjects were ex-
smokers between 50 to 80 years of age and with a smoking history of ≥ 10 pack-years (the 
number of packs of cigarettes smoked per day multiplied by the number of years the patient 
has smoked).  Subjects with bronchiectasis were ex-smokers (n=4) and never-smokers 
(n=10) between 40 to 85 years of age.  An expert chest radiologist (>20y experience) 
qualitatively examined CT data for evidence of bronchiectasis and emphysema. 
3.2.2 Pulmonary Function Tests 
Spirometry and whole body plethysmography was performed using a body plethysmograph 
(MedGraphics Corporation, St. Paul, Minnesota, USA) to measure the forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC) and static lung volumes 
including total lung capacity (TLC), inspiratory capacity (IC), residual volume (RV), and 
functional residual capacity (FRC), airways resistance (RAW), and the diffusing capacity of 
lung for carbon monoxide (DLCO) using the attached gas analyzer.  All measurements were 
performed according to the American Thoracic Society (ATS) guidelines.35 
3.2.3 Image Acquisition 
MRI was performed with a whole-body 3T Discovery MR750 system (General Electric 
Health Care [GEHC], Milwaukee, Wisconsin, USA) capable of performing multinuclear 
imaging.  All MR images were acquired in the coronal slice orientation.  Conventional 1H 
MRI was performed 5 minutes prior to hyperpolarized 3He MRI.  Subjects were instructed 
to maintain normal tidal breathing and then from functional residual capacity (FRC) inhale 
a 1.0L mixture of 4He/N2.  For the purposes of this study and in order to aid direct 
comparisons, all MRI and CT images were acquired at FRC+1.0L in order for consistency.  
By having all subjects inhale 1.0L of gas after passive expiration, we ensured consistent 
lung volumes across all imaging methods.  We also note that in order to truly capture the 
same lung volume consistently, our approach of using a measured volume for inhalation is 
straightforward and easily undertaken even supine in the CT or MR scanner.  1H MRI was 
acquired with subjects in breath-hold position using a whole-body radiofrequency coil and 
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a 1H fast spoiled gradient-recalled echo (FGRE) sequence with a partial echo (total data 
acquisition time=12s; repetition time [TR]/echo time [TE]/flip-angle=4.3ms/1.0ms/30°; 
field-of-view [FOV]=40×40cm2; matrix=128×80 [zero-padded to 128×128]; partial echo 
percent=62.5%; bandwidth [BW]=62.50kHz; number of excitations [NEX]=1; number of 
slices=14; slice thickness=15mm).  For all MRI breath-hold maneuvers, oxygen saturation 
(SPO2) was continuously monitored using a digital pulse oximeter. 
Hyperpolarized 3He MRI was performed using a single channel rigid elliptical transmit-
receive chest coil (RAPID Biomedical, Rimpar, Wuerzburg, Germany).  A polarizer 
system (HeliSpin; Polarean, Durham, North Carolina, USA) was utilized to polarize the 
3He gas, which achieved polarization levels of approximately 40%.  Doses of 5mL/kg of 
body weight were diluted with medical-grade N2 gas (Spectra Gases, Branchburg, New 
Jersey, USA) and administered in 1.0L Tedlar bags (Jensen Inert Products, Coral Springs, 
Florida, USA).  Hyperpolarized 3He ventilation images were acquired with subjects in 
breath-hold position after inspiration of a 1.0L 3He/N2 mixture using a fast gradient-
recalled echo method with a partial echo (total data acquisition time=10s; TR/TE/flip-
angle=3.8ms/1.0ms/7°; FOV=40×40cm2; matrix=128×80 [zero-padded to 128×128]; 
partial echo percent=62.5%; BW=62.50kHz; NEX=1; number of slices=14; slice 
thickness=15mm).  The flip angle was determined using a constant flip angle approach 
where flip angle (α) depends on the number of phase encoding steps (Y-gradient steps).  
Thus, 𝛼𝛼 = tan−1 �2/𝑁𝑁, where N was a number of Y-gradient steps.  Therefore for this 
pulse sequence, where there are 128 Y-gradient steps, a 7.12° flip angle was used.  
Hyperpolarized 3He diffusion-weighted images were acquired using a FGRE sequence 
with centric k-space sampling (total data acquisition time=14s; TR/TE/flip-
angle=6.8ms/4.5ms/8°; FOV=40×40cm2; matrix=128×128; BW=62.50kHz; NEX=1; 
number of slices=7; slice thickness=30mm).  Two interleaved images were acquired with 
and without additional diffusion sensitization (G=1.94G/cm; b=1.6s/cm2; rise-and-fall 
time=0.5ms; gradient duration=0.46ms; diffusion time=1.46ms).   
Dynamic free tidal-breathing 1H MRI was acquired over a period of 125s at a rate of four 
frames per second using an optimized balanced steady state free precession sequence 
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(bSSFP) and respiratory bellows.  We used a fast imaging employing steady state pulse 
sequence (FIESTA, GEHC) with total data acquisition time=125s, TE/TR/flip-
angle=0.6ms/1.9ms/15°, FOV=40×40cm, matrix = 256×256, BW=250kHz, NEX=1, 
number of phases=500, slice thickness=15mm, and a 32-channel torso coil (GEHC).  A 
single coronal slice was obtained with slice thickness=15mm.   The number of phases refers 
to the number of images acquired from one specific location over time.  In other words, we 
acquired multiple frames of one single coronal slice over a certain time span.  The slice 
was prescribed on an axial localizer and was positioned slightly posterior to the cardiac 
silhouette in an effort to eliminate artifacts due to cardiac motion but allow visualization 
of the aorta. 
CT was acquired using a 64 slice Lightspeed VCT scanner (GEHC) at FRC+1.0L of N2 
gas using a spiral acquisition (detector configuration=64×0.625mm; peak x-ray tube 
voltage=120kVp; effective x-ray tube current=100mA; x-ray tube rotation time=500ms; 
pitch=1.0).  Image reconstruction was performed using a standard convolution kernel for 
1.25mm isotropic resolution. 
3.2.4 Image Analysis 
Segmentation of 3He MRI and FDMRI ventilation was performed using custom software 
generated using MATLAB R2013a (Mathworks, Natick, Massachusetts, USA), as 
previously described.26  3He MRI apparent diffusion coefficient (ADC) maps were 
generated as previously described.36  The relative area of the CT density histogram with 
attenuation values < -950HU (RA950) was determined using MATLAB R2013a 
(Mathworks).  Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, 
USA) was used to quantify WA% and lumen area LA.   
Image analysis of dynamic free-breathing 1H MRI was performed using MATLAB R2013a 
(Mathworks).  Non-rigid registration was used to co-register the temporal series of tidal-
breathing 1H MRI slices using a modality independent neighbourhood descriptor (MIND) 
deformable registration method.37  A specific reference image was used so that the 
corresponding lung volume was consistent with 3He MRI volumes.  Pulmonary voxel 
intensities from the registered free-breathing 1H MRI were aligned along a time axis and 
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discrete Fourier transforms were performed on the signal intensity oscillation pattern.  The 
frequency of the first ventilation harmonic (corresponding to the respiratory rate) was 
determined for every voxel, the magnitude of which was used to generate a ventilation 
map. 
The Dice Similarity Coefficient (DSC)38 was used to quantify the regional overlap for 3He 
MRI and FDMRI ventilation as well as the spatial relationship of CT RA950 density maps 
with FDMRI ventilation defect volume. 
3.2.5 Statistics 
Independent t-tests, tests for normality (determined with a Shapiro-Wilk test), and analysis 
of variance (ANOVA) with post-hoc analysis using the Holm-Bonferroni correction were 
performed using SPSS Statistics V22.0 (SPSS Inc., Chicago, Illinois, USA).  Pearson 
correlation coefficients (r) were used to determine the correlation between measurements 
using SPSS Statistics V22.0 (SPSS Inc.).  Measurement agreement was evaluated using 
the Bland-Altman method using GraphPad Prism V6.0 (GraphPad Software Inc., La Jolla, 
California, USA).  Correlation coefficients were compared using the Fisher z′ 
transformation for each r value.21  Results were considered significant when the probability 
of two-tailed type I error (α) was less than 5% (p<.05). 
3.3 Results 
Table 3-1 shows the demographic and pulmonary function test measurements for all 
subjects (69±10yrs) as well as the 12 COPD (67±9yrs) and 14 bronchiectasis subjects 
(70±11yrs).  For COPD subjects, three were GOLD grade I, four were GOLD grade II, and 
five were GOLD grades III/IV.  CT evidence of emphysema only was reported in seven 
COPD subjects and there was CT evidence of both emphysema and bronchiectasis in five 
COPD subjects. 
  
 83 
 
Table 3-1 Subject demographic and pulmonary function measurements 
Mean (±SD) All (n=26) 
Bronchiectasis  
(n=14) 
COPD 
(n=12) 
Sig Dif  
(p) 
Age yrs  69 (10) 70 (11) 67 (9) .5 
Male n 11 4 7 -- 
BMI kg·m-2 25 (4) 23 (4) 27 (4) .02 
Pack years 31 (40) 4 (10) 63 (39) <.001 
FEV1 %pred  64 (22) 68 (22) 60 (23) .4 
FVC %pred 82 (22) 73 (20) 91 (22) .04 
FEV1/FVC % 60 (16) 70 (12) 50 (14) .001 
TLC %pred 107 (18) 98 (14) 117 (16) .003 
RV/TLC % 51 (10) 54 (11) 49 (9) .3 
RAW %pred  138 (41) 135 (48) 141 (33) .7 
DLCO %pred 57 (19) 60 (18) 53 (21) .3 
Sig Dif: Significant difference between subgroups (p<.05) determined by ANOVA; SD: 
standard deviation; %pred: percent of predicted value; BMI: body mass index; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; TLC: total lung capacity; 
RV: residual volume; RAW: airways resistance; DLCO: diffusing capacity of lung for carbon 
monoxide. 
Figure 3-1 shows coronal FDMRI and 3He MRI ventilation registered to the 1H MRI of 
the thorax, as well as RA950 and 3He ADC maps for two representative COPD and two 
representative bronchiectasis subjects.  As shown in Figure 3-1, for all four subjects there 
were qualitatively similar ventilation patterns derived from FDMRI and 3He MRI.  In 
COPD subjects, regional ventilation defects were also qualitatively similar to regional 
emphysema apparent in the RA950 density maps and the brighter regions of 3He MRI ADC 
maps. 
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Figure 3-1 Ventilation and CT imaging for representative COPD and bronchiectasis 
subjects 
FDMRI in magenta co-registered with 1H MRI. 3He MRI static ventilation in aqua co-
registered with 1H MRI.  CT density masks where yellow = attenuation < -950 Hounsfield 
units (RA950) and 3He MRI ADC maps, both reflective of emphysema for COPD subjects 
(S1 and S2) and Bronchiectasis subjects (S3 and S4). 
Table 3-2 provides imaging measurements for COPD and bronchiectasis subjects.  FDMRI 
(94±4%) and 3He MRI (79±12%) ventilation measurements were significantly different 
(p<.001).  FDMRI VDP (6±4%) was also significantly different than 3He MRI VDP 
(21±12%) (p<.001).  As expected, 3He MRI ADC was significantly greater in COPD as 
compared to bronchiectasis subjects (p<.001) and all CT measurements (RA950, WA%, and 
LA) were significantly greater in COPD as compared to bronchiectasis subjects.  
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Table 3-2 Imaging measurements 
Mean (±SD) All (n=26) 
Bronchiectasis 
(n=14) 
COPD 
(n=12) 
Sig Dif  
(p) 
FDMRI Ventilation % 94 (4) 95 (3) 93 (6) .3 
3He MRI Ventilation % 79 (12) 82 (9) 76 (14) .2 
FDMRI VDP % 6 (4) 5 (3) 7 (6) .3 
3He MRI VDP % 21 (12) 18 (9) 24 (14) .2 
3He MRI ADC cm2/s 0.35 (0.13) 0.27 (0.05) 0.43 (0.12) <.001 
CT RA950 % 5 (7) 2 (3) 9 (8) .005 
CT WA % 57 (2) 58 (2) 56 (2) .009 
CT LA mm2 46 (14) 40 (10) 53 (15) .01 
Sig Dif: significant difference between groups (p<.05) by ANOVA; SD: standard 
deviation; VDP: ventilation defect percent; ADC: apparent diffusion coefficient; RA950: 
relative area of the lung with attenuation values <-950HU; WA: wall area; LA: lumen area. 
Figure 3-2 shows the linear correlation of FDMRI with 3He MRI VDP and the agreement 
between measurements for both COPD and bronchiectasis subjects.  Although FDMRI and 
3He MRI VDP were significantly different, as shown in Table 3-2, these measurements 
were strongly correlated in COPD (r=.88, p=.0001), but not bronchiectasis subjects (r = .1, 
p>.05).  Bland-Altman analysis showed a bias of -16±9% (-35%-5% 95% CI) for FDMRI 
(Figure 3-2) and this bias increased with increasing VDP for COPD subjects.  FDMRI 
VDP was also strongly correlated with RA950 (r=.80, p=.002) and 3He MRI ADC (r=.71, 
p=.01) for COPD subjects, both of which are well-established measurements of 
emphysema.8,16 
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Figure 3-2 Correlations for FDMRI with 3He MRI and CT RA950 
A) FDMRI VDP linear regression with 3He MRI VDP (COPD: r=.88, r2=.78, p=.0001, 
y=0.35x–1.07 and Bronchiectasis: r=-.1, r2=.009, p>.05, y=-0.03x+5.92)  
B) Bland-Altman analysis of agreement for FDMRI and 3He MRI VDP (COPD: bias=-
16±9%, lower limit=-35%, upper limit=2%; Bronchiectasis: bias=-13±10%, lower limit=-
32%, upper limit=6%).  
C) FDMRI VDP linear regression with CT RA950 (COPD: r=.80, r2=.64, p=.002, 
y=0.59x+2.10; Bronchiectasis: r=-.23, r2=.05, p>.05, y=-.21x+5.85) 
D) FDMRI VDP linear regression with 3He MRI ADC (COPD: r=.71, r2=.51, p=.01, 
y=28x+5; Bronchiectasis: r=.16, r2=.03, p>.05, y=9.4x+2.9).  
Dotted lines =95% confidence intervals. 
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Given the strong correlation between FDMRI and 3He MRI VDP for COPD subjects, we 
evaluated the spatial relationships for ventilation and ventilation defects derived from using 
both these methods.  These data are shown in Table 3-3 and for representative COPD (S1 
and S2) and bronchiectasis subjects (S3 and S4) in Figure 3-3.  Table 3-3 provides mean 
DSC for FDMRI and 3He MRI ventilation and ventilation defects.  The DSC for FDMRI 
and 3He MRI ventilation was 86% for both subject groups.  In a similar fashion, the spatial 
overlap of FDMRI ventilation with lung regions >-950HU was 92% and 93% for COPD 
and bronchiectasis subjects respectively.  For ventilation defects, the spatial relationship of 
FDMRI and 3He MRI ventilation defects was 20±17% and 14±9% for COPD and 
bronchiectasis subjects respectively.  In COPD subjects, the DSC for FDMRI ventilation 
defects with lung regions <-950HU, reflective of emphysema was 19±20%.  For 
bronchiectasis subjects, the spatial overlap of FDMRI and lung regions <-950HU (2±3%) 
was significantly lower than the spatial overlap of FDMRI and 3He MRI ventilation defects 
(20±17%) (p<.001). 
Table 3-3 Quantitative spatial relationships for FDMRI Ventilation and Ventilation 
defects 
Mean DSC (±SD) All (n=26) 
Bronchiectasis 
(n=14) 
COPD 
(n=12) 
Sig Dif  
(p) 
Ventilation      
  FDMRI–3He MRI % 86 (5) 86 (4) 86 (7) .8 
  FDMRI–RA>950 % 92 (3) 93 (2) 92 (3) .5 
Ventilation Defects     
  FDMRI–3He MRI % 16 (13) 14 (9) 20 (17) .2 
  FDMRI–RA950 % 10 (16) 2 (3) 19 (20) .005 
Sig Dif: Significant difference between groups (p<.05) by ANOVA; DSC: Dice Similarity 
Coefficient; VDP: ventilation defect percent; ADC: apparent diffusion coefficient; RA950: 
relative area <-950HU; RA>950: relative area >-950HU. 
Some of these spatial relationships are also shown in Figure 3-3, where the regional 
similarities of FDMRI with 3He static ventilation images are visually apparent for COPD 
subjects S1 and S2 and less obvious for bronchiectasis subjects S3 and S4.  In particular 
for the bronchiectasis subjects, there is little evidence of emphysema and therefore there is 
negligible overlap between RA950 and ventilation defects.  
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Figure 3-3 Spatial relationship of FDMRI with 3He MRI ventilation and emphysema for 
representative subjects with COPD and Bronchiectasis 
Left panel: Spatial overlap (green) of FDMRI (purple) and 3He MRI (aqua) ventilation co-
registered with 1H MRI and airway tree in brown. Right panel: Spatial overlap (green) of 
FDMRI (purple) ventilation defects and RA950 mask (yellow) co-registered with CT for 
COPD subjects S1 and S2 and Bronchiectasis subjects S3 and S4.   
Dice coefficients for FDMRI–3He MRI ventilation: S1=88%, S2=86%, S3=91%, S4=84% 
and FDMRI defects–RA950: S1=41%, S2=56%, S3=1%, S4=0%. 
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Table 3-4 summarizes the significant correlations for FDMRI VDP with 3He MRI, CT, 
and pulmonary function measurements for the COPD and bronchiectasis subgroups.  There 
were significant correlations for FDMRI VDP with 3He MRI VDP and ADC, RAW and 
RA950 (p<.05) for COPD subjects.  For bronchiectasis subjects there was a significant 
correlation between FDMRI VDP and LA (p<.05).  For COPD subjects, the FDMRI and 
3He MRI VDP correlations were not significantly different; however, for bronchiectasis 
subjects, there were significant differences. 
Table 3-4 Pearson Correlations for FDMRI and 3He MRI 
 FDMRI VDP % 3He MRI VDP % Fisher z′ 
 Bronchiectasis (n=14) 
COPD 
(n=12) 
Bronchiectasis 
(n=14) 
COPD 
(n=12) B C 
 r/p r/p r/p r/p p p 
FEV1 %pred .41/.1 -.22/.5 -.73/.003 -.42/.2 .001 .6 
FVC %pred .31/.3 .20/.5 -.60/.02 -.04/.9 .02 .7 
RV/TLC % -.31/.3 -.19/.6 .65/.02 -.07/.8 .01 .8 
RAW %pred -.23/.4 .60/.04 .47/.09 .56/.06 .08 .9 
DLCO %pred .08/.8 -.57/.05 -.36/.2 -.61/.04 .3 .9 
FDMRI Ventilation % ~-1/<.001 ~-1/<.001 .1/.7 -.88/<.001 <.001 <.001 
FDMRI VDP % --/-- --/-- -.1/.7 .88/<.001 -- -- 
3He MRI Ventilation % .1/.7 -.88/<.001 ~-1/<.001 ~-1/<.001 <.001 <.001 
3He MRI VDP % -.10/.7 .88/<.001 --/-- --/-- -- -- 
3He MRI ADC (cm2/s) .16/.6 .71/.01 .35/.2 .76/.004 .6 .8 
CT RA950 % -.23/.4 .80/.002 -.04/.9 .72/.008 .6 .7 
CT WA % -.35/.2 -.07/.8 .29/.3 -.18/.6 .1 .8 
CT LA mm2 .58/.03 .43/.2 -.09/.7 .59/.04 .08 .6 
r: Pearson correlation coefficients; %pred: percent of predicted value; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; RV/TLC: residual 
volume/total lung capacity; RAW: airways resistance; DLCO: Diffusing capacity for carbon 
monoxide; VDP: ventilation defect percent; ADC: apparent diffusion coefficient; RA950: 
relative area of the lung with attenuation < -950HU; WA: wall area; LA: lumen area. 
3.4 Discussion 
In this proof-of-concept study, we evaluated 26 patients including 12 subjects with COPD 
and another 14 with bronchiectasis and observed: 1) in all subjects, FDMRI VDP was 
significantly less than 3He MRI VDP, 2) in COPD but not bronchiectasis subjects, FDMRI 
and 3He MRI ventilation and VDP were quantitatively correlated and these values showed 
strong spatial relationships with one another and with RA950 maps, and, 3) in COPD 
subjects only there were significant and similar correlations for FDMRI and 3He MRI VDP 
with pulmonary function test and CT measurements. 
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In all subjects, FDMRI VDP was significantly less than 3He MRI VDP.  It is difficult to 
completely understand why FDMRI VDP was significantly less and FDMRI ventilation 
was significantly greater than 3He MRI measurements in all subjects.  However, one 
explanation may be derived from the underlying principles of the two methods and how 
they generate or capture ventilation information.  Inhaled contrast gas methods provide 
static breath-hold snapshots of where the high contrast inhaled gas travels to and resides 
during the scanning period of 8-15s.  In this manner, very high contrast and signal-to-noise 
ventilation images can be easily generated and processed.  In contrast, but similar to four-
dimensional CT (4DCT) which produces three-dimensional image datasets through 
time,39,40 FDMRI generates ventilation contrast based on image signal differences during 
the breathing cycle as air enters and leaves the pulmonary system and tissue contracts and 
expands.  This is a more indirect approach that relies on robust and accurate image 
processing methods to co-register the dynamic free tidal-breathing 1H MRI.  This method 
also relies on the inherent image signal intensity and signal-to-noise ratios of pulmonary 
images from a system that is inherently air-filled.  In CT, the attenuation values for air as 
compared to tissue provide significant contrast.  However, the contrast derived from the 
1H signal changes are inherently weak, and this certainly necessitates that the image 
processing methods used must be more complex and robust.  Previous work41 explored the 
spatial and quantitative relationship of 3He MRI and 4DCT ventilation measurements in a 
proof of concept demonstration in a small number of non-small cell lung cancer patients.  
There was excellent spatial correspondence for the ventilation maps derived using static 
MRI and free-breathing CT imaging approaches with no significant differences in 
ventilation.  These results provided good evidence that ventilation maps and measurements 
generated using vastly different image acquisition and analysis methods as well as 
breathing maneuvers provided similar regional and quantitative ventilation information.   
It is important to note that 3He MRI ventilation percent and VDP are not independent 
measurements since these simply sum to 100%.  However, because here we are directly 
comparing VDP which is a relatively small volume and ventilation which is a large volume 
for both FD and 3He MRI, we think it’s important to use and compare both values.  This is 
especially important in order to show spatial relationships such as the Dice coefficient that 
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is highly dependent on the relative size of the comparators.  We think this is also important 
because the 3He ventilation MRI depicts gas distribution, whereas, FDMRI ventilation 
reflects the ventilation fundamental frequency and signal intensity changes related to this 
value.  Because of this, spatial overlap analyses were conducted for both ventilation maps 
and ventilation defect maps obtained using both 3He and FDMRI. 
In COPD, but not bronchiectasis subjects, FDMRI and 3He MRI ventilation were 
quantitatively and spatially related.  In addition, FDMRI and 3He MRI VDP were 
quantitatively correlated and showed strong spatial relationships with RA950 maps – those 
regions that reflected emphysematous destruction or air in CT images.  We were surprised 
to observe such differences in the spatial and quantitative correlations for FDMRI and 3He 
MRI in COPD as compared to bronchiectasis subjects.  One explanation can be derived 
from the presence of thick mucus (which appears as greater 1H signal intensity relative to 
that of parenchyma tissue) in the airways and parenchyma in bronchiectasis that may lead 
to registration error.  To generate FDMRI ventilation images, registration algorithms must 
account for the movement of the diaphragm and any registration error will result in regions 
of high signal intensity (e.g. mucus pooling in bronchiectasis subjects) oscillating at the 
same frequency as respiration.  This registration error can result in apparently increased 
ventilation, which may or may not accurately reflect truly ventilated regions.  Thus, in 
bronchiectasis subjects, there may be regions that appear as ventilated in FDMRI that are 
in fact not ventilated due to misalignment of the mucus’ boundaries via the deformable 
registration process.  We must acknowledge that all three imaging methods measure very 
different physical parameters.  For example, while CT provides a measurement of regional 
lung tissue density, 3He MRI provides a functional estimate of pulmonary ventilation and 
alveolar dimensions using diffusion-weighted imaging.  FDMRI on the other hand, 
provides an estimate of ventilation by quantifying the signal intensity contributions 
throughout the compression and expansion of the lung parenchyma via the cardiac and the 
respiratory cycles.  However, we recently showed that in COPD subjects, 3He MRI 
ventilation defects often co-localize with large emphysematous bullae.42  In fact, we 
previously observed this in patients with advanced emphysema and because of this work 
hypothesized that this spatial co-localization was related to the long time constants for 
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filling of emphysematous bullae and not airways disease.  Here and in light of these 
previous findings, we directly evaluated the spatial co-localization of emphysematous 
regions with FDMRI and 3He MRI ventilation defects.  The spatial relationships observed 
for FDMRI and 3He MRI ventilation defects with RA950 in the current study suggest that 
in patients with emphysema, ventilation defects generated using FDMRI may also be 
derived to the long time-constants for lung filling.  Our findings further support the notion 
that these methods (i.e. FDMRI, 3He MRI, and CT), though very different, are probing and 
interrogating similar functional but likely not structural information in COPD subjects.  It 
appears that a free-breathing method like FDMRI, shows some dependence on the very 
long time constants for filling emphysematous bullae, and this finding should be considered 
when using FDMRI for COPD imaging. 
Finally, in COPD subjects only, there were significant and similar correlations for FDMRI 
and 3He MRI VDP with pulmonary function test and CT measurements.  These are 
important findings that further support and suggest that both methods provide similar 
functional information in COPD subjects even though they are different methods.  In 
contrast, for bronchiectasis subjects, there was a significant correlation between FDMRI 
VDP and airway lumen area.  This suggests that elevated lumen area (corresponding to 
dilated airways) may be related to low proton density. 
We recognize and acknowledge that this work was limited by the relatively small sample 
size.  In addition, we studied mainly subjects with moderate COPD (8/12 subjects with 
GOLD grade II or III) and given our understanding of the heterogeneity of COPD patients, 
caution should be used when extrapolating our results to a broader COPD group. Fourier 
decomposition has recently emerged as a pulmonary functional MRI method, with the 
promise of serial lung function measurements without a dependence on polarized or other 
inhaled gases or multinuclear capabilities.  This opens up the opportunity for functional 
lung imaging on conventional MRI scanners - available more universally, albeit the final 
measurements are dependent on more sophisticated image processing methods.  It should 
be noted that one of the challenges associated with pulmonary proton MRI methods, is the 
weak pulmonary proton signal intensity that is further diminished at higher field strengths 
because of the relationship between field-strength and T2* effects.  Previous pilot and 
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development studies at 1.5T, have shown qualitative agreement for regional ventilation and 
perfusion measurements with the clinical reference standard SPECT/CT.28  Moreover, 
recent studies have also demonstrated the reproducibility of FDMRI ventilation- and 
perfusion-weighted images in healthy volunteers.32  Finally FDMRI-to-3He MRI 
comparisons in animals showed similar regional abnormalities including pulmonary 
embolism, atelectasis, and air trapping.30   
To our knowledge, there has been no prospective comparison of FDMRI with 3He MRI at 
3T in subjects with COPD and bronchiectasis.  Consistent with previous studies we showed 
similar regional ventilation abnormalities using FDMRI and 3He MRI in COPD subjects 
and these appear to be dominated by the presence of regional emphysematous bullae.  In 
summary, FDMRI and 3He MRI ventilation and VDP were strongly correlated in COPD, 
but not bronchiectasis subjects.  In COPD subjects only, FDMRI ventilation defects were 
also spatially related with 3He MRI ventilation defects and CT measurements of 
emphysema. 
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CHAPTER 4 
4 FREE-BREATHING FUNCTIONAL PULMONARY 
MRI: RESPONSE TO BRONCHODILATOR AND 
BRONCHOPROVOCATION IN SEVERE ASTHMA 
Based on the free-breathing pulmonary 1H MRI approach developed in Chapter 3, we 
wanted to determine the potential application for Fourier-decomposition MRI in 
evaluating ventilation heterogeneity in patients with severe asthma, both pre- and post-
salbutamol as well as post-methacholine challenge.  We qualitatively and quantitatively 
compared these measurements to those derived from 3He MRI. 
The contents of this chapter were previously published in the journal Academic Radiology: 
DPI Capaldi, K Sheikh, RL Eddy, F Guo, S Svenningsen, P Nair, DG McCormack, and G 
Parraga for the Canadian Respiratory Research Network. Acad Radiol 2017; 
24(10):1268-1276.  Permission to reproduce this article was granted by Elsevier 
Publishing and is provided in Appendix A.  
4.1 Introduction 
Asthma is a chronic and often debilitating airways disease, characterized by intermittent 
worsening of breathlessness, cough, chest-tightness and wheeze and is typically diagnosed 
based on spirometry measurements of bronchodilator reversibility1 or response to 
methacholine challenge2 using the forced expiratory volume in one second (FEV1).3  While 
current asthma therapies were developed based on FEV1 improvements,4 this measurement 
of airflow limitation is relatively insensitive to small airway obstruction,5,6 which  is 
believed to be the main sight of inflammation and airway remodeling (or pre modeling) in 
asthma.7  For many children and adults with asthma, disease control remains elusive and a 
recent survey identified that over 90% of Canadian asthmatics reported poorly-controlled 
disease and nearly half did not participate in any exercise of any type due to asthma 
symptoms.8  This unacceptable disease morbidity and the large and growing number of 
asthma patients of all ages has motivated the development of pulmonary imaging 
approaches to generate new and more sensitive biomarkers of small airway dysfunction.  
To date however, it has been complex to utilize such imaging biomarkers in the 
development of new therapies in clinical trials9 or to guide therapy decisions in individual 
patients.   
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In asthmatics, thoracic computed tomography (CT) can be used to provide asthma 
biomarkers of gas-trapping,10 airway remodeling11 such as airway wall thickening and 
lumen narrowing,12 and dynamic changes in ventilation using xenon-enhanced dual energy 
CT.13  Although ultra-low dose CT methods using iterative adaptive reconstruction 
methods are now under development,14 because of radiation dose concerns, the clinical use 
of CT in asthmatics has been limited, especially in mild disease and in children.15-17  Other 
examples include positron emission tomography (PET)18 and single photon emission 
computed tomography (SPECT),19,20 both of which have been used in the research setting 
to evaluate regional ventilation heterogeneity in asthmatics.18-20 
Magnetic resonance imaging (MRI) methods also provide a way to measure lung structure 
and function.  In particular, inhaled-noble gas MRI ventilation defects21-27 were shown to 
be spatially persistent over time,21 related to airway abnormalities,22 worsened in response 
to bronchoconstriction23 and improve post-bronchodilator.24  Inhaled-gas MRI ventilation 
defects also correlate with pulmonary function measurements,25,26 CT evidence of gas-
trapping,26 disease severity,22,25 inflammation,22 and asthma control.27  Other examples 
include oxygen-enhanced T1 mapping of ventilation patterns in asthmatics28,29 and a 
number of conventional 1H MRI methods.30-35  For example, 1H signal intensity at different 
lung volumes may be used to estimate regional ventilation30 and was recently compared 
with hyperpolarized 3He MRI.31   Fourier decomposition 1H MRI (FDMRI) is another 
approach32 that generates ventilation and perfusion maps in free-breathing participants in 
about two minutes using balanced steady state free precession pulse sequences without 
cardiac or respiratory gating.  FDMRI ventilation defects were previously observed to be 
spatially related to SPECT-CT defects33 and 3He MRI ventilation defects in animal 
models34 and COPD patients.35   
To our knowledge, FDMRI has not been evaluated in patients with severe asthma, and this 
is important because FDMRI may be an important tool for evaluating ventilation and 
perfusion abnormalities in asthmatics in whom repeated CT is not clinically acceptable and 
at centres where multinuclear MRI is not available.  Therefore, here our objective was to 
directly compare FDMRI with 3He MRI VDP in severe and poorly controlled asthmatics.  
Based on previous results,24,35 we hypothesized that FDMRI VDP would be quantitatively 
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related to 3He MRI VDP and show similar responses to both methacholine and salbutamol 
in patients with severe asthma. 
4.2 Materials and Methods 
4.2.1 Study Logistics and Participants 
Sixteen asthmatics (49±10yrs) provided written informed consent to ethics board approved 
and Health Insurance Portability and Accountability Act compliant protocols 
(https://clinicaltrials.gov NCT02351141, NCT02263794).  We enrolled patients between 
18 and 70 years of age with a diagnosis of severe asthma, according to the Global Initiative 
for Asthma (GINA),1 from two academic tertiary care centres (Robarts Research Institute, 
Western University, London, Canada; Firestone Institute for Respiratory Health, McMaster 
University, Hamilton, Canada).  All participants underwent pulmonary function tests, 
multiple breath gas washout, dynamic free-breathing 1H, static 1H and hyperpolarized 3He 
MRI, at baseline and 20 minutes after salbutamol administration, within a single two-hour 
visit.  Asthmatics with FEV1 > 70%predicted also underwent methacholine challenge (MCh), 
as per American Thoracic Society (ATS) guidelines2 with MRI performed at the 
provocative concentration that lowered FEV1 by 20% (PC20) and 20 minutes post-
salbutamol after MCh test completion. 
4.2.2 Spirometry, Plethysmography and Multiple Breath Nitrogen 
Washout 
Spirometry and whole body plethysmography were performed using a MedGraphics Elite 
Series plethysmograph (MedGraphics Corporation, St. Paul, Minnesota, USA), according 
to ATS guidelines36 before and after administration of four separate doses of 100μg of 
salbutamol (Apo-Salvent CRC Free Inhalation Aerosol Apotex, Toronto, Ontario, Canada) 
through a pressurized metered dose inhaler using an AeroChamber Plus spacer (Trudell 
Medical International, London, Canada).  Methacholine challenge was performed 
according to ATS guidelines2 using the two-minute tidal breathing method up to and 
including PC20 using an AeroEclipse II Breath Actuated Nebulizer (Trudell Medical 
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International).  After PC20 imaging was completed, salbutamol was administered.  During 
MCh only, spirometry was performed using a handheld ndd EasyOne spirometer (ndd 
Medizintechnik AG, Zurich, Switzerland).  Multiple breath gas washout was performed 
using the ndd EasyOne Pro LAB system (ndd Medizintechnik AG, Zurich, Switzerland) 
equipped with an ultrasonic flow and molar mass sensor to measure the lung clearance 
index (LCI), as previously described.27 
4.2.3 Image Acquisition 
MRI was performed in a single two-hour visit at baseline, post-MCh and post-salbutamol 
in those participants in whom MCh could be safely completed; in all others, MRI was 
performed at baseline and post-salbutamol.  MRI was performed on a whole body 3 Tesla 
Discovery MR750 (General Electric Health Care [GEHC], Milwaukee, Wisconsin, USA) 
system with broadband imaging capability.37  All images were acquired in the coronal 
plane.  Static breath hold 1H MRI was acquired with subjects in breath hold using a whole 
body radiofrequency coil38 and fast spoiled gradient recalled echo (FGRE) sequence with 
a partial echo (total-acquisition-time=16s; repetition-time[TR]/echo-time[TE]/flip-
angle=4.7ms/1.2ms/30°;field-of-view [FOV]=40×40cm2, bandwidth[BW]=24.4kHz; 
matrix=128×80 [zero-padded to 128×128]; partial-echo-percent=62.5%; number-of-
slices=15-17; slice-thickness=15mm, 0-gap).  Hyperpolarized 3He static ventilation MRI 
was performed using a single channel, rigid elliptical transmit/receive chest coil (RAPID 
Biomedical GmbH, Wuerzburg, Germany) and two dimensional multi-slice FGRE 
sequence with a partial echo during a single breath-hold (total-acquisition-time=10s; 
TR/TE/flip-angle=3.8ms/1.0ms/7°; FOV=40×40cm2, BW=48.8kHz; matrix=128×80 
[zero-padded to 128×128]; partial-echo-percent=62.5%; number-of-slices=15-17; slice-
thickness=15mm, 0-gap).  Polarization was approximately 40% using a commercial 
polarizer system (HeliSpin, Polarean, Durham, North Carolina, USA.  All breath hold 
maneuvers were performed with the subject instructed to inhale a 1.0L gas mixture from a 
Tedlar® bags (Jensen Inert Products, Coral Springs, Florida, USA) after passive expiration 
(functional residual capacity [FRC]).37  Hyperpolarized 3He gas was diluted with medical 
grade N2 (Spectra Gases, Newark, New Jersey, USA) and delivered in a 1.0L Tedlar® bag.  
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Oxygen saturation (SPO2) was continuously monitored using a digital pulse oximeter for 
all breath hold maneuvers.  
Dynamic free breathing 1H MRI was acquired for a single coronal slice using a 32 channel 
torso coil (GEHC) including respiratory bellows to monitor the patient’s respiratory rate 
using an optimized balanced steady state free precession (bSSFP) sequence (total-
acquisition-time=125s; TR/TE/flip-angle=1.9ms/0.6ms/15°; FOV=40×40cm2; 
BW=250kHz; matrix=256×256; number-of-slices=1; slice-thickness=15mm; number-of-
excitations=1; number-of-phases=500).35 
4.2.4 Image Analysis 
Ventilation abnormalities were quantified using the ventilation defect percent (VDP) which 
is the ventilation defect volume (VDV) normalized to the thoracic cavity volume (TCV).  
Hyperpolarized inhaled noble gas MR ventilation images were segmented and registered 
to the 1H MRI thoracic cavity as previously described38 by a single observer with four years 
segmentation experience.  Briefly, 3He MR static ventilation images were segmented using 
a k-means approach that classified voxel intensity values into five clusters (signal 
void=cluster 1 [C1] or VDV, hypo-intense=cluster 2 [C2] to hyper-intense signal=cluster 
5 [C5]) to generate cluster maps.   
Figure 4-1 provides a schematic of the approach used to generate and quantify FDMR 
ventilation images using MATLAB R2016a (Mathworks).35  Dynamic free breathing 1H 
MR images were co-registered to a reference with lung volume consistent with inhaled-gas 
MRI volume (FRC+1L) using a modality independent neighbourhood descriptor (MIND) 
deformable registration method.39  Discrete fast Fourier transforms were performed on the 
signal intensity oscillation pattern generated from the pulmonary voxel intensities in the 
co-registered free breathing 1H images.  The magnitude of the first ventilation harmonic 
(which corresponded to the respiratory rate) was determined for each and every voxel and 
this was used to generate the FDMR ventilation image.  Figure 4-1 also shows the 
schematic of FDMRI semi-automated segmentation method where the reference 1H MRI 
was segmented to generate the thoracic volume using a continuous max-flow segmentation 
algorithm and hierarchical k-means clustering was used to segment the FDMR ventilation 
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images into the same five clusters used to segment the hyperpolarized inhaled noble gas 
ventilation images.38 
 
Figure 4-1 FDMRI ventilation map and analysis pipelines 
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A) Schematic for FDMRI ventilation map generation: i) co-registered MRI aligned along 
the time axis; ii) oscillating signal intensity pattern upon which discrete fast Fourier 
transforms performed; iii) magnitude of the frequency of the first ventilation harmonic 
determined for every voxel; iv) FDMRI ventilation maps generated. 
B) Schematic of FDMRI VDP semi-automated segmentation: Anatomical 1H MRI 
segmented, k-means VDP segmentation where cluster 1 (C1) = ventilation-defects, clusters 
2-to-5 (C2-C5) = hypo-intense-to-hyper-intense ventilation. 
4.2.5 Statistics 
The Shapiro-Wilk test was used to determine the normality of the data and when data were 
not normally distributed, non-parametric tests were performed.  Differences between time-
points were determined using Wilcoxon signed rank paired t-test for non-parametric data.  
A repeated measures ANOVA was performed to investigate treatment (baseline, post MCh, 
and post salbutamol) and measurement (3He MRI and FDMRI) effects and the Mauchly’s 
test of sphericity was used to test the assumption of sphericity.  Relationships were 
determined using Spearman coefficients (ρ).  Agreement between imaging methods were 
determined using the Bland-Altman method.40  All statistics were performed using SPSS 
Statistics V24.0 (SPSS Inc., Chicago, Illinois, USA).  Results were considered significant 
when the probability of two-tailed type I error (α) was less than 5% (p<.05) 
4.3 Results 
4.3.1 Patient Characteristics 
Table 4-1 shows participant demographic information as well as pulmonary function test 
measurements, asthma medication, and asthma control measurements for 16 asthmatics 
(49±10yrs) including seven patients with severe disease (50±10yrs) and nine patients with 
severe and uncontrolled1 disease (49±11yrs).  For the nine patients with poorly-controlled 
disease, ACQ score was significantly greater (p=.01), although they were prescribed 
maximal, guideline-based therapies including long acting β2 agonists (LABA) and high-
dose inhaled corticosteroids (ICS).1 
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Table 4-1 Asthma demographics, medication, control and pulmonary function tests 
Mean (±SD) Asthma All (n=16) Severe (n=7) Severe Uncontrolled (n=9) 
Age yrs  49 (10) 50 (10) 49 (11) 
Male n 6 2 4 
BMI kg·m-2 28 (4) 28 (5) 28 (4) 
FEV1 %pred  66 (24) 64 (19) 68 (28) 
FVC %pred 84 (14) 85 (12) 83 (16) 
FEV1/FVC % 61 (15) 59 (14) 63 (17) 
RV %pred 140 (35) 142 (27) 139 (42) 
TLC %pred 106 (13) 104 (13) 108 (14) 
RV/TLC % 43 (10) 46 (7) 41 (11) 
FRC %pred 115 (25) 120 (20) 111 (29) 
RAW %pred 170 (61) 161 (45) 176 (74) 
LCI 9.2 (2.6)† 9.8 (2.6) 8.6 (3.7)~ 
ACQ score 2.0 ± 1.2† 1.2 (0.6) 2.6 (1.2)~ 
AQLQ score 5.0 ± 1.4† 5.8 (0.8) 4.4 (1.5)~ 
mMRC dyspnea score 0.9 ± 0.7 0.7 (0.8) 1.0 (0.8) 
Borg dyspnea 1.4 ± 1.5 0.6 (0.7) 2.1 (1.7) 
ICS n [%] 16 [100] 7 [100] 9 [100] 
OCS n [%] 6 [40] 2 [29] 4 [44] 
SABA n [%] 14 [93] 6 [86] 8 [89] 
LABA n [%] 16 [100] 7 [100] 9 [100] 
SAMA n [%] 3 [20] 1 [14] 2 [22] 
LAMA n [%] 4 [27] 1 [14] 3 [33] 
Anti-IgE n [%] 3 [20] 1 [14] 2 [22] 
LTRA n [%] 7 [47] 3 [43] 4 [44] 
%pred=percent-of-predicted-value; BMI=body-mass-index; FEV1=forced-expiratory-
volume-in-one-second; FVC=forced-vital-capacity; RV=residual-volume; TLC=total-
lung-capacity; FRC=functional-residual-capacity; RAW=airways-resistance; LCI=lung-
clearance-index; ICS=Inhaled Corticosteroids; OCS=Oral Corticosteroid; SABA=Short-
Acting β2-Agonist; LABA=Long-Acting β2-Agonist; SAMA=Short-Acting 
Anticholinergic; LAMA=Long-Acting Anticholinergic; Anti-IgE=Anti-immunoglobulin 
E; LTRA=Leukotriene Receptor Antagonists; ACQ=Asthma Control Questionnaire; 
AQLQ=Asthma Quality of Life Questionnaire; mMRC=modified Medical Research 
Council; †n=15; ~n=8. 
4.3.2 Ventilation Response to Salbutamol 
Figure 4-2 shows centre coronal 3He MRI and FDMRI slices for participant S8 with severe 
uncontrolled asthma (56yr old male, FEV1=37%pred) and another participant, S4 with 
severe asthma (57yr old female, FEV1=52%pred).  Pre-salbutamol, there were numerous and 
large inhaled gas MRI and FDMRI ventilation defects in both patients and these 
qualitatively improved, post-salbutamol.  As shown in Table 4-2 and Figure 4-2, for all 
asthmatics, VDP significantly decreased (3He MRI p=.02 and FDMRI; p=.02) post-
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salbutamol. Table 4-2 also provides lung clearance index as well as MRI VDP 
measurements for all 16 patients. 
Table 4-2 Subject listing of hyperpolarized inhaled gas MRI, FDMRI and multiple breath 
gas washout measurements for each time-point 
 Pre-Salbutamol PC20 Post-Salbutamol 
 3He FD LCI 3He FD LCI 3He FD LCI 
 VDP (%)  VDP (%)  VDP (%)  
Severe 
S1 3.6 0.7 7.7 5.2 1.6 -- 2.6 1.5 7.3 
S2 7.0 7.6 9.5 -- -- -- 3.3 5.5 10.1 
S3 2.2 0.6 6.7 -- -- -- 2.4 1.7 6.1 
S4 9.1 4.9 13.5 -- -- -- 7.4 2.6 13.2 
S5 17.0 1.6 11.7 -- -- -- 17.5 1.2 9.7 
S6 10.3 2.3 11.9 -- -- -- 9.6 1.3 10.8 
S7 1.0 0.6 7.4 -- -- -- 0.5 0.7 7.7 
   Mean 7.2 2.6 9.8 5.2 1.6 -- 6.2 2.1 9.3 
   ±SD 5.6 2.7 2.6 -- -- -- 5.9 1.6 2.4 
Severe-Uncontrolled 
S8 27.7 7.9 17.5 -- -- -- 24.2 5.4 15.5 
S9 5.2 0.2 8.6 6.0 8.1 -- 7.0 1.5 8.2 
S10 1.9 0.2 7.1 8.0 5.3 -- 1.8 1.5 7.7 
S11 2.9 4.9 7.1 -- -- -- 2.4 3.3 6.6 
S12 2.1 1.2 6.2 15.8 5.9 -- 1.2 0.2 6.5 
S13 3.2 1.5 6.4 -- -- -- 3.1 0.7 6.4 
S14 32.1 4.7 -- -- -- -- 17.2 5.1 -- 
S15 5.7 9.0 7.5 -- -- -- 5.7 6.1 7.4 
S16 14.6 1.6 8.7 -- -- -- 3.5 0.3 8.8 
   Mean 10.6 3.5 8.6 10.0 6.4 -- 7.4 2.7 8.4 
   ±SD 11.6 3.3 3.7 5.1 1.5 -- 8.0 2.3 3.0 
LCI=lung-clearance-index; VDP=ventilation-defect-percent: PC20=Provocative-
concentration that decreased the forced-expiratory-volume-in-one-second (FEV1) by 20%. 
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Figure 4-2 Ventilation MRI for severe and severe-uncontrolled asthmatics 
A) Hyperpolarized inhaled gas (cyan) and FDMRI (magenta) for a representative severe 
asthmatic (female, age=57yrs, baseline FEV1=52%pred, post-salbutamol FEV1=60%pred) 
and severe-uncontrolled asthmatic (male, age=56yrs, baseline FEV1=37%pred, post-
salbutamol FEV1=36%pred) at baseline and post-salbutamol. Yellow arrows show 
ventilation defect spatial relationships.   
B) Box and whisker plot (box=25th to 75th percentile; whiskers=minimum to maximum) 
for VDP baseline and post-salbutamol for 3He MRI (n=12, baseline VDP=11.1±10.1%, 
post-salbutamol VDP=8.1±7.6%, p=.02) and FDMRI (n=12, baseline VDP=3.9±3.0%, 
post-salbutamol VDP=2.8±2.1%, p=.02). 
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4.3.3 Ventilation Response to Methacholine Challenge and Salbutamol 
Rescue 
Figure 4-3 shows centre coronal MRI slices for a representative participant S1 (45yr old 
female, FEV1=95%pred, severe uncontrolled asthma) who underwent MCh.  There was 
qualitatively greater 3He MR and FDMR ventilation abnormalities post-MCh and these 
decreased post-salbutamol.  It is also important to point out that FDMRI ventilation defects 
were qualitatively less visibly obvious compared to 3He MRI defects.  As shown in Table 
4-2, 3He VDP and FDMRI VDP significantly increased (worsened) at PC20 (n=4; baseline: 
3He VDP=3±1%, FDMRI VDP=1±0.2%; methacholine: 3He VDP=9±2%, FDMRI 
VDP=5±2%) and significantly decreased post-salbutamol (3He VDP=3±1%, FDMRI 
VDP=2±1%, all p=.02), and there was a significant difference between imaging methods 
for these VDP differences (p=.01). 
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Figure 4-3 Methacholine Challenge 
A) Representative severe asthmatic centre coronal slice 3He MRI (cyan) and FDMRI 
(magenta) female, age=45yrs, baseline FEV1=95%pred, PC20=0.123mg/mL, post-
salbutamol FEV1=101%pred at baseline (3He VDP=3.6%, FDMRI VDP=0.7%), post-MCh 
(3He VDP=5.2%, FDMRI VDP=1.6%), and post-salbutamol (3He VDP=2.6%, FDMRI 
VDP=1.5%). 
B) Box and whisker plot (box=25th to 75th percentile; whiskers=minimum to maximum) 
for 3He MRI VDP and FDMRI VDP at baseline (n=4, 3He VDP=3.2±0.8%, FDMRI 
VDP=0.6±0.2%), post-MCh (n=4, 3He VDP=8.8±2.4%, FDMRI VDP=5.1±1.5%) and 
post-salbutamol (n=4, 3He VDP=3.1±1.3%, FDMRI VDP=1.2±0.7%). 
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4.3.4 Relationships and Agreement 
Figure 4-4 shows the relationships of FDMRI and 3He MRI VDP and their agreement.  
While FDMRI VDP was correlated with 3He MRI VDP (ρ=.61, p=.01), Bland-Altman 
analysis showed a significant bias of -6.0±8.6% (95% limit of agreement: -23% to 11%).  
Table 4-3 summarizes the significant correlations for 3He MRI and FDMRI VDP with LCI 
and other pulmonary function measurements.  There were significant relationships for 
FDMRI VDP with 3He MRI VDP (ρ=.61, p=.01) as well as with FRC (ρ=.61, p=.01), RV 
(ρ=.54, p=.04), and RAW (ρ=.57, p=.02) but not with LCI (ρ=.49, p=.06), FEV1 (ρ=-.45, 
p=.08), or FEV1/FVC (ρ=-.43, p=.09). 
Table 4-3 Relationship for hyperpolarized inhaled gas MRI and FDMRI with pulmonary 
function and LCI 
 Spearman ρ (p)  
 3He MRI VDP % FDMRI VDP % 
  (n=16)  (n=16) 
FEV1 %pred -.78 (.0006) -.45 (.08) 
FVC %pred -.53 (.03) -.43 (.09) 
FEV1/FVC % -.75 (.001) -.38 (.1) 
RV %pred .45 (.08) .51 (.04) 
TLC %pred .19 (.5) .35 (.2) 
RV/TLC % .46 (.07) .28 (.3) 
FRC %pred .72 (.002) .61 (.01) 
RAW %pred .80 (.0004) .57 (.02) 
LCI .85 (.0001)# .49 (.06)# 
3He MRI VDP % -- .61 (.01) 
FDMRI VDP % .61 (.01) -- 
ρ=Spearman-correlation-coefficients; %pred=percent-of-predicted-value; FEV1=forced-
expiratory-volume-in-one-second; FVC=forced-vital-capacity; RV=residual-volume; 
TLC=total-lung-capacity; FRC=functional-residual-capacity; RAW=airways-resistance; 
LCI=lung-clearance-index; VDP=ventilation-defect-percent; #n=15. 
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Figure 4-4 Relationships for FDMRI with 3He MRI 
A)  FDMRI VDP was significantly correlated with 3He MRI VDP (n=16, ρ=.61, p=.01, 
y=0.1x+1.9).   
B)  Bland-Altman analysis of agreement for FDMRI with 3He MRI VDP (n=16, bias=-
6.0±8.6%, lower limit=-22.9%, upper limit=10.8%). 
Dotted lines indicate the 95% confidence intervals. 
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4.4 Discussion 
In a recent survey,8 the vast majority of asthma patients described their asthma as poorly 
controlled and nearly half reported that asthma symptom severity limited day-to-day 
activities or regular exercise.  This dire situation reflects a lack of sensitive and specific 
asthma biomarkers that may be used to guide asthma treatment in individual patients or 
used as intermediate endpoints in clinical trials of new treatments.  We and others9 think 
that biomarkers of ventilation heterogeneity and imaging biomarkers in particular may 
provide one solution to this challenging problem.  In this regard, here we evaluated 
ventilation heterogeneity in a proof-of-concept study in 16 patients with severe and severe 
with poorly-controlled asthma and observed: 1) FDMRI and 3He MRI VDP significantly 
decreased post-salbutamol, 2) both FDMRI and 3He MRI VDP significantly increased in 
response to methacholine and decreased post-bronchodilator, and, 3) FDMRI VDP was 
significantly correlated with 3He MRI VDP but also significantly underestimated VDP 
relative to 3He MRI VDP.  
Ventilation defect measurements generated using FDMRI and 3He MRI significantly 
responded to salbutamol and methacholine.  Previous work also showed that 3He MRI VDP 
significantly improved post-salbutamol in mild to moderate asthmatics.24  However, to our 
knowledge, this is the first study to investigate FDMRI, 3He MRI and LCI measurements 
of ventilation heterogeneity in asthmatics with severe disease.  Salbutamol-dependent 
airway smooth muscle relaxation and dilation is reflected by increased asthmatic airway 
calibre and this is believed to result in decreased ventilation heterogeneity measured using 
LCI and inhaled gas MRI.24  Importantly, FDMRI results observed here suggest that the 
inhaled-gas MRI static ventilation maps and dynamic free breathing FDMRI ventilation 
maps provide similar but not the same functional information in asthmatics.  Differences 
in the functional information measured using inhaled-gas MRI and FDMRI may stem from 
the airway abnormalities themselves and the different time constants for lung filling that 
are the consequence of these airway abnormalities.  For example, in asthmatics, inhaled-
gas MRI ventilation defects reflect lung regions with long time constants for filling that are 
beyond the 10-15s acquisition time of scanning.  In contrast, multi-breath free-breathing 
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FDMRI ventilation defects reflect airway and parenchyma abnormalities35 that do not fill 
during a much longer, two minute acquisition window, similar to previous work using 
multi-breath wash-in inhaled gas MRI.41 
In four patients who could safely undergo methacholine challenge, FDMRI and 3He MRI 
VDP significantly changed in response to both methacholine and salbutamol.  To our 
knowledge, this is the first time FDMRI ventilation maps have been evaluated during 
methacholine challenge and the responses were comparable with 3He MRI VDP measured 
here, and previously described.23  Previous work in mild-moderate asthmatics using 
diffusion-weighted 3He MRI suggested that ventilation defects captured at PC20 may be 
due to air trapping induced by methacholine.42  To support this notion, in another study, air 
trapping induced using a balloon catheter in a porcine model was also detected using both 
FDMRI and 3He MRI.34  Based on these previous results34 and the current investigation, 
FDMRI ventilation defects measured post-methacholine challenge, likely stem from hyper-
responsive and constricted airways which is an important translational finding for asthma 
centres that don’t have access to inhaled-gas MRI. 
While FDMRI and 3He MRI VDP were correlated, there was a bias toward lower FDMRI 
VDP and this was also previously observed in COPD patients.35  Given what we know 
about the time constants for lung filling and the fact that the inhaled gas methods capture 
a 10-15s snapshot and free breathing MRI methods capture abnormalities over at least two 
minutes of breathing, these differences are intuitively reasonable.35  The bias or 
underestimate of FDMRI VDP relative to 3He MRI VDP may be a result of the differences 
in how these two methods generate or capture ventilation information.  Inhaled gas 
methods capture a 10-15s snapshot where very high contrast and signal-to-noise ventilation 
images can be easily generated.  In contrast, free breathing MRI methods capture 
abnormalities over at least two minutes of breathing where the ventilation contrast is 
generated by the signal differences during the breathing cycle as tissue contracts and 
expands due to air entering and leaving the pulmonary system.  These results provide 
evidence that these two different methods of generating MR ventilation maps, although 
different, may probe and interrogate similar lung functional information related to regions 
of airway remodeling/hyper-responsiveness and gas-trapping.  Regardless, MR ventilation 
 114 
 
maps, generated using different methods, provide similar lung functional information 
related to regions of airway remodeling/hyper-responsiveness and gas trapping.  
We recognize a number of study limitations, including the small number of patients 
evaluated.  We also focused on severe asthmatics and those with poor control in order to 
capture information relevant to an important clinical problem and, because of this, the vast 
majority of patients were unable to perform methacholine challenge.  An inherent 
limitation of pulmonary 1H MRI is the low signal intensity due to intrinsically low proton 
density and T2* effects43 but recent research44 that exploits shorter echo times may 
overcome this challenge.  We also acknowledge that different imaging parameters 
(FDMRI=single 2D slice time series and 3He MRI=multi-slice 2D acquisition) may limit 
the generalizability of a direct comparison between methods.  While complex image-
processing methods are required for FDMRI and these still require standardization and 
validation, newly developed MR acquisition methods44 will enhance translational 
potential. 
In summary, FDMRI VDP was less sensitive to methacholine and salbutamol, and under-
estimated VDP as compared to 3He MRI.  While newly improved MR acquisition 
methods44 will enhance translational potential, FDMRI is currently limited to single slice 
acquisitions and the complex image-processing methods needed still require 
standardization and validation.   Nevertheless, new functional biomarkers of asthma that 
can be acquired on conventional MR scanners are crucially needed to help understand and 
guide treatment decisions in those asthmatics in whom maximal, guideline based care has 
not improved disease severity or control. 
  
 115 
 
4.5 References 
(1) Global Initiative for Asthma. Global Strategy for Asthma Management and 
Prevention, <www.ginasthma.org> (2016). 
(2) Crapo, R. O. et al. Guidelines for methacholine and exercise challenge testing-
1999. This official statement of the American Thoracic Society was adopted by the 
ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: 309-
329. 
(3) Busse, W. W. Asthma diagnosis and treatment: filling in the information gaps. J 
Allergy Clin Immunol 2011; 128: 740-750. 
(4) Gjevre, J. A., Hurst, T. S., Taylor-Gjevre, R. M. & Cockcroft, D. W. The American 
Thoracic Society’s spirometric criteria alone is inadequate in asthma diagnosis. 
Can Respir J 2006; 13: 433-437. 
(5) Burgel, P. R. The role of small airways in obstructive airway diseases. Eur Respir 
Rev 2011; 20: 23-33. 
(6) Macklem, P. T. & Mead, J. Resistance of central and peripheral airways measured 
by a retrograde catheter. J Appl Physiol 1967; 22: 395-401. 
(7) Tulic, M. K., Christodoulopoulos, P. & Hamid, Q. Small airway inflammation in 
asthma. Respir Res 2001; 2: 333-339. 
(8) The Lung Association. Asthma Control in CanadaTM Survey 2016, 
<http://mb.lung.ca/file_download/2c91f259-3586-48d9-8496-63530f7f4c9a> 
(2016). 
(9) Trivedi, A. et al. Using imaging as a biomarker for asthma. Journal of Allergy and 
Clinical Immunology 2017; 139: 1-10. 
(10) Newman, K. B., Lynch, D. A., Newman, L. S., Ellegood, D. & Newell, J. D. 
Quantitative Computed-Tomography Detects Air Trapping Due to Asthma. Chest 
1994; 106: 105-109. 
(11) Aysola, R. S. et al. Airway Remodeling Measured by Multidetector CT Is Increased 
in Severe Asthma and Correlates With Pathology. Chest 2008; 134: 1183-1191. 
(12) Little, S. A. et al. High resolution computed tomographic assessment of airway wall 
thickness in chronic asthma: reproducibility and relationship with lung function and 
severity. Thorax 2002; 57: 247-253. 
(13) Kim, W. W. et al. Xenon-enhanced dual-energy CT of patients with asthma: 
dynamic ventilation changes after methacholine and salbutamol inhalation. AJR Am 
J Roentgenol 2012; 199: 975-981. 
 116 
 
(14) Gordic, S. et al. Ultralow-dose chest computed tomography for pulmonary nodule 
detection: first performance evaluation of single energy scanning with spectral 
shaping. Invest Radiol 2014; 49: 465-473. 
(15) Smith-Bindman, R. et al. Use of Diagnostic Imaging Studies and Associated 
Radiation Exposure for Patients Enrolled in Large Integrated Health Care Systems, 
1996-2010. Jama-Journal of the American Medical Association 2012; 307: 2400-
2409. 
(16) de Gonzalez, A. B. et al. Projected Cancer Risks From Computed Tomographic 
Scans Performed in the United States in 2007. Archives of Internal Medicine 2009; 
169: 2071-2077. 
(17) Smith-Bindman, R. et al. Radiation Dose Associated With Common Computed 
Tomography Examinations and the Associated Lifetime Attributable Risk of 
Cancer. Archives of Internal Medicine 2009; 169: 2078-2086. 
(18) Venegas, J. G. et al. Self-organized patchiness in asthma as a prelude to 
catastrophic shifts. Nature 2005; 434: 777-782. 
(19) King, G. G., Eberl, S., Salome, C. M., Meikle, S. R. & Woolcock, A. J. Airway 
closure measured by a Technegas bolus and SPECT. American Journal of 
Respiratory and Critical Care Medicine 1997; 155: 682-688. 
(20) King, G. G., Eberl, S., Salome, C. M., Young, I. H. & Woolcock, A. J. Differences 
in airway closure between normal and asthmatic subjects measured with single-
photon emission computed tomography and technegas. American Journal of 
Respiratory and Critical Care Medicine 1998; 158: 1900-1906. 
(21) de Lange, E. E. et al. Changes in regional airflow obstruction over time in the lungs 
of patients with asthma: evaluation with 3He MR imaging. Radiology 2009; 250: 
567-575. 
(22) Svenningsen, S. et al. What are ventilation defects in asthma? Thorax 2014; 69: 63-
71. 
(23) Samee, S. et al. Imaging the lungs in asthmatic patients by using hyperpolarized 
helium-3 magnetic resonance: assessment of response to methacholine and exercise 
challenge. J Allergy Clin Immunol 2003; 111: 1205-1211. 
(24) Svenningsen, S. et al. Hyperpolarized (3) He and (129) Xe MRI: differences in 
asthma before bronchodilation. J Magn Reson Imaging 2013; 38: 1521-1530. 
(25) de Lange, E. E. et al. Evaluation of asthma with hyperpolarized helium-3 MRI: 
correlation with clinical severity and spirometry. Chest 2006; 130: 1055-1062. 
(26) Fain, S. B. et al. Evaluation of structure-function relationships in asthma using 
multidetector CT and hyperpolarized He-3 MRI. Acad Radiol 2008; 15: 753-762. 
 117 
 
(27) Svenningsen, S., Nair, P., Guo, F., McCormack, D. G. & Parraga, G. Is ventilation 
heterogeneity related to asthma control? Eur Respir J 2016; 48: 370-379. 
(28) Ohno, Y. et al. Oxygen-enhanced MRI vs. quantitatively assessed thin-section CT: 
pulmonary functional loss assessment and clinical stage classification of 
asthmatics. Eur J Radiol 2011; 77: 85-91. 
(29) Zhang, W. J. et al. Dynamic oxygen-enhanced magnetic resonance imaging of the 
lung in asthma -- initial experience. Eur J Radiol 2015; 84: 318-326. 
(30) Zapke, M. et al. Magnetic resonance lung function--a breakthrough for lung 
imaging and functional assessment? A phantom study and clinical trial. Respir Res 
2006; 7: 106. 
(31) Pennati, F. et al. Assessment of regional lung function with multivolume (1)H MR 
imaging in health and obstructive lung disease: comparison with (3)He MR 
imaging. Radiology 2014; 273: 580-590. 
(32) Bauman, G. et al. Non‐contrast‐enhanced perfusion and ventilation assessment of 
the human lung by means of fourier decomposition in proton MRI. Magn Reson 
Med 2009; 62: 656-664. 
(33) Bauman, G. et al. Pulmonary functional imaging: qualitative comparison of Fourier 
decomposition MR imaging with SPECT/CT in porcine lung. Radiology 2011; 260: 
551-559. 
(34) Bauman, G. et al. Lung ventilation‐and perfusion‐weighted Fourier decomposition 
magnetic resonance imaging: In vivo validation with hyperpolarized 3He and 
dynamic contrast‐enhanced MRI. Magn Reson Med 2013; 69: 229-237. 
(35) Capaldi, D. P. et al. Free-breathing Pulmonary (1)H and Hyperpolarized (3)He 
MRI: Comparison in COPD and Bronchiectasis. Acad Radiol 2015; 22: 320-329. 
(36) Miller, M. R. et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. 
(37) Parraga, G. et al. Hyperpolarized 3He ventilation defects and apparent diffusion 
coefficients in chronic obstructive pulmonary disease: preliminary results at 3.0 
Tesla. Invest Radiol 2007; 42: 384-391. 
(38) Kirby, M. et al. Hyperpolarized 3He magnetic resonance functional imaging 
semiautomated segmentation. Acad Radiol 2012; 19: 141-152. 
(39) Heinrich, M. P. et al. MIND: Modality independent neighbourhood descriptor for 
multi-modal deformable registration. Medical Image Analysis 2012; 16: 1423-
1435. 
(40) Altman, D. G. Practical statistics for medical research.  (CRC press, 1990). 
 118 
 
(41) Hamedani, H. et al. Regional Fractional Ventilation by Using Multibreath Wash-in 
(3)He MR Imaging. Radiology 2016; 279: 917-924. 
(42) Costella, S. et al. Regional pulmonary response to a methacholine challenge using 
hyperpolarized (3)He magnetic resonance imaging. Respirology 2012; 17: 1237-
1246. 
(43) Yu, J., Xue, Y. & Song, H. K. Comparison of lung T2* during free‐breathing at 1.5 
T and 3.0 T with ultrashort echo time imaging. Magn Reson Med 2011; 66: 248-
254. 
(44) Bauman, G., Pusterla, O. & Bieri, O. Ultra-fast Steady-State Free Precession Pulse 
Sequence for Fourier Decomposition Pulmonary MRI. Magn Reson Med 2016; 75: 
1647-1653. 
 
 119 
 
CHAPTER 5 
5 FREE-BREATHING PULMONARY MR IMAGING TO 
QUANTIFY REGIONAL VENTILATION 
To further the potential application of free-breathing 1H MRI, we developed a whole-lung 
free-breathing pulmonary 1H MRI technique to measure regional specific-ventilation in 
patients with asthma and healthy-volunteers.  We compared these specific-ventilation 
measurements with hyperpolarized 3He MRI ventilation in healthy and asthmatic 
participants, and, determined the relationships between 1H MRI specific-ventilation and 
hyperpolarized 3He MRI and pulmonary function measurements. 
The contents of this chapter have been submitted to the journal Radiology: DPI Capaldi, 
RL Eddy, S Svenningsen, F Guo, JSH Baxter, AJ McLeod, P Nair, DG McCormack, and G 
Parraga and is accepted for publication in Radiology 2018 (in-press).  
5.1 Introduction 
Asthma is a chronic inflammatory airway disease,1 characterized clinically by an 
intermittent and unpredictable worsening of severe dyspnea and wheezing.  Asthma is 
diagnosed and monitored using the spirometry measurement of the forced-expiratory-
volume-in-one-second (FEV1).2  Although relatively inexpensive and straightforward to 
implement, spirometry only measures global airflow-obstruction, cannot provide regional 
information2,3 and it is inherently insensitive to the structural and functional abnormalities 
in the small airways4 where inflammation and remodeling occur.5  These limitations have 
motivated the development of pulmonary functional imaging approaches. 
To overcome some of these limitations, multi-detector computed-tomography (MDCT) of 
the chest has been used to quantify air-trapping6 and airway-remodeling7 in asthmatics.8-11   
Four-dimensional (4D) CT has also been used to quantify specific-ventilation,12 which is 
defined as tidal-volume normalized to functional-residual-capacity.13  4DCT specific-
ventilation,12 is measured based on the difference in lung-tissue-density at tidal inspiration 
and expiration as air enters and leaves voxels.  Magnetic resonance (MR) imaging has also 
been exploited to measure both lung structure and function in asthmatics.14   For example, 
hyperpolarized 3He MRI measures inhaled gas distribution15 while oxygen-enhanced 1H 
MRI also provides maps of signal enhancement due to oxygen16-18 by exploiting 
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differences in T1-weighted images acquired whilst breathing pure oxygen and room air.  1H 
MR imaging ventilation maps may also be generated without exogenous-contrast19-23 by 
measuring differences in 1H signal intensity at different lung volumes.19,20  Free-breathing 
Fourier-decomposition 1H MR imaging (FDMR imaging) is another approach that uses 
deformable-registration to generate ventilation-weighted images21,22 that are sensitive to 
bronchoconstriction in asthmatics.23   
In this proof-of-concept investigation, our objective was to: 1) develop a way to generate 
specific-ventilation measurements, based on conventional, free-breathing 1H MRI without 
exogenous contrast, 2) compare 1H MRI specific-ventilation with hyperpolarized 3He MRI 
ventilation in healthy and asthmatic participants, and 3) determine the relationships 
between 1H MRI specific-ventilation and hyperpolarized 3He MRI and pulmonary-function 
measurements. 
5.2 Materials and Methods 
5.2.1 Participants and Pulmonary Function Tests 
Participants aged 18-85, provided written-informed-consent to an ethics-board approved 
prospectively-planned investigation that was Health-Insurance-Portability-and-
Accountability-Act (HIPAA) compliant  (healthy-volunteers: NCT03169673; asthmatics: 
NCT02351141 and NCT02263794); participants were consecutively recruited between 
January and June 2017 based on inclusion/exclusion criteria provided in the Supplement 
that also provides a description of the pulmonary function tests performed. 
5.2.2 Image Acquisition 
All MR imaging acquisitions were performed in the coronal plane using a whole body 3.0 
Tesla Discovery MR750 (General-Electric-Health-Care [GEHC], Milwaukee, WI, USA) 
system as follows: 1) static breath-hold 1H MR imaging, 2) static breath-hold 
hyperpolarized 3He MR imaging, and, 3) free-breathing 1H MR imaging. Static breath hold 
1H MR imaging was acquired using a whole body radiofrequency coil and fast spoiled 
gradient-recalled-echo (FGRE) sequence (partial-echo-acquisition; total-acquisition-
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time=16s; TR/TE/flip-angle[FA]=4.7ms/1.2ms/30°; FOV=40×40cm2, BW=24.4kHz; 
matrix=128×80 [zero-padded to 128×128]; partial-echo-percent=62.5%; number-of-
slices[NS]= 15-17; slice-thickness[ST]=15mm, 0-gap).  Hyperpolarized 3He static 
ventilation MR imaging was performed using a single channel, rigid elliptical 
transmit/receive chest coil (RAPID Biomedical GmbH, Wuerzburg, Germany) and 2D 
multi-slice FGRE sequence (partial-echo-acquisition; total-acquisition-time=10s; 
TR/TE/FA=3.8ms/1.0ms/7°; FOV=40×40cm2, BW=48.8kHz; matrix=128×80 [zero-
padded to 128×128]; partial-echo-percent=62.5%; NS=15-17; ST=15mm, 0-gap).  A 
commercial polarizer (HeliSpin, Polarean, Durham, North Carolina, USA) was used to 
polarize 3He to 40%.  Participants inhaled a 1.0L gas mixture (30%/70% by volume 
hyperpolarized 3He/ultrahigh pure N2) after passive expiration to FRC. As shown in Figure 
5-1, free-breathing 1H MR imaging was acquired using a 32-channel torso coil (GEHC), 
with respiratory bellows to monitor respiratory rate and an optimized balanced-steady-
state-free-precession sequence (total-acquisition-time=160-200s; 
TE/TR/FA=0.6ms/1.9ms/15°; FOV=40×40cm2; BW=250kHz; matrix=256×256; NS=13-
15; ST=15mm; number-of-excitations=1; number-of-phases=51, 0-gap). 
5.2.3 Image Analysis 
Image processing was performed using MATLAB R2016a (Mathworks, Natick, 
Massachusetts, USA).  Hyperpolarized 3He MRI was quantified as previously described24 
with details provided in the Supplement (DPIC with 4 years of experience).   
As shown in Figure 5-1, the free-breathing images acquired were used to generate 1H MR 
imaging specific ventilation maps, and the Hilbert transform was used to identify the 
respiratory signal 𝐵𝐵(𝑈𝑈), in the respiratory bellow data with both real and imaginary 
components.  Using the phase component of 𝐵𝐵(𝑈𝑈), each imaging time point 𝑈𝑈 was linked to 
respiratory phase (from -π to π).  For each free-breathing 1H MR coronal slice time series, 
a 3D dataset for a single respiratory cycle was created via weighted interpolation, where 
the third dimension is respiratory phase 𝜃𝜃.  Each free-breathing 1H MR image at time 𝑈𝑈 
contributed to the corresponding slice in the interpolated image at phase 𝜃𝜃 with weight: 
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 𝑤𝑤(𝑈𝑈,𝜃𝜃)  ∝ 𝐻𝐻−𝛽𝛽|∠𝐵𝐵(𝑡𝑡)−𝜃𝜃| (5-1) 
where 𝐵𝐵(𝑈𝑈) is the respiratory bellow signal and 𝛽𝛽 is the exponential decay parameter (𝛽𝛽 =
𝜋𝜋
10
 ).   Ten 𝜃𝜃  values were used to reflect the number of phases, as previously described for 
4DCT.25,26  Optical-flow deformable-registration was used to co-register each 2D multi-
slice interpolated dataset into coordinate space27 so that spatially corresponding voxels 
were determined in the inspiration and expiration phases.  Each interpolated dataset was 
registered to its neighbouring interpolated dataset in the direction of increasing 𝜃𝜃, creating 
a series of dense deformation fields.  All images were registered to a single phase by 
compounding these deformation fields, creating a dataset with lung/cardiac motion 
removed.  The reference phase was halfway between the tidal inspiration and expiration 
volumes.21  Specific-ventilation (𝑆𝑆𝑆𝑆) is expressed without units and represents the 
proportion of inhaled gas moving into the lung during normal breathing as follows: 
 
𝑆𝑆𝑆𝑆 = ∆𝑆𝑆
𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒
= 𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒 − 𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒
𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒
 (5-2) 
where 𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑖𝑖𝑖𝑖𝑖𝑖𝑒𝑒and 𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤𝑒𝑒𝑒𝑒𝑒𝑒are the air volume fractions at inspiration and expiration, 
respectively.  Since MR imaging signal-intensity (𝑆𝑆𝑆𝑆) is approximately inversely 
proportional to lung air volume:19 
 
𝑆𝑆𝑆𝑆 ∝�  1
𝑆𝑆𝑤𝑤𝑡𝑡𝑤𝑤
 (5-3) 
We know, by substituting Equation 5-3 into Equation 5-2, that: 
 
𝑆𝑆𝑆𝑆 ≈
𝑆𝑆𝑆𝑆𝑡𝑡𝑒𝑒𝑖𝑖 − 𝑆𝑆𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖
𝑆𝑆𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖
 (5-4) 
where 𝑆𝑆𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖and 𝑆𝑆𝑆𝑆𝑡𝑡𝑒𝑒𝑖𝑖 are the MR signal-intensities at inspiration and expiration, 
respectively.  Using the co-registered tidal inspiration and expiration volumes, specific-
ventilation maps were generated as shown in Figure 5-1.  The reference phase used to 
register the interpolated dataset was segmented using a multiregional segmentation 
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approach, as previously described.28  A primal-dual optimization technique was 
implemented to solve the convex segmentation optimization problem,28 resulting in the 
segmented lung.  The segmented lung region was then applied to the 4DMR imaging 
specific-ventilation maps and the mean value was calculated. 
To interrogate the spatial relationship between specific-ventilation and hyperpolarized 3He 
MR imaging ventilation, hyperpolarized 3He MR imaging was registered to 1H MR 
imaging using landmarks24 and 1H MR imaging was registered via modality-independent-
neighborhood-descriptor (MIND) deformable registration29 to the reference phase of the 
interpolated dataset.  The deformation field was applied to hyperpolarized 3He MR imaging 
using voxel-wise similarity measurements of the two images, as well as diffusion-
regularization of the deformation field and optimization using the Gauss-Newton 
framework.29  Finally, the mean 1H MR imaging specific-ventilation was calculated within 
well-ventilated and ventilation defected regions.  Images were evaluated once because the 
segmentation approaches have high reproducibility.24,28 
In each subject, 4DMRI specific-ventilation was partitioned in five regions of equal vertical 
extent and the mean values were computed and is provided in the Supplement. To perform 
statistical analysis in larger lung regions and to evaluate regional gravitational differences, 
lung maps were segmented into two equal lung regions in the anterior-posterior direction, 
representing the gravitational dependent and independent regions for supine participants; 
mean 4DMRI specific-ventilation was calculated in both lung regions.  
5.2.4 Statistics 
Non-parametric statistical tests were used due to the small sample sizes.30  Differences 
between groups were determined using Mann-Whitney tests and relationships were 
determined using Spearman (ρ) correlation coefficients.  Significant differences for 
specific-ventilation measurements in well-ventilated versus poorly ventilated lung regions 
and anterior versus posterior lung regions of interest were measured using paired t-tests. 
All statistics were performed using GraphPad Prism 7.00 (GraphPad Software Inc., San 
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Diego, CA, USA) and results considered significant when the probability of two-tailed type 
I error (α) was less than 5% (p<.05). 
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Figure 5-1 4DMR Imaging Specific-Ventilation Acquisition and Analysis Pipeline 
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Acquisition: Multi-slice free-breathing 1H MR imaging acquired in the posterior-to-
anterior direction for whole lung coverage with corresponding respiratory bellow data 
trace. 
Analysis: Respiratory phase sorting for a single slice over time where the colors are 
associated with the time that each image (time O-X) is acquired corresponding to the color 
points on the respiratory bellow trace.  Four-dimensional interpolation was performed on 
the respiratory phase sorted images to generate respiratory phase binned images.  Yellow 
bar indicates the level of the diaphragm on tidal inspiration image. MR imaging specific-
ventilation heat-maps were generated on a voxel-by-voxel basis after co-registration of 
tidal inspiratory and tidal expiratory MR imaging volumes to provide a local distribution 
of specific ventilation shown for a representative healthy volunteer. 
5.3 Results 
5.3.1 Participants 
Thirty participants (15M/15F; 48[34]yrs/51[27]yrs; p=.9) were evaluated, including 23 
asthmatics (11M/12F; 57[18]yrs/53[18]yrs; p=.7) and seven healthy volunteers (4M/3F; 
26[4]yrs/23[9]yrs; p=.9) with no history of chronic or acute respiratory disease.  Table 5-1 
shows subject demographics, pulmonary-function-tests and imaging measurements.  
Healthy volunteers were significantly younger and reported greater FEV1 (p<.0001), FVC 
(p=.01), and FEV1/FVC (p<.0001) as well as lower BMI (p=.003), RV (p=.008), RV/TLC 
(p<.0001), and RAW (p<.0001) than asthmatics. 
  
 127 
 
Table 5-1 Participant Demographics and MRI Findings 
Parameter 
Median (IQR) 
Healthy 
(n=7) 
Asthma 
(n=23) 
Sig Dif 
p 
Age yrs  25 (4) 54 (17) <.0001 
Male n 4 11 -- 
Male age yrs 26 (4) 57 (18) .002 
Female n 3 12 -- 
Female age yrs 23 (9) 53 (18) .009 
BMI kg/m2 21 (4) 28 (6) .003 
FEV1 %pred 96 (10) 73 (22) <.0001 
FVC %pred 99 (8) 85 (22) .01 
FEV1/FVC % 82 (9) 67 (18) <.0001 
RV %pred 104 (37) 134 (29) .008 
TLC %pred 101 (13) 104 (12) .6 
RV/TLC % 25 (11) 41 (10) <.0001 
RAW %pred 61 (30) 167 (117) <.0001 
Sig Dif: Significant difference between subgroups (p<.05) determined using Mann-
Whitney test; IQR=interquartile range; %pred=percent of predicted value; FEV1=forced 
expiratory volume in one second; FVC=forced vital capacity; RV=residual volume; 
TLC=total lung capacity; RAW=airways resistance. 
5.3.2 Hyperpolarized 3He MR Imaging Ventilation and 1H MR Imaging 
Specific-Ventilation 
Figure 5-2 and Figure 5-3 shows representative 1H MR imaging specific-ventilation and 
hyperpolarized 3He MR imaging static ventilation (anterior-center-posterior) maps for an 
asthmatic and healthy volunteer.  As shown in Table 5-1, there was significantly larger 1H 
MR imaging specific-ventilation for healthy (0.14[0.05]) as compared to asthmatic 
volunteers (0.08[0.06], p<.0001); hyperpolarized 3He MR imaging ventilation-percent was 
also significantly greater for healthy (99[1]%) versus asthmatic (94[5]%, p<.0001) 
participants. 
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Figure 5-2 3He MRI and 4DMRI for a Representative Healthy Subject 
Hyperpolarized 3He MRI static-ventilation (cyan) and 4DMRI specific-ventilation (heat-
map) co-registered to anatomical 1H MRI (grey-scale) for anterior, center and posterior 
coronal slices for healthy female: age=22yrs, FEV1=111%pred, RV/TLC=17%, 3He MRI 
ventilation-percent=100%, 4DMRI specific-ventilation=0.18, plethysmography specific-
ventilation=0.43. 
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Figure 5-3 3He MRI and 4DMRI for Representative Asthmatics 
Hyperpolarized 3He MRI static-ventilation (cyan) and 4DMRI specific-ventilation (heat-
map) co-registered to anatomical 1H MRI (grey-scale) for anterior, center and posterior 
coronal slices for A) female with asthma: age=27yrs, FEV1=71%pred, RV/TLC=34%, 3He 
MRI ventilation-percent=97%, 4DMRI specific-ventilation=0.08, plethysmography 
specific-ventilation=0.21; and B) female with asthma: age=42yrs, FEV1=75%pred, 
RV/TLC=40%, 3He MRI ventilation-percent=93%, 4DMRI specific-ventilation=0.13, 
plethysmography specific-ventilation=0.14.  Yellow arrows identify ventilation defects. 
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5.3.3 Correlations 
Figure 5-4 and Table 5-2 show that 1H MRI specific-ventilation was significantly 
correlated with hyperpolarized 3He MRI ventilation-percent (ρ=.67, p<.0001) and 
plethysmography specific-ventilation (ρ=.54, p=.002).   Table 5-2 reveals that MRI 
measurements were significantly correlated with FEV1 (specific-ventilation: ρ=.65, 
p=.0001; ventilation-percent: ρ=.52, p=.003), FEV1/FVC (specific-ventilation: ρ=.75, 
p<.0001; ventilation-percent: ρ=.64, p=.001), and RV/TLC (specific-ventilation: ρ=-.68, 
p<.0001; ventilation-percent: ρ=-.66, p<.0001).   
Table 5-2 3He MRI Ventilation and 1H MRI Specific-Ventilation Correlations with 
Pulmonary Function 
 Spearman Correlation Coefficient ρ (p) [CI] 
  
3He MRI 
Ventilation-Percent % 
4DMRI 
Specific-Ventilation 
 (n=30) (n=30) 
FEV1 %pred .52 (.003) [.19 - .75] .65 (.0001) [.36 - .82] 
FEV1/FVC % .64 (.0001) [.35 - .82] .75 (<.0001) [.52 - .88] 
RV %pred -.52 (.003) [-.75 - -.19] -.55 (.002) [-.77 - -.23] 
RV/TLC % -.66 (<.0001) [-.83 - -.39] -.68 (<.0001) [-.84 - -42] 
RAW %pred -.58 (.0008) [-.78 - -.27] -.51 (.004) [-.74 - -.17] 
Specific-Ventilation .32 (.08) [-.05 - .62] .54 (.002) [.21 - .76] 
3He MRI Ventilation-Percent % -- .67 (<.0001) [.40 - .83] 
4DMRI Specific-Ventilation .67 (<.0001) [.40 - .83] -- 
CI=confidence interval; %pred=percent of predicted value; FEV1=forced expiratory volume 
in one second; FVC=forced vital capacity; RV=residual volume; TLC=total lung capacity; 
RAW=airways resistance; Specific-Ventilation=plethysmography measurement of specific-
ventilation. 
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Figure 5-4 Relationships for 4DMRI Specific-Ventilation with 3He MRI Ventilation-
Percent and Plethysmography Specific-Ventilation 
A) 3He MRI ventilation-percent and 4DMRI specific-ventilation were significantly 
correlated (ρ=.67, p<.0001, y=55x+89). 
B) Plethysmography specific-ventilation and 4DMRI specific-ventilation were 
significantly correlated (ρ=.54, p=.002, y=1.09x+0.15). 
Dotted lines indicate the 95% confidence intervals. 
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Figure 5-5 shows co-registered hyperpolarized 3He MR imaging and 1H MR imaging for 
a representative asthmatic with a focal right upper lobe ventilation defect and the spatial 
relationship with a specific-ventilation void.  Non-rigid co-registration of hyperpolarized 
3He and 1H MR imaging maps showed that 1H MR imaging specific-ventilation was 
significantly worse in hyperpolarized 3He MR imaging ventilation-defects (0.05±0.04) as 
compared to well-ventilated lung regions (0.09±0.05; p<.0001) in asthmatics.  Figure 5-5 
also shows that specific-ventilation was significantly larger in the gravitational dependent 
(0.20±0.07) versus independent (0.12±0.03; p=.02) lung regions in healthy participants, 
but not in asthmatics (dependent=0.09±0.05, independent=0.07±0.05; p=.1). 
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Figure 5-5 Spatial Correspondence of free-breathing 4DMRI Specific-Ventilation and 3He 
MRI Static Ventilation Maps 
A) Three-dimensional co-registration of 4DMR imaging specific-ventilation (heat-map) 
and static 3He MR imaging ventilation (transparent cyan), with Coronal on left panel, 
Sagittal (right upper panel) and Axial views (right lower panel) showing anatomical 1H 
MR imaging in grey-scale (in the sagittal and coronal panels) for a female with asthma: 
age=27yrs, FEV1=71%pred, RV/TLC=34%, 3He MR imaging ventilation-percent=97%, 
specific-ventilation=0.21, 4DMR imaging specific-ventilation whole-lung/ventilated-
region/ventilation-defect-region=0.08/0.08/0.02. 
B) 4DMR imaging specific-ventilation was significantly increased in the dependent 
(0.20±0.07) versus the nondependent (0.12±0.03) region of the lung (p=.02) in the healthy 
subjects.  In the asthmatics, no gravitational dependence was observed 
(dependent=0.09±0.05, nondependent=0.07±0.05, p=.1). 
C) 4DMR imaging specific-ventilation was significantly less in the 3He MR ventilation-
defects (0.05±0.04) versus the ventilated (0.09±0.05) regions of the lung (p<.0001) in the 
asthmatic subjects. 
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5.4 Discussion 
In a proof-of-concept demonstration in 30 participants, conventional free-breathing 1H MR 
imaging and retrospective respiratory phase co-registration and interpolation was used to 
generate 1H MR imaging specific-ventilation measurements.  Our results showed: 1) 1H 
MR imaging specific-ventilation was significantly diminished in asthmatics compared to 
healthy volunteers, 2) quantitative and spatial correlations with static breath-hold 
hyperpolarized 3He MR imaging ventilation and a significant correlation with 
plethysmography specific-ventilation, and, 3)  a significant difference in 1H MR imaging 
specific-ventilation in the gravitational dependent lung region in healthy volunteers but not 
asthmatics.   
As expected, MR imaging ventilation and specific-ventilation measurements were 
significantly greater in healthy participants as compared to asthmatics.  This is consistent 
with static multi-volume 1H MR imaging signal-intensity measurements in asthmatic and 
healthy participants.20  Diminished MR imaging specific-ventilation in the asthmatic lung 
may reflect gas-trapping, airway-remodeling or inflammation, similar to previously 
described studies that showed CT radio-density6 and ultra-short echo-time (UTE) MR 
imaging signal intensity differences31 in asthma patients compared to healthy volunteers. 
1H MR imaging specific-ventilation was significantly related to plethysmography specific-
ventilation and FEV1/FVC, indicating a relationship with airflow obstruction.  Correlations 
with RV and RV/TLC were consistent with the notion that gas-trapping reduced specific-
ventilation, similar to previous work that showed multi-volume UTE MR imaging was 
related to pulmonary-function-tests in asthmatics.31  The relationship between 1H MR 
imaging and plethysmography-measured specific-ventilation was consistent with a 
previous investigation using oxygen-enhanced MR imaging with multiple-breath 
washout.32 
In asthmatics, 1H MR imaging specific-ventilation was significantly diminished within 
ventilation defects as compared to well-ventilated regions.  This suggests that different 
static breath-hold and dynamic MR imaging methods may interrogate similar airway 
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abnormalities that influence the time constants for lung filling or ventilation.  
Hyperpolarized 3He MR imaging measures inhaled gas distribution during a 10-15s breath-
hold, while 1H MR imaging specific-ventilation maps are generated, (like 4DCT specific-
ventilation12) over a few minutes of tidal breathing.  This important difference suggests 
that both methods may also reflect the different time-constants for lung filling, which we 
think can be exploited clinically and in research studies. We also observed gravitational 
differences in healthy participants,18,32 but not in asthmatics, similar to previous findings.20  
Although other studies using static breath-hold 1H MRI observed differences in 
asthmatics,20 4D modeling of airflow demonstrated differences between breath-hold and 
dynamic breathing when evaluating ventilation heterogeneity in asthmatics,33 which may 
explain some of our results.  Gravitational differences in 3He MRI have also been observed 
whereby ventilation defects were larger in posterior regions of interest in asthmatics, 
suggestive of gas-trapping.34,35   
We acknowledge a number of study limitations including the relatively small sample size 
and modest correlations between our 1H MRI specific-ventilation measurement compared 
to both the reference plethysmography specific-ventilation measurement (ρ=.54, p=.002) 
and hyperpolarized 3He MRI (ρ=.67, p<.0001).  We must also acknowledge that because 
all of these measurements were performed in the same small subject group, caution must 
be taken when extending these results to a general population.  Free-breathing protocols 
may be influenced by irregular breathing patterns, previously observed using 4DCT,36 so 
some patients will require coaching or support.37  There was also a significant age 
difference between healthy and asthmatic volunteers (p<.0001), as a result of consecutive 
recruitment between January and June 2017 based on inclusion/exclusion criteria (provided 
in the Supplement), which is important to consider because lung aging has been shown to 
influence lung ventilation.38 Furthermore, other confounding factors, such as the 
differences in the demographics, may contribute to the overall differences observed 
between the two subject groups.  The difference between MRI specific-ventilation and 
plethysmography specific-ventilation may stem from a number of issues.  For example, 
MR imaging specific-ventilation is based on the difference in signal-intensities between 
co-registered volumes, which may be biased by poor co-registration.  Moreover, 
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differences in position are important to consider since previous studies showed the effect 
of body position on lung volumes.39,40  While supine, FRC and tidal-volume are lower than 
when upright but to different extents;39 this would result in greater specific-ventilation in 
the supine position, which we did not observe.  These measurements are also influenced 
by arm position40 and may have influenced our results.  1H MRI specific-ventilation was 
significantly diminished within ventilation defects as compared to well-ventilated regions, 
which provides some preliminary evidence that in these patients the time constants for 
filling were dominated by longer timescales, although a voxel-wise comparison may help 
to better ascertain spatial differences.  Unfortunately, while it is theoretically possible to 
measure 3He MRI specific ventilation in free-breathing human subjects, it is not feasible 
because of the exorbitant cost of 3He gas and the safety concerns related to repeated 
breathing of anoxic gas mixtures (mixtures with O2 are not possible because this accelerates 
polarization signal decay). 3He MRI measures gas distribution during a 10-15s breath-
hold,41 while 4DMR specific-ventilation images are generated, (like 4DCT12) over two to 
three minutes of tidal breathing. As such, the two methods are not measuring the same 
quantity and they likely interrogate different lung functional information related to airway 
calibre that influence the time constants for lung filling and emptying.  It is important to 
point out that the current approach is based on the assumption that changes in signal 
intensity during tidal breathing were due to air volume changes.  However, both blood and 
tissue contribute to the MRI signal and it is likely that heart rate/blood flow influences were 
captured during the two minutes of breathing.  We have not explicitly accounted for this in 
our calculations because of the dominant role that the movement of air in and out of the 
lungs plays in the MRI signal intensity fluctuations.  We also note that here we observed 
changes in signal density distributions that were very similar to what was observed using 
UTE MRI42 that is a proton density sensitive method and CT43 -the clinical gold standard 
for lung density measurements. 
Regional specific-ventilation imaging was demonstrated in a small group of participants 
using free-breathing 1H MR imaging without exogenous contrast.  While other MRI 
techniques acquire images in breath-hold at multiple lung volumes20,44 or free-breathing 
images for a single slice,19,22,23,45 this approach provides another way to generate whole 
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lung functional maps that probe functional abnormalities using conventional equipment 
and pulse sequences while patients are free-breathing.  This method may be useful for 
younger asthmatics who are difficult to treat and may need interventional procedures.   
In summary, using conventional 1H MRI without exogenous contrast, we developed a way 
to rapidly generate regional specific-ventilation measurements that correlate with 
plethysmography specific-ventilation and static breath-hold hyperpolarized 3He MRI 
ventilation measurements.  This method may offer new diagnostic approaches for 
pulmonary medicine in more typical clinical settings. 
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5.6 Supplement  
5.6.1 Materials and Methods 
5.6.1.1 Study Participants 
We recruited participants from a local tertiary care center and by advertisement.  For all 
participants, the exclusion criteria consisted of: 1) serious claustrophobia, 2) unable to 
perform spirometry, 3) body mass index >40, and, 4) any MR imaging contraindications 
(i.e. metal/electronic/magnetic implants).  Inclusion criteria for healthy volunteers 
consisted of: 1) medical history with no chronic or acute respiratory disease and stable 
health, 2) age 18-75, and, 3) smoking history <1 pack-years.  Inclusion criteria for 
asthmatics consisted of: 1) clinical diagnosis of asthma with β2-agonist reversibility of 
FEV1>12%, or methacholine FEV1 provocative concentration that decreased FEV1 by 20% 
(PC20) ≤ 8 mg/ml if not administered inhaled corticosteroid (ICS), or ≤ 16mg/ml if 
administered ICS, 2) no history of other chronic disease, 3) age 18-85, and, 4) smoking 
history < 1 pack-years. 
5.6.1.2 Pulmonary Function Tests  
Spirometry and plethysmography were performed using a MedGraphics Elite Series 
plethysmograph (MedGraphics Corporation, St. Paul, Minnesota, USA) according to the 
American-Thoracic-Society/European-Respiratory-Society guidelines1 to measure FEV1, 
forced-vital-capacity (FVC), total-lung-capacity (TLC), residual-volume (RV), tidal-
volume (TV), functional-residual-capacity (FRC) and airways resistance (RAW).  
Plethysmography-derived specific-ventilation was calculated as TV divided by FRC, as 
previously described.2 
5.6.1.3 Hyperpolarized 3He MR Image Processing  
Hyperpolarized 3He MR static ventilation images were segmented using a k-means 
approach that classified voxel intensity values into five clusters as follows: 1) signal-void 
= cluster 1 (C1) or ventilation defect volume, and 2) ventilation volume = cluster 2-5. 
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Ventilation boundaries were segmented using a seeded region-growing algorithm of the 1H 
MR imaging thoracic cavity, as previously described.3 
5.6.2 Results 
Figure 5-6 shows the 4DMRI specific-ventilation maps and signal-intensity distributions 
for the two lung volumes used to generate 4DMR specific-ventilation images (tidal-
inspiration and tidal-expiration volumes) for a representative healthy-volunteer and 
asthmatic.  The signal-intensity distributions for the healthy volunteer demonstrated a shift 
towards lower signal-intensities and narrowed distribution at the greater lung volume.  For 
the asthmatic, the qualitative difference between tidal inspiration and tidal expiration was 
smaller. 
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Figure 5-6 Generation of 4DMR Specific-Ventilation Images 
4DMRI specific-ventilation heat-maps (black=low-specific-ventilation to yellow=high-
specific-ventilation), which is a dimensionless physical quantity that reflects the proportion 
of inhaled gas moving into the lung during normal breathing, were generated on a voxel-
by-voxel basis after co-registration of tidal inspiratory and tidal expiratory MRI volumes 
to provide a local distribution of specific-ventilation, as shown for a representative healthy 
volunteer and an asthmatic.  Signal intensity histograms are also shown at two lung 
volumes (tidal inspiration [black] and tidal expiration [gray]), and shows a shift toward 
lower signal intensities and narrowed distribution at a higher lung volume. 
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Figure 5-7 Gravity-dependence Analysis in Healthy Volunteer and Patients with Asthma 
Individual variations of mean values of 4DMRI specific-ventilation along ventro-dorsal 
direction (vertical axis) from the least (one) to the most (five) gravity-dependent levels. 
Each piecewise line represents a single subject. 
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CHAPTER 6 
6 CONCLUSIONS AND FUTURE DIRECTIONS 
In this final chapter, I will provide a summary and overview of the important findings and 
conclusions presented in Chapters 2-5.  The limitations specific to each study and general 
limitations will also be provided with some potential solutions.  Finally, I will end with 
some future directions based on what we observed using non-contrast enhanced pulmonary 
imaging. 
6.1 Overview and Research Questions 
COPD and asthma affect hundreds of millions of people throughout the world1 and this 
number is projected to increase.  Ultimately, this will overwhelm the healthcare system and 
result in a substantial economic burden.2  Despite the many years of research, current 
therapies are lacking,3,4 leaving patients with dismal prognoses.  Clearly, the management 
and treatment of lung disease patients is inadequate and this is in part due to the way in 
which these patients are currently diagnosed and monitored using measurements of airflow 
obstruction.  Although these global measurements of airflow limitation are easy to 
implement and reproducible,5 they do not provide any regional information about the 
different underlying pathophysiology in lung disease patients.  Accordingly, this has 
motivated the development and research of other approaches to regionally evaluate lung 
function using pulmonary imaging for longitudinal monitoring and image-guided 
treatments. 
Numerous pulmonary imaging techniques are being developed to quantify structure and 
function regionally within the lungs.  However, they are not all well suited for longitudinal 
monitoring because of the potential risks associated with exposure to ionizing radiation,6-8 
specifically for CT and nuclear medicine imaging, which is particularly concerning for 
young adults and pediatric populations.  In contrast, pulmonary MRI is not limited by 
radiation exposure and provides regional measurements of lung function with the potential 
for longitudinal monitoring of patients and image-guided treatment.  Specifically with the 
use of inhaled hyperpolarized noble gases (3He and 129Xe), one can regionally quantify 
pulmonary ventilation by visualizing lung regions accessed by gas during a breath-hold, 
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and alternatively, regions that are not accessed.  The ventilation images that appear in 
hyperpolarized noble gas MRI have been shown to be reproducible,9,10 related to relevant 
clinical measurements,11-13 and sensitive to treatment response,14,15 in both asthma and 
COPD patients.  Despite numerous studies, clinical translation of these imaging approaches 
have been hampered due to a number of key limitations including: 1) relatively high cost 
associated with inhaled gas contrast; and, 2) requirement of multi-nuclear MR hardware 
and analysis software and specialized personal, restricting these techniques to a few 
specialized research centres.  With this in mind, there has been growing interest in the 
development of pulmonary MRI and CT approaches that do not depend on inhaled gas 
contrast agents to overcome the challenges associated with resource accessibility.  The 
development and validation of these clinically meaningful non-contrast enhanced 
pulmonary MR and CT imaging biomarkers is critically required to accelerate pulmonary 
MRI and CT translation from the research workbench to the clinical workflow for patient 
care. 
The overarching objective of this thesis was to develop and evaluate patients with lung 
disease using MR and CT imaging biomarkers of pulmonary structure and function without 
the use of inhaled exogenous contrast agents or specialized equipment.  The specific 
research questions addressed were: 1) Do measurements of emphysema and gas-trapping 
derived from parametric response maps of co-registered inspiratory-expiratory CT images 
relate to ventilation heterogeneity quantified using hyperpolarized 3He MRI? (Chapter 2); 
2) Can non-contrast enhanced free-breathing pulmonary 1H MRI measurements of 
ventilation heterogeneity be developed to measure ventilation abnormalities in subjects 
with COPD and bronchiectasis, and are these measurements related to pulmonary function 
tests and 3He MRI ventilation defects? (Chapter 3); 3) Can we apply the developed method 
in Chapter 3 to patients with severe asthma to evaluate ventilation heterogeneity, both pre- 
and post-salbutamol as well as post-methacholine challenge? (Chapter 4); and, 4) Can we 
extend the free-breathing pulmonary 1H MRI approach developed in Chapter 3 to capture 
whole-lung measurements of regional specific-ventilation in healthy volunteers and 
patients with asthma? (Chapter 5) 
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6.2 Summary and Conclusions 
In Chapter 2 we developed and directly compared CT PRM with 3He MRI ventilation 
measurements of gas-trapping and emphysema in ex-smokers with and without COPD.  
We determined the quantitative and spatial relationships of PRM gas-trapping and PRM 
emphysema measurements with MRI measurements of parenchymal tissue integrity and 
ventilation.  We found that in 58 ex-smokers with (n=32) and without (n=26) COPD, 3He 
MRI ventilation defect percent was significantly correlated with CT PRM measurements 
of gas-trapping (r=.58, p<.001) and emphysema (r=.68, p<.001).  3He MRI ADC 
measurements were also significantly correlated with PRM gas-trapping (r=.55, p<.001) 
and PRM emphysema (r=.62, p<.001).  Spatial CT-MRI relationships in all ex-smokers 
showed that 3He MRI ADC was significantly elevated in regions of PRM gas-trapping as 
compared to normal tissue (p<.05).   In patients with mild and moderate COPD (n=25), 
3He MRI ventilation defects were quantitatively and spatially related to PRM gas-trapping 
(mild COPD - gas-trapping: SOC=36±28%, emphysema: SOC=1±2%, p=.001; moderate 
COPD - gas-trapping: SOC=34±28%, emphysema: SOC=7±15%, p=.006), while in severe 
COPD (n=7), MRI ventilation defects were quantitatively and spatially related to both 
PRM-gas-trapping and emphysema (gas-trapping: SOC=36±18%, emphysema: 
SOC=64±30%, p=.01).  These observations are important because while 3He MRI is 
unlikely to be translated clinically, this information may be used to help better understand 
PRM gas-trapping measurements, which may be more widely adopted for clinical 
phenotyping of COPD patients. 
We then developed and compared pulmonary ventilation abnormalities derived from 
FDMRI with 3He MRI in subjects with COPD and bronchiectasis in Chapter 3.  We 
observed that in 26 subjects, including 12 COPD subjects and 14 bronchiectasis subjects, 
that for the COPD subjects, FDMRI and 3He MRI VDP was 7±6% and 24±14%, 
respectively (p<.001, bias=-16±9%).  In COPD subjects, FDMRI was significantly 
correlated with 3He MRI VDP (r=.88, p=.0001), 3He MRI ADC (r=.71, p<.05), and RAW 
(r=.60, p<.05).  In subjects with bronchiectasis, FDMRI (5±3%) and 3He MRI VDP 
(18±9%) were significantly different (p<.001) and not correlated (p>.05).  The Dice 
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Similarity Coefficient for FDMRI and 3He MRI ventilation was 86±7% for COPD and 
86±4% for bronchiectasis subjects (p>.05).  This work showed similar regional ventilation 
abnormalities using FDMRI and 3He MRI in COPD subjects and these appear to be 
dominated by the presence of regional emphysematous bullae.  This work demonstrated 
that FDMRI and 3He MRI ventilation defects were strongly correlated in COPD, but not 
bronchiectasis subjects. 
In Chapter 4 we evaluated ventilation heterogeneity in patients with severe asthma, both 
pre- and post-salbutamol as well as post-methacholine challenge, using FDMRI and 3He 
MRI.  We observed in 16 severe asthmatics that hyperpolarized 3He MRI (p=.02) and 
FDMRI (p=.02) VDP significantly improved post-salbutamol and for four asthmatics who 
could perform MCh (n=4), 3He and FDMRI VDP significantly increased at the provocative 
concentration of methacholine resulting in a 20% decrease in FEV1 and decreased post-
bronchodilator (p=.02), with a significant difference between methods (p=.01).  FDMRI 
VDP was moderately correlated with 3He VDP (ρ=.61, p=.01), but under-estimated VDP 
relative to 3He VDP (-6±9%).  While 3He MRI VDP was significantly correlated with the 
lung-clearance-index, FDMRI was not (ρ=.49, p=.06).  This work demonstrated that 
FDMRI VDP generated in free-breathing asthmatic patients was correlated with static 
inspiratory breath-hold 3He MRI VDP, but under-estimated VDP relative to 3He MRI VDP.  
Although less sensitive to salbutamol and MCh, FDMRI VDP may be considered for 
asthma patient evaluations at centres without inhaled-gas MRI. 
In Chapter 5 of this thesis, we developed a whole-lung free breathing pulmonary 1H MRI 
technique to measure regional specific-ventilation and evaluated asthmatics and healthy 
volunteers.  We compared 1H MRI specific-ventilation with hyperpolarized 3He MRI 
ventilation in healthy and asthmatic participants, and, determined the relationships between 
1H MRI specific-ventilation and hyperpolarized 3He MRI and pulmonary-function 
measurements.  We observed in 30 participants, including seven healthy volunteers and 23 
asthmatics, 1H MR imaging specific-ventilation (p<.0001) and hyperpolarized 3He MR 
imaging ventilation-percent (p<.0001) were both significantly greater in healthy volunteers 
as compared to asthmatics.  For all subjects, 1H MRI specific-ventilation was also 
correlated with plethysmography specific-ventilation (ρ=.54, p=.002) and hyperpolarized 
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3He MRI ventilation-percent (ρ=.67, p<.0001), as well as FEV1 (ρ=.65, p=.0001), 
FEV1/FVC (ρ=.75, p<.0001), RV/TLC (ρ=-.68, p<.0001) and RAW (ρ=-.51, p=.004).  1H 
MRI specific-ventilation was significantly greater in the gravitational-dependent versus 
non-dependent lung in healthy volunteers (p=.02), but not in the asthmatics (p=.1).  In 
asthmatics, co-registered 1H MRI specific-ventilation and hyperpolarized 3He MRI maps 
showed that specific-ventilation was diminished in corresponding 3He MRI ventilation-
defects as compared to well-ventilated regions (p<.0001).  We demonstrated in this study 
that using conventional 1H MRI without exogenous contrast, could rapidly generate whole-
lung regional specific-ventilation measurements, which correlated with plethysmography 
specific-ventilation and static breath-hold hyperpolarized 3He MRI ventilation 
measurements.  This method may offer new diagnostic approaches for pulmonary medicine 
in more typical clinical settings. 
In summary, we provided: 1) evidence that CT parametric response maps were 
quantitatively and spatially related to ventilation measurements using 3He MRI in ex-
smokers with and without airflow limitation; 2) evidence that the ventilation defect 
measurements derived from non-contrast enhanced free-breathing MRI are related to 
ventilation abnormalities generated from 3He MRI in patients with COPD; 3) evidence that 
the measurements derived from non-contrast enhanced free-breathing MRI are sensitive to 
treatment response to bronchodilation and bronchoconstriction in patients with severe 
asthma; and, 4) a new non-contrast enhanced whole-lung free-breathing 1H MRI method 
to evaluate regional specific-ventilation in patients with asthma. 
6.3 Limitations 
The significant limitations from Chapters 2-5 will be discussed in this section of the thesis.  
The study specific limitations are also provided in the Discussion section of each of the 
respective Chapters. 
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6.3.1 Study Specific Limitations 
Chapter 2: Pulmonary Imaging Biomarkers of Gas-trapping and Emphysema in COPD: 
3He MR Imaging and CT Parametric Response Maps 
In the study presented in Chapter 2, we sought to better understand the quantitative and 
spatial relationships between CT PRM and 3He MRI imaging biomarkers in ex-smokers 
with and without COPD.  This work was limited by the relatively small study group and 
the fact that we mainly evaluated ex-smokers with mildly abnormal and normal spirometry, 
which was prospectively planned and driven by our interest to investigate very early or 
mild disease.  Given our understanding of the heterogeneity of COPD patients, we must be 
cautious about extrapolating our results.   
Another limitation is the influence of deformable registration error on the results presented 
in this study.  Similar to 4DCT,16 Fourier decomposition MRI,17 and paired 
inspiratory/expiratory CT,18-20 PRM exploits the image signal differences as the lung tissue 
expands and contracts from inspiration to expiration.  All these approaches rely on either 
computational or intuitive co-registration of inspiratory and expiratory CT and assume that 
the abnormal presence of air can be regionally related to emphysema and/or functional 
small airways disease.  Thus, deformable image registration errors pose a challenge, which 
has been previously reported for PRM in the liver.21  A direct comparison of the results 
generated here with results stemming from commercially available software, such as 
Apollo Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, USA) or Lung Density 
Analysis software (IMBIO, Minneapolis, Minnesota, USA), would allow for a better 
understanding on how image registration influences CT parametric response maps.  Any 
potential differences between the generated maps would likely stem from the different 
image registration/warping algorithms used to register the inspiratory and expiratory CT 
volumes since the density thresholds used are generally the same. 
Finally, hyperpolarized 3He MRI is still limited to a few research facilities worldwide and 
is unlikely to be translated clinically due to the depleted global supply of 3He gas.  
However, with recent improvements in 129Xe polarization22 and the development of 19F 
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MRI,23 inhaled gas MRI may yet be considered for regulatory approval and future clinical 
workflow. 
Chapter 3: Free-breathing Pulmonary 1H and Hyperpolarized 3He MRI: Comparison in 
COPD and Bronchiectasis 
In the study presented in Chapter 3, we developed a free-breathing 1H MRI method to 
evaluate pulmonary ventilation abnormalities in subjects with COPD and bronchiectasis.  
First, we only acquired a single free-breathing 1H MR image.  This limited our ability to 
directly compare the ventilation measurements derived from FDMRI with those generated 
from 3He MRI. 
One of the challenges associated with pulmonary 1H MRI methods, is the weak pulmonary 
1H signal intensity that is further diminished at higher field strengths because of the 
relationship between field-strength and T2* effects.  Furthermore, MR signal intensity is 
dependent on positioning the patient within the RF coil, resulting in potential inter-scan 
variability.  Previous pilot and development studies at 1.5T have shown qualitative 
agreement for regional ventilation and perfusion measurements with the SPECT/CT.24  
Moreover, recent studies have also demonstrated the reproducibility of FDMRI ventilation- 
and perfusion-weighted images in healthy volunteers.25  
Finally, Fourier decomposition has recently emerged as a pulmonary functional MRI 
method, albeit the ventilation measurements are dependent on more sophisticated image 
processing methods.  FDMRI generates ventilation contrast based on image signal 
differences during the breathing cycle as air enters and leaves the pulmonary system and 
tissue contracts and expands.  This relies on robust and accurate image registration methods 
to co-register the free tidal-breathing 1H MR image data.  Consequently, deformable 
registration error poses a challenge when generating FDMR ventilation weighted images.  
To generate FDMR ventilation-weighted images, registration algorithms must account for 
the movement of the diaphragm and any registration error will result in regions of high 
signal intensity (e.g. mucus pooling in bronchiectasis subjects) oscillating at the same 
frequency as respiration.  Accordingly, this registration error can result in apparently 
increased ventilation, which may or may not accurately reflect truly ventilated regions.  
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Thus, there may be regions that appear as ventilation in FDMRI that are in fact not 
ventilated due to misalignment of these regions of high signal intensity via the deformable 
registration process. 
Chapter 4: Free-breathing Functional Pulmonary MRI: Response to Bronchodilator and 
Bronchoprovocation in Severe Asthma 
In Chapter 4, we applied the developed FDMRI approach in Chapter 3 in patients with 
severe asthma to evaluate treatment response to bronchodilation as well as 
bronchoconstriction.  We also focused on severe asthmatics and those with poor control in 
order to capture information relevant to an important clinical problem and, because of this, 
the vast majority of patients were unable to perform methacholine challenge (n=4).   
As mentioned before, an inherent limitation of pulmonary 1H MRI is the low signal 
intensity due to intrinsically low proton density and T2* effects,26 but recent research27 that 
exploits shorter echo times may overcome this challenge.  FDMRI is also currently limited 
to single slice acquisitions and this limits the generalizability of a direct comparison 
between this method and hyperpolarized 3He MRI (FDMRI=single 2D slice time series 
and 3He MRI=multi-slice 2D acquisition).  Furthermore, there is no standardization of the 
complex image-processing methods used to generate FDMR ventilation-weighted images. 
Finally, inhaled hyperpolarized 3He MRI static ventilation maps and dynamic free 
breathing FDMRI ventilation maps provide similar but not the same functional 
information, making it challenging to perform a direct comparison between the two 
imaging techniques.  The differences in the functional information measured using inhaled-
gas MRI and FDMRI may stem from the different time constants for lung filling that are 
the consequence of different airway abnormalities.  For example, in asthmatics, 3He MRI 
ventilation defects reflect lung regions with long time constants for filling that are beyond 
the 10-15s acquisition time of scanning.  In contrast, multi-breath free-breathing FDMRI 
ventilation defects reflect airway and parenchyma abnormalities28 that do not fill during a 
much longer, two minute acquisition window.  A comparison between FDMRI and 
previous work using multi-breath wash-in inhaled gas MRI29 may be better suited in 
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probing the relationship of inhaled noble gas MRI and non-contrast enhanced MRI 
ventilation measurements.  
Chapter 5: Free-breathing Pulmonary MR Imaging to Quantify Regional Ventilation 
In Chapter 5, we developed a whole lung free-breathing pulmonary 1H MRI approach to 
generate regional measurements of specific-ventilation and evaluated asthmatics and 
healthy volunteers.  There was a significant age difference between healthy and asthmatic 
volunteers, as a result of consecutive recruitment between January and June 2017.  This is 
important to consider because lung aging has been shown to influence lung ventilation.30  
Furthermore, other confounding factors, such as the differences in the demographics, may 
contribute to the overall differences observed between the two subject groups.   
As mentioned before, image registration error poses a challenge when measuring MRI 
specific-ventilation since this imaging biomarker is based on the voxel-wise difference in 
signal-intensities between co-registered volumes.  It should be noted that we did not 
acquire specific-ventilation measurements in the same body position using 
plethysmography (sitting upright) and imaging (supine).  Differences in body position, as 
well as arm position, have been shown in previous studies to influence lung volumes 
involved in calculating specific-ventilation (FRC and TV).31,32 
Another limitation is that 3He MRI measures gas distribution during a 10-15s breath-hold,33 
while 1H MR specific-ventilation images are generated, (like 4DCT34) over two to three 
minutes of tidal breathing.  Accordingly, the two methods are not measuring the same 
quantity and they likely interrogate different lung functional information related to airway 
calibre that influence the time constants for lung filling and emptying.  Furthermore, free-
breathing protocols may be influenced by irregular breathing patterns, previously observed 
using 4DCT,35 so some patients will require coaching or support.36    
It is important to point out that we did not explicitly account for heart rate/blood flow 
contribution to the MRI signal intensity in our calculations because of the dominant role 
that the movement of air in and out of the lungs plays in the MRI signal intensity 
fluctuations.  The current approach is based on the assumption that changes in signal 
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intensity during tidal breathing were due to air volume changes.  Although the observed 
changes in signal density distributions were very similar to what was observed using UTE 
MRI37 and CT,38 ideally, a mass correction to correct for respiratory-induced changes in 
tissue perfusion (applied previously to 4DCT16) could be applied here to account for 
changes in blood distribution between the exhale and inhale phases.  
6.3.2 General Limitations 
In Chapters 2-5, there was a small number of subjects evaluated in each study.  This was 
due in part because of the design of the studies and the inability to perform rigorous power 
calculations since there was little prior knowledge of the imaging biomarkers generated 
from non-contrast enhanced imaging data.  Caution must be taken when extrapolating the 
results presented in these studies to the broader population of asthmatic and COPD patients.  
Regardless, these exploratory studies provide the foundation for future studies which 
should be aimed in evaluating larger groups of patients to confirm the results observed.  
One limitation to the studies presented in Chapters 2-5 was the use of whole lung imaging 
biomarkers of signal intensity, relative areas of diseased lung, or ventilation to evaluate 
pulmonary abnormalities in asthma and COPD patients.  These global measurements of 
lung function, although suitable for comparison and validation with other global measures 
of airflow obstruction (i.e. spirometry), tend to eliminate the heterogeneity in regional 
ventilation abnormalities visible on images.  It is well known that static ventilation images 
generated from hyperpolarized noble gas MRI are not binary (i.e. 0=non-ventilated vs 
1=ventilated); they provide a gradient of signal intensities from hyper-intense to signal 
void regions within the lungs, as shown in Figure 1-11.  Analysis methods that were 
implemented to generate the ventilation defect percent can also be used to generate clusters 
of signal intensities, as shown in Figure 4-1, to quantify hyper-intense, normal, and hypo-
intense signal regions.39  Further studies should be performed to investigate these regions 
in addition to the non-ventilated regions in both asthma and COPD patients.  Furthermore, 
threshold methods, such as those implemented in Chapter 2, either under40 or over41 
estimate disease depending on the choice of threshold value.  Alternative approaches have 
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been proposed that leverage principal component analysis (PCA) to overcome the use of a 
single predefined threshold.42,43 
Another important limitation to the studies presented in Chapters 2-5 was the use of 3He 
gas and the limited availability of this gas for medical imaging.  The high cost of 3He gas, 
due to the depleting global supply of 3He,44 has limited hyperpolarized 3He MRI to a few 
research facilities worldwide and is unlikely to be translated clinically.  As mentioned in 
Section 1.5.2.1, the transition to 129Xe and 19F gases has been the focus of the inhaled gas 
MRI community, where with recent improvements in 129Xe polarization22 and the 
development of 19F MRI,23 inhaled gas MRI may yet be considered for regulatory approval 
and future clinical workflows.  Regardless, future studies involving 19F and hyperpolarized 
129Xe MRI are required to validate the results presented using 3He MRI and how these 
results may differ when comparing to the non-contrast enhanced imaging techniques 
presented in this thesis. 
Finally, all the non-contrast enhanced imaging methods developed in Chapters 2-5 rely 
on sophisticated image processing methods, which may limit clinical translation.  
Furthermore, there is a dependence on these image analysis methods to be robust, accurate, 
and reproducible.  Consequently, any error in the image analysis pipeline, such as 
deformable registration error, poses a challenge when generating these imaging biomarkers 
of pulmonary disease.  Thus, future studies should focus on the standardization and 
validation of software used to analyze these images.  This will be important moving 
forward since the advancement of pulmonary imaging toward clinical implementations 
requires large-scale and multi-centre evaluation of clinically-relevant biomarkers. 
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6.4 Future Directions 
6.4.1 Regional Ventilation Heterogeneity: Three Dimensional 
Ventilation Clustering of Hyperpolarized Noble Gas MRI 
In Chapters 2-5, we evaluated lung disease using the ventilation defect percent generated 
from hyperpolarized 3He MRI.  Although VDP is a robust measure that is reproducible9,10 
and related to relevant clinical measurements,11-13 the ventilation defect percent does not 
fully exploit the rich information and spatial content that is inherent to the hyperpolarized 
noble-gas MR ventilation images, as mentioned in Section 6.3.2.45  As shown in Figure 
6-1, specific cases can be identified whereby the VDP for two subjects is the same, but the 
ventilation patterns are visibly different.  This may suggest that there are measureable 
differences in ventilation heterogeneity that are not reflected by VDP.  Hence, the objective 
of this proof-of-concept study was to develop an automated algorithm that quantifies the 
ventilation heterogeneity readily displayed in pulmonary functional inhaled noble-gas 
MRI.  We hypothesize that the incorporation of both the magnitude and spatial location of 
ventilation defects when analyzing inhaled noble-gas MR ventilation images could provide 
further clinically relevant information that would be complementary to VDP and reflect 
clinical measurements of ventilation heterogeneity, such as LCI. 
The proposed three-dimensional clustering algorithm iteratively traces the non-ventilated 
volumes until the maximum sphere (or multiple spheres of the same size) that can be filled 
within the volume are found.  Once the largest sphere (or multiple spheres of the same size) 
was identified, this volume(s) was removed from the non-ventilated volume.  This was 
iteratively repeated until the non-ventilated volume was replaced by spheres.  Thus, the 
algorithm determines the minimum number of spheres of unequal sizes required to fill a 
specified volume.  This is similar to previous work where unequal sphere packing was 
investigated in connection with radiosurgical treatment planning.46 
Mathematically, this approach can be implemented using a naïve greedy algorithm.  
Let 𝑆𝑆 = {𝑏𝑏1, 𝑏𝑏2, … , 𝑏𝑏𝑖𝑖}, be a set with 𝐻𝐻 elements where each element 𝑏𝑏𝑖𝑖 = 𝐵𝐵𝑖𝑖(𝑟𝑟, 𝐻𝐻) is an 
open sphere of radius 𝑟𝑟 at locations 𝐻𝐻.  Our goal is to determine the minimum number of 
spheres of unequal sizes, thus resulting in the following minimization problem: 
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 min
𝑆𝑆
{‖𝑆𝑆‖0}  ∶  𝑆𝑆 ∈ 𝐑𝐑𝑖𝑖 (6-1) 
where we want to minimize the cardinality of the set 𝑆𝑆 and ∀ (𝑏𝑏 ∈ 𝑆𝑆) ∃ (𝑟𝑟, 𝐻𝐻).   
To insure that the spheres are filling the specified volume 𝐹𝐹, a constraint was implemented 
so that the intersection between the region that is being packed with spheres 𝐹𝐹 and the 
spheres 𝑏𝑏 is just 𝑏𝑏: 
 𝑏𝑏 ∩ 𝐹𝐹 = 𝑏𝑏 (6-2) 
Furthermore, to prevent overlapping between spheres, the overlap between two spheres (𝑏𝑏 
and 𝑏𝑏′) would result in the null set:  
 𝑏𝑏 ∩ 𝑏𝑏′ = ∅ (6-3) 
A volume constraint was imposed so that the total volume of spheres is equal to the volume 
of the specified region 𝐹𝐹: 
 �𝑆𝑆(𝑏𝑏) = 𝑆𝑆(𝐹𝐹)
𝑏𝑏∈𝑆𝑆
 (6-4) 
To further simplify the problem, there is no location constraint with regards to where the 
spheres are positioned. 
Computationally, MATLAB R2016a (Mathworks) was used to solve the minimization 
problem.  In the discrete case, three-dimensional matrices were used to store visual 
information of where the volumes are located using binary values (0=background; 
1=foreground).  We resampled the segmented 3He MRI from 3.125x3.125x15mm3 into 
approximately 5x5x5mm3 voxel space to ensure isotropic resolution prior to 
implementation.  The ventilation defect regions were completely packed with spheres, 
where the minimum sphere diameter was equal to one voxel. 
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Figure 6-1 shows the output from the proposed algorithm with ventilation defects and 
ventilated regions being clustered for two representative subjects (COPD and 
bronchiectasis) with the same VDP.  For the ventilation defect clustering, ventilation is 
shown in blue and ventilation defects are shown as spheres with different volumes shown 
in colour (red=13-voxels-diameter to yellow=3-voxels-diameter).  The COPD subject had 
a large upper lobe ventilation defect that was reflected by larger sphere sizes that 
corresponded to 25% of the total defect volume.  In contrast, the bronchiectasis subject had 
ventilation defect regions that mostly consisted of smaller spheres. 
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Figure 6-1 Ventilation defect clusters for two subjects (COPD and bronchiectasis) with 
the same ventilation defect percent 
For ventilation defect clusters, the algorithm outputs a three-dimensional volume of 
ventilation in aqua and ventilation defects represented by spheres ranging in voxel 
diameters of 3-5 voxels (yellow) to voxel diameters of 9-13 voxels (red).  Voxel= 
5x5x5mm3. 
Figure 6-2 shows a cumulative volume sum for each sphere normalized to the total lung 
volume (cluster ventilation defect percent) and this was performed to better demonstrate 
what was visually observed in Figure 6-1.  When cluster voxel diameter is plotted in 
relation to normalized volume, there are numerous smaller spheres, and no large 
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homogeneous regions in the non-ventilated volume for the bronchiectasis subject.  
Alternatively, for the COPD subject, there is a mixture of small and large spheres in the 
non-ventilated volume.  To complement the results generated using the algorithm, the lung 
clearance index, which reports a global measure of ventilation heterogeneity made at the 
mouth, was also greater in the bronchiectasis (LCI=20.8) as compared with the COPD 
subject (LCI=14.6). 
 
Figure 6-2 Cluster ventilation defect percent for the same two subjects in Figure 6-1 
Ventilation defect volume normalized to the total ventilation defect volume (cluster 
ventilation defect percent) by cluster (sphere) size for COPD (gray) and bronchiectasis 
(black) subjects.  Voxel= 5x5x5mm3.  
The proposed ventilation defect cluster algorithm provides a way to identify and quantify 
differences in regional ventilation heterogeneity a measurement that is similar to LCI, an 
established global measure of ventilation inhomogeneity made at the mouth. 
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6.4.2 Free-breathing Pulmonary 1H MRI in Non-small Cell Lung 
Cancer: Relationships with 4DCT and Noble Gas MRI 
Measurements of Ventilation 
Hyperpolarized 3He MRI has previously been investigated as a way to identify well-
functioning lung regions in patients with non-small-cell lung cancer (NSCLC) for 
functional avoidance targets in radiotherapy.47  For a number of reasons, the clinical 
translation of this approach to guide radiotherapy planning has been limited.  As an 
alternative, FDMRI using clinically available MRI systems and pulse sequences provides 
a non-contrast enhanced method to generate ventilation-weighted maps.  Free-breathing 1H 
MRI exploits Fourier decomposition of MRI signal intensity differences and non-rigid 
registration to generate ventilation-weighted functional maps.17  Similarly, 4DCT has been 
proposed to generate ventilation-weighted maps to serve as functional avoidance maps, and 
has been implemented in clinical trials (i.e., NCT02528942).  Here, our objective was to 
generate free-breathing 1H MRI ventilation in patients with NSCLC as an alternative way 
to guide radiation therapy, and compare it to both hyperpolarized 3He MRI and 4DCT 
ventilation maps. 
We have performed preliminary analysis in a small proof-of-concept study in which stage 
IIIA/IIIB NSCLC patients (n=9, 67±7yr) provided written informed consent to a double-
blinded randomized controlled clinical trial (NCT02002052) that aimed to compare 
outcomes related to MR image-guided versus conventional radiation therapy planning.  
Hyperpolarized 3He MRI, FDMRI, and 4DCT ventilation maps were generated as 
previously described,28,48,49 and semi-automated segmentation was used to generate the 
VDP for all three imaging methods.39 
Figure 6-3 shows FDMRI, hyperpolarized 3He MRI and 4DCT ventilation maps for a 
representative NSCLC patient.  There was strong qualitative spatial agreement for 
ventilation defects in the left lung where the tumour mass has partially stunted the 
ventilation resulting in a ventilation defect.   
 164 
 
 
Figure 6-3 MRI and 4DCT ventilations images of a representative patient with stage III 
non-small-cell lung cancer 
For a 74yrs female; pack year=12yrs; FEV1=61%pred; DLCO=54%pred; FDMRI VDP=15%; 
3He MRI VDP=26%; 4DCT VDP=51%. 
A) FDMRI in magenta co-registered to anatomical 1H MRI in gray-scale. 
B) Hyperpolarized 3He MRI in blue co-registered to anatomical 1H MRI in gray-scale. 
C) 4DCT ventilation in hot co-registered to anatomical CT in gray-scale. 
The yellow arrows indicate corresponding regions of ventilation defect visible across all 
imaging techniques. 
Figure 6-4 shows the relationships and agreement for MRI and 4DCT measurements.  
FDMRI VDP was correlated with 3He MRI VDP (r=.69, p=.04) and 4DCT VDP (r=.73, 
p=.02), although Bland-Altman analysis indicated that there were biases of -10±8% [-26%, 
7%] and -19±8% [-35%, -3%] for 3He and 4DCT, respectively. 
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Figure 6-4 Relationships for FDMRI with 3He MRI and 4DCT  
A) FDMRI VDP was significantly correlated with 3He MRI VDP (r=.69, p=.04). 
B) FDMRI VDP was significantly correlated with 4DCT VDP (r=.73, p=.02). 
C) Bland-Altman analysis of agreement for FDMRI VDP with 3He MRI VDP (bias=-
10±8%, [-26%, 7%]). 
D) Bland-Altman analysis of agreement for FDMRI with 4DCT VDP (bias=-19±8%, [-
35%, -3%]). 
Dotted lines indicate the 95% confidence intervals. 
While FDMRI ventilation imaging is currently limited to only a single slice and is therefore 
inherently two-dimensional, results showed that regional FDMRI ventilation abnormalities 
were spatially related to inhaled gas MRI ventilation defects as well as 4DCT-derived 
ventilation.  Importantly, this result suggests that free-breathing pulmonary 1H MRI 
provides similar functional information compared to hyperpolarized noble-gas MRI and 
free-breathing CT techniques that are currently implemented in clinical trials for functional 
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lung avoidance.  This may allow for clinical translation of MRI-guided radiotherapy 
planning since this technique does not require exogenous contrast agents and can be easily 
implemented using clinically available MRI systems and pulse sequences. 
6.4.3 Pulmonary Imaging Platform - Graphical User Interface to 
Evaluate and Generate Lung Imaging Biomarkers 
In all of the studies presented in Chapters 2-5, image processing methods were developed 
and evaluated to generate imaging biomarkers of pulmonary structure and function in 
asthma and COPD patients.  As mentioned in Section 6.3.2, the complexity of these image 
processing methods may limit clinical translation.  Accordingly, there is a need for an easy-
to-use, standardized, and validated pulmonary image processing and analysis toolbox for 
broad research use and clinical translation.50,51  This will be important moving forward 
since the advancement of pulmonary MRI and CT toward clinical implementations requires 
large-scale and multi-centre evaluation of clinically-relevant biomarkers. 
 
Figure 6-5 Pulmonary Imaging Platform (PIP™) graphical user interface 
Image datasets are imported into the software where users will have access to the image 
processing methods developed to generate the imaging biomarkers of lung structure and 
function.  
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As shown in Figure 6-5, the Pulmonary Imaging Platform (PIP™) is a graphical user 
interface (GUI) oriented software with a number of features, including: 1) multi-view 
three-dimensional volume rendering;52 2) surface rendering (using Visualization Toolkit); 
3) fiducial placing; 4) image seeding; and, 5) blending/overlapping.  The GUI will integrate 
all of the individual image analysis processes presented in Chapters 2-5, including: 1) 
inspiration-expiration CT parametric response mapping analysis (Chapter 2); 2) whole 
lung and regional noble gas MRI measurements (Chapters 2-5); 3) two-dimensional free-
breathing 1H MRI ventilation weighted maps (Chapter 3 and Chapter 4); and, 4) three-
dimensional free-breathing 1H MRI specific-ventilation measurements (Chapter 5).  
While PIP™ only currently provides a set of commonly used lung imaging biomarkers, the 
software is flexible and sustainable to be expanded to include currently developing 
analyses.  Once validated, new imaging biomarkers may be easily incorporated to PIP™ 
and distributed to end users.  Future work will involve dissemination of PIP™ to the 
pulmonary imaging research community to further validate and improve the imaging 
biomarkers generated from this software. 
6.5 Significance and Impact 
Unfortunately, hospitalization, mortality rates, and costs associated with lung disease 
patients continue to rise, and health economists warn that this upward trend will continue 
and will very soon overwhelm the global healthcare system.53  In light of this dire situation, 
new management strategies are urgently required to combat this growing healthcare crisis.  
For patients with chronic lung disease, pulmonary function tests provide a global 
measurement of lung function, which are easy to implement and reproducible.5  As a result, 
these tests are universally accepted for clinical use and are considered the clinical standard 
for the diagnosis and evaluation of response to treatment.  The limitations of spirometry, 
including: 1) only providing a global measurement of lung function; 2) the relative 
insensitivity to early disease stages;3 and, 3) weakly related to important clinical 
outcomes,54,55 has motivated the development of alternative approaches to evaluate 
pulmonary diseases.  Specifically, pulmonary imaging methods, such as MRI and CT, have 
been proposed to provide objective measurements of regional lung pathologies in asthma 
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and COPD.  Until now, pulmonary MRI has focused on hyperpolarized noble gas MRI, 
which has yet to be translated clinically and is restricted to a few specialized research 
centres.  To facilitate broad clinical applications of pulmonary imaging techniques, it is 
urgent to develop new diagnostic approaches for pulmonary medicine using clinically 
available equipment. 
In this thesis, we have developed and evaluated methods of obtaining imaging biomarkers 
of pulmonary structure and function without the use of exogenous contrast agents or 
specialized equipment.  The work presented here confirms that there are qualitative and 
quantitative similarities between the non-contrast enhanced methods and those generated 
from inhaled noble gas MRI in identifying regional lung disease.  Armed with this 
knowledge, there is enormous potential for these imaging methods to be implemented at 
any imaging centre around the world and be used as intermediate endpoints in clinical trials 
to evaluate novel therapies and possibly guide treatment.  The development and validation 
of these clinically meaningful non-contrast enhanced pulmonary MR and CT imaging 
biomarkers will accelerate the translation of pulmonary imaging from “the benchtop to the 
bedside” where imaging will play an integral part of the clinical workflow for patients with 
lung disease. 
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Natural Science and Engineering Research Council of Canada (NSERC) 
Awarded to highly qualified Canadians with leading edge scientific and 
research skills for Canadian industry, government and universities 
National ($90,000) 
 
2017 Radiological Society of North America (RSNA) Trainee Research Prize 
Radiological Society of North America Annual Scientific Meeting 2017 
Awarded to honor the most outstanding scientific contribution submitted 
and accepted to the RSNA international meeting for presentation  
International (USD $1,000) 
 
2017-2018 Doctoral Excellence Research Awards 
Schulich School of Medicine and Dentistry, Western University 
Recognized for having a tri-agency doctoral scholarship (NSERC) 
Institutional ($5,000) 
 
2017-2018 Western Graduate Research Scholarship 
Department of Medical Biophysics, Western University 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more 
Institutional ($7,600) 
 
2017  Nellie Farthing Fellowship in the Medical Sciences 
Schulich School of Medicine and Dentistry, Western University 
Established in 1960 with money bequeathed by Nellie Farthing to Western 
University to create a Fellowship for full-time doctoral students in the 
Medical Sciences that recognized and rewarded excellence in research 
Institutional ($3,000) 
 
2017  Alfred Jay Award for Translational Research 
Department of Medical Biophysics, Western University 
Awarded annually to a graduate student demonstrating innovation in the 
development of a clinical diagnostic or therapeutic procedure during their 
studies 
Institutional ($2,000) 
 
2017  1st Place - Best Oral Presentation Award 
Imaging Network of Ontario Meeting 
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Recognized for having the top oral presentation out of all participates at 
the annual meeting  
National ($350) 
 
2017  Best Scientific Exhibition Award 
International Workshop on Pulmonary Functional Imaging Meeting 
Selected as one of ten awardees of IWPFI 2017 for the best scientific 
exhibition works 
International 
 
2016-2017 Western Graduate Research Scholarship 
Department of Medical Biophysics, Western University 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more 
Institutional ($7,600) 
 
2016-2017 Doctoral Excellence Research Awards 
Schulich School of Medicine and Dentistry, Western University 
Recognized for having a tri-agency doctoral scholarship (NSERC) 
Institutional ($5,000) 
 
2016  Canadian Student Health Research Forum Funding Competition 
Canadian Institutes of Health Research (CIHR) 
Selected by CIHR to receive funding to reimburse travel and 
accommodations for 
participation in the 2014 Canadian Student Health Research Forum 
National ($1,000) 
 
2016  Publication of the Month 
Schulich School of Medicine and Dentistry, Western University 
Recognized for having the top publication at the Schulich School of 
Medicine and Dentistry for the month of April 2016 
Institutional 
 
2016  Drs. Madge and Charles Macklin Fellowship for Publication Nominee 
Schulich School of Medicine and Dentistry, Western University 
Selected by the Department of Medical Biophysics to compete for an award 
based on the significance of the candidate’s 1st author publication in a high 
impact peer reviewed journal 
Institutional 
 
2016 Canadian Student Health Research Forum National Student Research 
Poster Competition Participant 
Canadian Institutes of Health Research (CIHR) 
Nominated by the University of Western Ontario as being within the top 5% 
of doctoral students in the field of health sciences 
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National 
 
2016  1st Place - The Lucille & Norton Wolf Trainee Publication Award 
London Health Research Day 2016 
Awarded to the top peer-reviewed publication from a trainee or medical 
residents and fellows of the Schulich School of Medicine & Dentistry 
working in labs across Schulich Medicine & Dentistry 
Regional ($2,000) 
 
2016  Trainee (Educational) Stipend 
  International Society for Magnetic Resonance in Medicine Annual Meeting 
Awarded to support the attendance of students, postdoctoral and clinical 
trainees to present abstracts at the international scientific meeting held in 
Singapore, Singapore 
International (USD $475) 
 
2015-2016 Western Graduate Research Scholarship 
Department of Medical Biophysics, Western University 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more 
Institutional ($7,600) 
 
2015  Magna Cum Laude Merit Award 
International Society for Magnetic Resonance in Medicine Annual Meeting 
Awarded to those whose abstract score was in the top 15% of those 
submitted for review to be presented at the annual international meeting 
International 
 
2015 The Queen Elizabeth II Graduate Scholarship in Science and 
Technology 
Ontario Graduate Scholarship (OGS) 
A merit based scholarship (based on academic standing) that encourages 
excellence in graduate studies and is available to students in all disciplines 
of academic study 
Provincial ($15,000) declined 
 
2015-2018 Postgraduate Scholarship – Doctoral (PGSD3) 
Natural Science and Engineering Research Council of Canada (NSERC) 
Awarded to high-calibre students who are engaged in doctoral programs in 
the natural sciences or engineering 
National ($63,000) 
 
2015  Top 80 Posters: Judges’ Selection 
London Health Research Day 2015 
Awarded to those whose abstract score was in the top 80 abstracts 
submitted 
 188 
 
Regional 
 
2015  Trainee (Educational) Stipend 
  International Society for Magnetic Resonance in Medicine Annual Meeting 
Awarded to support the attendance of students, postdoctoral and clinical 
trainees to present abstracts at the international scientific meeting held in 
Toronto, Canada 
International (USD $360) 
 
2014-2015 Western Graduate Research Scholarship 
Department of Medical Biophysics, Western University 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more 
Institutional ($7,800) 
 
2014  Radiological Society of North America Trainee Research Prize Finalist 
Radiological Society of North America Annual Scientific Meeting 2014 
Awarded to one of the highest ranked abstracts submitted for the Trainee 
Research Prize 
International 
 
2014  Trainee (Educational) Stipend 
  International Society for Magnetic Resonance in Medicine Annual Meeting 
Awarded to support the attendance of students, postdoctoral and clinical 
trainees to present abstracts at the international scientific meeting held in 
Milan, Italy 
International (USD $540) 
 
2013-2014 Western Graduate Research Scholarship 
Department of Medical Biophysics, Western University 
Awarded to a full time graduate student for stipend support who has 
maintained an average of 80% or more 
Institutional ($7,800) 
 
2012-2013 University of Windsor Outstanding Scholars Award in Physics 
  Department of Physics, University of Windsor 
Awarded to students with exceptional cumulative averages who are 
enrolled in Physics 
Institutional ($4,000) 
 
2009  University of Windsor Entrance Scholarship 
  University of Windsor 
Awarded to students with exceptional high school entrance averages 
Institutional ($1,250) 
 
2009  University of Windsor Outstanding Scholars Award in Physics 
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  Department of Physics, University of Windsor 
Awarded to students with exceptional cumulative averages who are 
enrolled in Physics 
Institutional ($2,000) 
 
  
ACADEMIC RESPONSIBILITIES 
 
2017  Graduate Research Assistant (3 term contract) 
  Maintenance and Management of Polarization Facility 
  Robarts Research Institute, Western University 
 
2016  Graduate Research Assistant (1 term contract) 
  Physics Quality Assurance Radiation therapy infrastructure 
  London Regional Cancer Centre and Department of Oncology 
  Western University 
 
  Graduate Research Assistant (3 term contract) 
  Maintenance and Management of Polarization Facility 
  Robarts Research Institute, Western University 
 
  Cancer Program Clinical Observership (1 term) 
  Shadowed Radiation Oncologists in Clinic 
  London Regional Cancer Centre and Department of Oncology 
  Western University 
 
  Medical Resident Research Trainee Supervision 
Resident (PGY-2 Internal Medicine): Colin J. Adams, MD 
Project: A comparison of MRI and CT for targeting areas for lung volume 
reduction procedures 
Abstract: MRI Stratification of COPD Patients for Bronchoscopic Lung 
Volume Reduction: A Cautionary Note 
Manuscript: On the potential role of MRI Biomarkers of COPD to Guide 
Bronchoscopic Lung Volume Reduction 
 
  Undergraduate Research Project Mentoring 
  Robert DiCesare (3rd year UG BMSc, Western University) 
Project: MRI ventilation used for targeting areas for lung volume reduction 
procedures 
Ryan Yip (3rd year UG BMSc, Western University - 6 week rotation project) 
Project: Reproducibility of 3He MRI segmentation 
Matthew Schweers (1st year UG BSc, Western University) 
Project: Database management and clerical duties 
 
2015  Undergraduate Research Project Mentoring 
  Robert DiCesare (2nd year UG BMSc, Western University) 
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Project: Reproducibility of 3He MRI segmentation 
Nanxi Zha BEng (2nd year MD, Schulich Research Opportunities Funded 
Project, Western University) 
Project: Second order texture analysis of noble gas MRI 
Manuscript: Second-Order Texture Measurements of 3He Ventilation MRI: 
Proof of Concept Evaluation of Asthma Bronchodilator Response 
 
2014  Graduate Research Assistant (1 term contract) 
  Physics Quality Assurance Radiation therapy infrastructure 
  London Regional Cancer Centre and Department of Oncology 
  Western University 
 
  Undergraduate Research Project Mentoring 
Nanxi Zha BEng (1st year MD, Schulich Research Opportunities Funded 
Project, Western University) 
Project: Parametric response mapping of co-registered 
inspiratory/expiratory CT 
Conference Paper: Principal component analysis of the CT density 
histogram to generate parametric response maps of COPD 
 
2013  Introductory Physics II (University of Windsor: 03-64-141) 
Proctored Exams and Laboratory Instructor (3 Labs) 
 
Introduction to Astronomy II (University of Windsor: 03-64-191) 
Proctored Exams 
 
2012  Introductory Physics II (University of Windsor: 03-64-141) 
Proctored Exams and Laboratory Instructor (1 Lab) 
 
Theoretical Methods (University of Windsor: 03-64-151) 
Proctored Exams and Marked Assignments 
 
 
PUBLICATIONS AND PRESENTATIONS 
 
Peer-Reviewed Journal Manuscripts (17 published/in-press) 
 
Published and In-Press (17 total; 8 first author) 
 
1. D.P.I. Capaldi, R.L. Eddy, S. Svenningsen, F. Guo, J.S.H. Baxter, A.J. McLeod, P. 
Nair, D.G. McCormack, G. Parraga.  Free-breathing Pulmonary MR Imaging to 
Quantify Regional Specific-Ventilation.  Radiology. February 22, 2018.  
doi.org/10.1148/radiol.2018171993 
 
2. C.J. Adams*, D.P.I. Capaldi*, R. Di Cesare, D.G. McCormack, G. Parraga, CRRN 
Investigators. On the potential role of MRI Biomarkers of COPD to Guide 
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Bronchoscopic Lung Volume Reduction. Academic Radiology.  October 2017.  
doi.org/10.1016/j.acra.2017.08.010 (* Co-first Author) 
 
3. D.P.I. Capaldi, G. Parraga.  Through the Looking Glass and What was Found There: 
More Imaging Biomarkers of COPD.  American Journal of Respiratory and Critical 
Care Medicine.  August 2017.  doi.org/10.1164/rccm.201707-1473ED 
 
4. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, F. Guo, S. Svenningsen, P. Nair, D.G. 
McCormack, G. Parraga.  Free-breathing Pulmonary MRI Ventilation Response to 
Bronchodilator and Provocation in Severe Asthma.  Academic Radiology.  May 2017.  
dx.doi.org/10.1016/j.acra.2017.04.012 
 
5. F. Guo, S. Svenningsen, M. Kirby, D.P.I. Capaldi, K. Sheikh, A. Fenster, G. Parraga.  
Thoracic CT-MRI Co-Registration for Regional Pulmonary Structure-Function 
Measurements of Obstructive Lung Disease.  Medical Physics.  February 2017. 
doi.org/10.1002/mp.12160.    ***This manuscript was featured on the cover of the 
journal (May 2017)*** 
 
6. A. Dasgupta, M. Kjarsgaard, D.P.I. Capaldi, K. Radford, F. Aleman, C. Boylan, L.C. 
Altman, T. Wight, G. Parraga, P.M. O’Byrne, P. Nair.  A pilot randomized clinical trial 
of mepolizumab in COPD with eosinophilic bronchitis. European Respiratory Journal. 
March 2017. doi.org/10.1183/13993003.02486-2016 
 
7. K. Sheikh, F. Guo, D.P.I Capaldi, A. Ouriadov, R.L. Eddy, S. Svenningsen, G. 
Parraga, CRRN Investigators.  Ultra-short Echo Time Magnetic Resonance Imaging 
Biomarkers of Asthma. Journal of Magnetic Resonance Imaging. October 2016. 
doi.org/10.1002/jmri.25503 
 
8. F. Guo, S. Svenningsen, R.L. Eddy, D.P.I. Capaldi, K. Sheikh, A. Fenster, G. Parraga.  
Anatomical Pulmonary MRI Multi-Region Segmentation using a Convex 
Optimization-Based Approach and Volume Proportion Prior.  Medical Physics.  May 
2016.  doi.org/10.1118/1.4948999 
 
9. D.P.I. Capaldi, F. Guo, G. Parraga.  Imaging How and Where We Breathe Oxygen: 
Another Big Short?  Journal of Thoracic Disease.  March 2016.  
doi.org/10.21037/jtd.2016.01.83 
 
10. N. Zha, D. Pike, S. Svenningsen, D.P.I. Capaldi, D.G. McCormack, G. Parraga.  
Second-Order Texture Measurements of 3He Ventilation MRI: Proof of Concept 
Evaluation of Asthma Bronchodilator Response.  Academic Radiology.  February 2016.  
doi.org/10.1016/j.acra.2015.10.010 
 
11. D.P.I. Capaldi, N. Zha, F. Guo, D. Pike, D.G. McCormack, M. Kirby, G. Parraga.  
Pulmonary Imaging Biomarkers of Gas Trapping and Emphysema in COPD: 3He MR 
Imaging and CT Parametric Response Maps.  Radiology.  January 2016.  
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doi.org/10.1148/radiol.2015151484.  ***This manuscript was featured on the cover of 
the journal (May 2016)*** 
 
12. D. Pike, M. Kirby, R.L. Eddy, F. Guo, D.P.I. Capaldi, A. Ouriadov, D.G. McCormack, 
G. Parraga.  Regional Heterogeneity of Chronic Obstructive Pulmonary Disease 
Phenotypes: Pulmonary 3He Magnetic Resonance Imaging and Computed 
Tomography.  Journal of Chronic Obstructive Pulmonary Disease.  January 2016. 
doi.org/10.3109/15412555.2015.1123682 
 
13. K. Sheikh*, D.P.I. Capaldi*, D.A. Hoover, G. Parraga, D.A. Palma, B.P. Yaremko.  
Magnetic resonance imaging biomarkers of chronic obstructive pulmonary disease 
prior to radiation therapy for non-small cell lung cancer.  European Journal of 
Radiology Open.  December 2015.  doi.org/10.1016/j.ejro.2015.05.003 (* Co-first 
Author) 
 
14. F. Guo, J. Yuan, M. Rajchl, S. Svenningsen, D.P.I. Capaldi, K. Sheikh, A. Fenster, G. 
Parraga.  Globally Optimal Joint Segmentation of Three-dimensional Pulmonary 1H 
and Hyperpolarized 3He MRI with Spatial Consistence Prior.  Medical Image Analysis.  
July 2015.  doi.org/10.1016/j.media.2015.04.001 
 
15. D.P.I. Capaldi, K. Sheikh, F. Guo, S. Svenningsen, R. Etemad-Rezai, H.O. Coxson, J. 
Leipsic, D.G. McCormack, G. Parraga.  Free-breathing Pulmonary 1H and 
Hyperpolarized 3He MRI: Comparison in COPD and Bronchiectasis.  Academic 
Radiology. March 2015. doi.org/10.1016/j.acra.2014.10.003 
 
16. M. Bhuiyan, E.V. Malyarenko, M.A. Pantea, D.P.I. Capaldi, A.E. Baylor, R.G. Maev.  
Time-Frequency Analysis of Clinical Percussion Signals using Matrix Pencil Method.  
Journal of Electrical and Computer Engineering.  January 2015.  
doi.org/10.1155/2015/274541 
 
17. D.A. Hoover, D.P.I. Capaldi, K. Sheikh, D.A. Palma, G.B. Rodrigues, R. Dar, E. Yu, 
B. Dingle, M. Landis, W. Kocha, M. Sanatani, M. Vincent, J. Younus, S. Gaede, G. 
Parraga, B.P. Yaremko.  Functional lung avoidance for individualized radiotherapy 
(FLAIR): Study protocol for a randomized, double-blind clinical trial.  BMC Cancer.  
December 2014.  doi.org/10.1186/1471-2407-14-934 
 
 
Under Review (1 total) 
 
1. F. Guo, D.P.I. Capaldi, M. Kirby, K. Sheikh, S. Svenningsen, D.G. McCormack, A. 
Fenster, G. Parraga.  Pulmonary Imaging Platform: A New Toolbox for Chronic Lung 
Disease Management using Pulmonary Magnetic Resonance Imaging.  Journal of 
Medical Imaging. Submitted - December 12 2017 (Manuscript ID: JMI 17360) 
 
 
In Preparation (3 total; 2 first author) 
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1. D.P.I. Capaldi, K. Sheikh, S. Svenningsen, D.G. McCormack, G. Parraga.  Magnetic 
Resonance Measurements of Regional Ventilation Heterogeneity: Three Dimensional 
Ventilation Clustering of Hyperpolarized Noble Gas MRI.  Academic Radiology. 
 
2. D.P.I. Capaldi, K. Sheikh, D.A. Hoover, T. Yamamoto, D.A. Palma, M. Daly, A. 
Warner, S. Kabus, M. Bal, B.P. Yaremko, G. Parraga.  Lung Expansion to Measure 
Ventilation in Non-Small Cell Lung Cancer Patients: Comparison between Fourier-
Decomposition Free-breathing Pulmonary 1H MRI and Four-Dimensional CT.  
International Journal of Radiation Oncology • Biology • Physics. 
 
3. A. Ouriadov, D.P.I. Capaldi, E. Lessard, F. Guo, H.M. Young, D.G. McCormack, G. 
Parraga.  Undersampled Diffusion-weighted 129Xe MRI Morphometry of Airspace 
Enlargement:  Feasibility in Chronic Obstructive Pulmonary Disease. Magnetic 
Resonance in Medicine. 
 
 
Book Chapters (1 total; 1 first author) 
 
1. D.P.I Capaldi, R.L. Eddy, G. Parraga.  Pulmonary MRI in Clinical Trials.  MRI of the 
Lung. 2nd Edition. Springer. November 2016.  doi.org/10.1007/174_2016_81 
 
 
Peer-Reviewed Conference Manuscript Proceedings (4 total; 1 first author) 
 
1. A.J. McLeod, D.P.I. Capaldi, J.S.H. Baxter, G. Parraga, X. Luo, T.M. Peters.  Analysis 
of Periodicity in Video Sequences through Dynamic Linear Modeling.  Medical Image 
Computing and Computer Assisted Intervention (MICCAI) 2017. doi.org/10.1007/978-
3-319-66185-8_44 
 
2. F. Guo, D.P.I. Capaldi, R. Di Cesare, A. Fenster, G. Parraga.  Registration Pipeline 
for Pulmonary Free-Breathing 1H MRI Ventilation Measurements.  Proceedings of the 
Society for Photo-optical Instrumentation Engineers (SPIE) 2017.  
doi.org/10.1117/12.2253879 
 
3. D.P.I. Capaldi, S. Svenningsen, I.A. Cunningham, G. Parraga.  Fourier-Based Linear 
Systems Description of Free-Breathing Pulmonary Magnetic Resonance Imaging.  
Proceedings of the Society for Photo-optical Instrumentation Engineers (SPIE) 2015.  
doi.org/10.1117/12.2081503 
 
4. N. Zha, D.P.I. Capaldi, D. Pike, D.G. McCormack, I.A. Cunningham, G. Parraga.  
Principal component analysis of the CT density histogram to generate parametric 
response maps of COPD.  Proceedings of the Society for Photo-optical Instrumentation 
Engineers (SPIE) 2015.  doi.org/10.1117/12.2076396 
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Peer-Reviewed Conference Abstracts (55 total; 24 first author; 5 submitted) 
 
1. A. Ouriadov, D.P.I. Capaldi, H. Young, M. Kirby, H.O. Coxson, D.G. McCormack, 
G. Parraga. Development of the Emphysema Biomarkers in COPD and Alpha-1 
Antitrypsin Deficiency Based on the Accelerated 129Xe MRI Morphometry Approach. 
International Conference of the American Thoracic Society Meeting Proceedings 2018 
(submitted) 
 
2. S. Svenningsen, R.L. Eddy, D.P.I. Capaldi, M. Kjarsgaard, K. Radford, G. Parraga, P. 
Nair. Effect of anti-Th2 Therapy on MRI Ventilation Heterogeneity in Prednisone 
Dependent Asthma. International Conference of the American Thoracic Society 
Meeting Proceedings 2018 (submitted) 
 
3. R.L. Eddy, H. Young, A. Kassay, D.P.I. Capaldi, S. Svenningsen, D.G. McCormack, 
G. Parraga.  Contributions of Large Versus Small Airways to MRI Ventilation 
Heterogeneity in Asthmatics.  International Society for Magnetic Resonance in 
Medicine Meeting Proceedings 2018 (submitted) 
 
4. A. Westcott, R.L. Eddy, D.P.I. Capaldi, H. Young, D.G. McCormack, G. Parraga.  
Novel Quantification of Ventilation Heterogeneity Patterns in Hyperpolarized 3He 
MRI.  International Society for Magnetic Resonance in Medicine Meeting Proceedings 
2018 (submitted) 
 
5. A. Ouriadov, D.P.I. Capaldi, D.G. McCormack, G. Parraga.  A Single Shot Whole 
Lung Method of Acquiring a Complete set of the Hyperpolarized Gas MRI-based 
Emphysema Biomarkers.  International Society for Magnetic Resonance in Medicine 
Meeting Proceedings 2018 (submitted) 
 
6. B.P. Yaremko, D.A. Hoover, D.P.I. Capaldi, K. Sheikh, G.B. Rodrigues, A.R. Dar, E. 
Yu, S. Gaede, J. Chen, A. Erickson, A. Warner, B. Dingle, M. Landis, W. Kocha, M. 
Sanatani, M. Vincent, J. Younus, S. Kuruvilla, D.A. Palma, G. Parraga.  Functional 
Lung Avoidance for Individualized Radiotherapy (FLAIR): Results of a Randomized, 
Double-Blind Clinical Trial.  American Society for Radiation Oncology 2017 
 
7. D.P.I. Capaldi, J.S.H. Baxter, A.J. McLeod, R.L. Eddy, S. Svenningsen, F. Guo, D.G. 
McCormack, G. Parraga.  Measuring Specific Ventilation using Four-dimensional 
Magnetic Resonance Ventilation Imaging: A Novel Physiological Biomarker of 
Asthma.  Radiological Society of North America Annual Meeting 2017 (Trainee Prize 
Winner) 
 
8. D.A. Hoover, T. Yamamoto, K. Sheikh, D.P.I. Capaldi, G. Parraga, D.A. Palma, M. 
Daly, A. Warner, S. Kabus, M. Bal, B.P. Yaremko.  Comparison of Hyperpolarized 
3He MRI and CT Ventilation From a Cohort of Patients On the FLAIR Double-Blind, 
Randomized Trial.  American Association of Physicist in Medicine Proceedings 2017 
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9. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, S. Svenningsen, M. Kirby, D.G. McCormack, 
G. Parraga, Canadian Respiratory Research Network.  Asthma Ventilation 
Abnormalities Measured using Fourier-Decomposition Free-breathing Pulmonary 1H 
MRI.  International Workshop for Pulmonary Functional Imaging 2017 (Best 
Scientific Exhibition Award) 
 
10. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, S. Svenningsen, M. Kirby, D.G. McCormack, 
G. Parraga, Canadian Respiratory Research Network.  Asthma Ventilation 
Abnormalities Measured using Fourier-Decomposition Free-breathing Pulmonary 1H 
MRI.  Canadian Respiratory Research Network Annual General Meeting 2017 
 
11. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, S. Svenningsen, M. Kirby, D.G. McCormack, 
G. Parraga, Canadian Respiratory Research Network.  Asthma Ventilation 
Abnormalities Measured using Fourier-Decomposition Free-breathing Pulmonary 
Proton Magnetic Resonance Imaging.  London Health Research Day 2017 
 
12. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, S. Svenningsen, M. Kirby, D.G. McCormack, 
G. Parraga, Canadian Respiratory Research Network.  Asthma Ventilation 
Abnormalities Measured using Fourier-Decomposition Free-breathing Pulmonary 1H 
MRI.  Imaging Network Ontario Symposium 2017 (1st Place - Best Oral Presentation 
Award) 
 
13. D.P.I. Capaldi, K. Sheikh, R.L. Eddy, S. Svenningsen, M. Kirby, D.G. McCormack, 
G. Parraga, Canadian Respiratory Research Network.  Asthma Ventilation 
Abnormalities Measured using Fourier-Decomposition Free-breathing Pulmonary 1H 
MRI.  International Society for Magnetic Resonance in Medicine Meeting Proceedings 
2017 
 
14. H.M. Young, D.P.I. Capaldi, K. Sheikh, D.G. McCormack, C.M. Yamashita, G. 
Parraga.  Ultra-Short Echo Time MRI Quantification of Airspace Enlargement in 
Bronchopulmonary Dysplasia and Alpha-1 Antitrypsin Deficiency: Parenchyma 
Destruction, Air trapping or Both?  International Society for Magnetic Resonance in 
Medicine Meeting Proceedings 2017 
 
15. R.L. Eddy, D.P.I. Capaldi, K. Sheikh, S. Svenningsen, D.G. McCormack, G. Parraga.  
Pulmonary MRI Ventilation Defects in Asthma: Stochastic or Deterministic?  
International Society for Magnetic Resonance in Medicine Meeting Proceedings 2017 
 
16. D.P.I. Capaldi, K. Sheikh, R. Di Cesare, D.A. Palma, G. Parraga. Is Ventilation 
Heterogeneity Related to Quality of Life Scores Post-Radiation Therapy in Non-Small 
Cell Lung Cancer Patients? International Conference of the American Thoracic Society 
Meeting Proceedings 2017 
 
17. R.L. Eddy, K. Sheikh, D.P.I. Capaldi, S. Svenningsen, C. Licskai, D.G. McCormack, 
G. Parraga. Ventilation Heterogeneity Reversibility: Asthma, COPD or ACOS? 
International Conference of the American Thoracic Society Meeting Proceedings 2017 
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18. R.L. Eddy, D.P.I. Capaldi, K. Sheikh, S. Svenningsen, D.G. McCormack, G. Parraga. 
Probability Mapping of Lung Functional Abnormalities in Asthma using MRI: Lung 
Atlas Explorations of Non-randomness. International Conference of the American 
Thoracic Society Meeting Proceedings 2017 
 
19. C.J. Adams, D.P.I. Capaldi, R. Di Cesare, D.G. McCormack, G. Parraga. MRI 
Stratification of COPD Patients for Bronchoscopic Lung Volume Reduction: A 
Cautionary Note. International Conference of the American Thoracic Society Meeting 
Proceedings 2017 
 
20. D.P.I. Capaldi, K. Sheikh, D.A. Hoover, B.P. Yaremko, D.A. Palma, G. Parraga.  
Free-Breathing Proton MRI Functional Lung Avoidance Maps to Guide Radiation 
Therapy.  American Association of Physicist in Medicine Proceedings 2016 
 
21. K. Sheikh, D.P.I. Capaldi, D.A. Hoover, B.P. Yaremko, D.A. Palma, G. Parraga.  
Pulmonary Functional Imaging Biomarkers of NSCLC to Guide and Optimize 
Functional Lung Avoidance Radiotherapy.  American Association of Physicist in 
Medicine Proceedings 2016 
 
22. D.P.I. Capaldi, N. Zha, F. Guo, D. Pike, D.G. McCormack, M. Kirby, G. Parraga.  
Pulmonary Imaging Biomarkers of Gas Trapping and Emphysema in COPD: 3He MR 
Imaging and CT Parametric Response Maps.  Canadian Student Health Research 
Forum 2016 (Canadian Student Health Research Forum Participant and Funding 
Competition Winner) 
 
23. A. Dasgupta, M. Kjarsgaard, D.P.I. Capaldi, K. Radford, F. Aleman, G. Parraga, P.M. 
O’Byrne, P. Nair.  Mepolizumab in COPD with eosinophilic bronchitis: A Randomized 
Clinical Trial.  European Respiratory Society 2016 
 
24. F. Guo, K. Sheikh, R. Eddy, D.P.I. Capaldi, D.G. McCormack, A. Fenster, G. Parraga.  
A Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical 
Workflows and Decision-making.  International Society for Magnetic Resonance in 
Medicine Meeting Proceedings 2016 
 
25. K. Sheikh, F. Guo, A. Ouriadov, D.P.I. Capaldi, S. Svenningsen, M. Kirby, D.G. 
McCormack, H.O. Coxson, G. Parraga.  Ventilation Estimates in Severe Uncontrolled 
Asthma using 3D Single breath-hold Ultra-short Echo Time MRI.  International 
Society for Magnetic Resonance in Medicine Meeting Proceedings 2016 
 
26. D.P.I. Capaldi, A. Lausch, K. Sheikh, F. Guo, D.G. McCormack, G. Parraga.  
Pulmonary Imaging Biomarkers of COPD for Personalized Treatment and Better 
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